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ABSTRACT 
 
DESIGN AND SYNTHESIS OF CDK-5 AND MEK-5 INHIBITORS AND 
SYNTHESIS TOWARDS TUBULYSIN ANALOGS 
 
 
 
By 
Ishveen Kaur Chopra 
May 2010 
 
Thesis supervised by: Dr. Patrick T. Flaherty 
CDK-5 is associated with hyperphosphorylation of the microtubule-associated 
protein tau, formation of neurofibrillary tangles, and possibly an acceleration of the 
neurodegenerative progression of Alzheimer’s disease.  C6-O linked benzimidazoles and 
C-4 benzamide and phenylacetamide benzimidazoles based on (R)-Roscovitine, a non-
selective inhibitor of CDK-5 were designed and synthesized.  
MEK-5, a member of the MAPK family, phosphorylates ERK-5 permitting cells 
to survive oxidative stress.  MEK-5 is upregulated in tumor cells and activated by 
mitogens; inhibition of this enzyme is a potential anti-cancer strategy.  Scaffolds from the 
following classes—benzimidazole, diphenylamine, flavones, and ortho-carboxyamide 
were examined for their capacity to be developed into potent and selective MEK-5 
inhibitors. 
v 
Tubulysin is a natural product that disrupts microtubule dynamics, blocks mitosis, 
and induces cell death.  It has been examined as a potential anti-cancer agent in hollow 
fiber assays.  Simple and reliable procedures were developed for the gram-scale synthesis 
of Mep-Ile dipeptide and Tup fragments of tubulysin. 
vi 
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ABSTRACT 
 
DESIGN AND SYNTHESIS OF CDK-5 AND MEK-5 INHIBITORS AND 
SYNTHESIS TOWARDS TUBULYSIN ANALOGS 
 
 
 
By 
Ishveen Kaur Chopra 
May 2010 
 
Thesis supervised by: Dr. Patrick T. Flaherty 
CDK-5 is associated with hyperphosphorylation of the microtubule-associated 
protein tau, formation of neurofibrillary tangles, and possibly an acceleration of the 
neurodegenerative progression of Alzheimer’s disease.  C6-O linked benzimidazoles and 
C-4 benzamide and phenylacetamide benzimidazoles based on (R)-Roscovitine, a non-
selective inhibitor of CDK-5 were designed and synthesized.  
MEK-5, a member of the MAPK family, phosphorylates ERK-5 permitting cells 
to survive oxidative stress.  MEK-5 is upregulated in tumor cells and activated by 
mitogens; inhibition of this enzyme is a potential anti-cancer strategy.  Scaffolds from the 
following classes—benzimidazole, diphenylamine, flavones, and ortho-carboxyamide 
were examined for their capacity to be developed into potent and selective MEK-5 
inhibitors. 
v 
Tubulysin is a natural product that disrupts microtubule dynamics, blocks mitosis, 
and induces cell death.  It has been examined as a potential anti-cancer agent in hollow 
fiber assays.  Simple and reliable procedures were developed for the gram-scale synthesis 
of Mep-Ile dipeptide and Tup fragments of tubulysin. 
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Chapter 1 
 
Biochemical Literature Review 
 
1.1 CDK-5 
1.1.1 Alzheimer’s disease: an overview 
Alzheimer’s disease is a progressive, degenerative disease of the brain.  Progressive 
cognitive impairment is the most important manifestation of this disease, leading to 
dementia in the elderly.1  It afflicts individuals primarily over 65 years of age, and it is 
estimated that 4.5 million Americans have Alzheimer’s disease and 26.6 million people 
affected globally.2   The underlying cause of Alzheimer’s disease is not fully understood,  
but the process of neurodegeneration is being elucidated.  Currently approved therapies 
include acetylcholinesterase inhibitors and the NMDA receptor antagonist memantine.  
These strategies offer only symptomatic relief.3 
Extraneuronal β-amyloid plaques (Aβ) and intraneuronal neurofibrillary tangles (NFTs) 
are neuropathological hallmarks of Alzheimer’s disease.4, 5  Amyloid plaques are 
composed of fibrillar amorphous deposits of the insoluble antiparallel β-sheet folded Aβ 
peptide (a 42 amino acid peptide).  NFTs are composed of paired helical filaments of 
hyperphosphorylated tau.  Tau is a microtubule-associated protein expressed throughout 
2 
the CNS but especially in axonal projections.  Tau protein is required for the stabilization 
of microtubules. 
 
1.1.2 Formation of amyloid plaques (Aβ) 
Amyloid precursor protein (APP) is not normally neurotoxic, but aberrant proteolytic 
cleavage of amyloid precursor protein (APP) generates Aβ.  The first toxic cleavage is 
carried out by the aspartyl protease β-secretase to generate soluble APP (β-APPs) plus a 
99-residue membrane associated C-terminal fragment, C99.  Alternatively, APP can be 
cleaved by α-secretase, a membrane-associated metalloprotease.  This second path 
generates α-APPs plus a 83-residue membrane associated C-terminal fragment, C-83.  A 
third enzyme, γ-secretase, cleaves the C-99 from β-secretase to produce the neurotoxic 
peptide Aβ.  Alternatively, γ-secretase converts C-83 to the benign peptide, p3 (Figure 
1). Familiar mutations in sAPP result in an increase in aberrant proteolysis6, greater 
amounts of insoluble Aβ, faster deposition of β-amyloid plaques, and an earlier onset of 
cognitive decline. 4,6 
 
Figure 1. Formation of amyloid plaques (Aβ)6. 
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1.1.3 Formation of NFTs 
Tau is a microtubule-associated protein (MAP) and its normative role is to stabilize 
microtubules (MTs).1  Tau protein is characterized by the presence of a MT-binding 
domain with multiple conserved tubulin-binding motifs1.  Tau consists of six isoforms 
expressed in the human adult brain.6  These are derived from a single gene with multiple 
alternative splicing strategies.  
The primary function of the MT-binding domain of tau is to bind and stabilize 
microtubules.  Binding of tau to MTs can be regulated by multiple phosphorylations on 
its serine and threonine residues.  Tau is also regulated by other post-translational 
modifications including glycosylation, ubiquitylation, nitration, and proteolysis.  Tau 
binding to MTs exists as a dynamic process that changes with normal physiological 
conditions in response to metabolic and cell cycle demands.  Kinases and phosphatases 
are the key enzymes in controlling this equilibrium process.8,9  
Tau binding equilibrium to MTs is affected under pathological conditions such as Aβ-
mediated toxicity, oxidative stress, inflammation, and increased prior phosphorylation of 
tau protein.  The phosphorylation at serine and threonine residues by certain proline 
directed kinases for example CDK-5, ERK-2, GSK3β, decrease tau binding to the 
microtubules resulting in microtubule destabilization.  Also, hyper-phosphorylated tau 
protein dissociates from neuronal microtubules, self-associates, and aggregates as helical 
filaments (PHFs) 18.  These insoluble aggregates give rise to neurofibrillary tangles 
(NFTs) which are characteristic of Alzheimer’s disease, but which have also been 
implicated in several other neurodegenerative disorders (Figure 2).1  Ca++ mediated 
activation of calpain generates the dimeric p25/CDK-5 complex that phosphorylates the 
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microtubule associated protein tau.  It is this phosphorylated form of tau generated by 
CDK-5 that is found in neurofibrillary tangles co-localized with the enzyme CDK-5.19  
Hyperphosphorylated tau cannot perform its normal role to stabilize microtubules, as a 
consequence, the axonal cytoskeletal structure is compromised. This compromised 
axonal structure may result in axon collapse, neurodegeneration, and processes leading to 
or contributing toward Alzheimer’s disease.  It is postulated that the presence of tau 
aggregates could be toxic and may upregulate sAPP biosynthesis providing a cyclic 
neurotoxic cascade.4  
 
Figure 2. Formation of NFTs.1 
 
1.1.4 Cyclin dependent kinases (CDKs) 
Cyclin dependent kinases (CDKs) are Ser/Thr kinases which require activation by a 
regulatory partner (cyclin or other cyclin-like protein).10  The overall structure of CDKs 
5 
consists of a small N-terminal domain made up of β-sheets and a large C-terminal domain 
comprised of α-helices. The ATP binding pocket is located between the two domains and 
the substrate peptide binds proximal to the terminal phosphate between these two 
domains.10  The structure of CDK-5/p25 complex is shown in Figure 3.  
 
Figure 3. Ribbon diagram of the CDK-5/p25 complex.  CDK-5 is shown in gray, p25 in blue. The 
ATP-binding pocket between the N and C terminal lobes of the kinase is occupied by (R)-
roscovitine (yellow).11 
 
At least 13 CDKs and 25 cyclin-like proteins have been reported from human genome 
sequencing10 (Figure 4).  CDKs are primarily involved in the regulation of cell cycle 
progression.  But they are involved in other physiological processes as well.  CDK-5 
regulates neuronal functions, while CDK-7, 8, 9, 11 are involved in regulation of 
transcription.10  
CDK activity can be regulated by multiple mechanisms.  First, association of CDKs with 
an appropriate cyclin subunit results in structural changes in the PSTAIRE loop allowing 
access of the ATP active site and the substrate binding site.12  The level of activating 
cyclin varies during the cell cycle, balanced by their synthesis and degradation.12  
6 
Additionally, CDK activity is regulated by T-loop phosphorylation controlled by CDK-
activating kinases (CAKs).  Although this is required by CDK-1, 2, 3, 4, and 6 this is not 
a requirement for CDK-5 activation.  Finally, natural peptidic inhibitors have been 
identified that can inhibit CDK-5 activity. 12, 13  It is unclear why CDK-5 becomes 
dysregulated in Alzheimer’s disease.  But it has been postulated that in certain individuals 
a feedback pathway where NFT’s generate sAPP upregulation has a toxic gain of 
function in neurons when sAPP is diverted to Aβ generation. 
 
Figure 4. Known CDKs with their regulatory partner and functions. Functions represented as 
transcription (brown), neurons (cyan), differentiation (orange), cell death (black), or other events 
(purple).10 
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1.1.5 CDK-5: an overview 
CDK-5, a unique member of the cyclin-dependent kinase family, was isolated in 1992 
from bovine brain.14  It shares about 60% amino acid sequence homology with human 
CDK-2 and 58% homology with mouse CDK1.14, 15  Unlike CDK-2 or CDK-4, it is not a 
cell cycle checkpoint kinase.  CDK-5 is expressed primarily in the nervous system and 
testes.14 
CDK-5 is a proline directed Ser/Thr kinase which phosphorylates either Ser202 or 
Thr205 immediately preceding a proline residue on the protein tau.  A survey of substrate 
preference for CDK-5 identified preference for a proline in the +1 (toward C-terminus) 
position and a basic residue in the +3 position.16  CDK-5 phosphorylates the sequence 
(S/T)PX(K/H/R), where S or T are substrate serine or threonine residues, X is any amino 
acid, and P is the requisite proline residue in the +1 position.  K, H, and R are the 
preferred amino acid residues lysine, histidine, and arginine.  CDK-1 and CDK-2 have 
overlapping substrate specificities with CDK-5. 
 
1.1.6 Regulation of CDK-5 activity 
 CDKs are mainly activated by association with an activator cyclin protein.  Similarly, 
CDK-5 also requires an activator protein for its activity.  This activator may be either a 
cyclin (e.g. cyclin D) or a cyclin-like protein.  The proteins p35 or p39 can activate CDK-
5.17  CDK-5 is unique among the CDKs as phosphorylation of the T-loop Ser159 is not a 
prerequisite for activation.18  The proteins p35 and p39 are expressed in mature neurons 
of the central nervous system.19  These proteins contain an amino-terminal sequence 
consistent with myristoylation suggesting that they are tethered to cell membranes.20  p35 
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is ubiquitylated and rapidly eliminated.  It has an estimated half-life of 20-30 minutes.21  
Although p35 and p39 have little primary sequence homology with the cyclins; modeling 
and mutagenesis studies have suggested that these CDK-5 activators can adopt a cyclin-
like tertiary structure.17  Additionally, crystallization of the CDK-5 and p25 complex 
identifies that p25 can adopt a cyclin-like tertiary structure.  Further, both in vivo and in 
vitro, p25 and p35 can activate CDK-5.19 
 
1.1.6 Role of CDK-5 in CNS development 
CDK-5 is involved in the regulation of cytoarchitecture of the CNS and may have a 
modulatory role in axonal extension.22, 23  It is also involved in the regulation of actin, 
microtubule, and intermediate-filament cytoskeletal components.24  It also modulates cell 
adhesion, transport and intracellular signaling. CDK-5 may be involved in synaptic 
functions including synaptogenesis, dopaminergic signaling, membrane transport and 
neurosecretion.25, 26 
 
1.1.7 CDK-5 deregulation and neurodegeneration 
Under neurotoxic conditions of increased calcium levels, calpain activity is increased and 
p35 is cleaved into p25 by calpain27 (Figure 5).  p25 is the 208 residue C-terminal 
proteolytic product from p35. Although both p35 and p25 can activate CDK-5, there are 
important differences. 28  First, p25 is less prone to ubiquitylation.  Second, p25 lacks a 
myristoylation motif and is unlikely to be membrane bound.  
p25 removes the autoinhibitory PSSLARE helix out of the ATP-binding site of CDK-5 
permitting the ATP and substrate binding to facilitate CDK-5 activity.29   
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CDK-5/p25 can produce the hyperphosphorylated form of tau found in NFTs.  Calpain 
activation, p25 accumulation, elevation of CDK-5 activity and CDK-5 co-localization in 
NFTs have all been observed in AD brain. 29-31  This association of CDK-5/p25 with 
NFTs in AD brains suggest that CDK-5 might be involved in the early stages of NFT 
formation.  This raises suggestion that the pharmacologically blocking CDK-5 mediated 
hyperphosphorylation of tau could attenuate NFT formation and reduce the neuro-
degenerative processes.32, 33 
 
Figure 5. CDK-5 deregulation and neurodegeneration.34 
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1.1.8 CDK inhibitors 
Multiple small molecule scaffolds have been successfully used as CDK inhibitors.10  
Many have (a)  low molecular weights (<600); (b) are flat, hydrophobic heterocycles; (c) 
act by competing with ATP for binding at the kinase ATP-binding site; (d) retain the 
backbone carbonyl H-bond acceptor and H-bond donor motifs utilized by the adenine of 
ATP; (e) optimize hydrophobic interactions. 
Most significantly, deviation from the adenine ring is essential for selectivity35 and is an 
established strategy.  Staurosporine38 is a large hydrophobic molecule and interacts with 
multiple different kinases.  Purines13 logically mimic ATP, and modification of 
heteroatom substituents has been shown to generate ATP competitive inhibitors.  
Pyrimidines13, 37 can be viewed as truncated analogs that retain the 6-membered ring of 
purines.  The oxindole class of inhibitors can be viewed as carbon analogs of the 6/5-
fused system.  Several categories of CDK inhibitors are discussed in this section. 18, 35 - 37  
An emphasis is based on binding identified by x-ray crystal structure analysis. 35 - 37  Most 
compounds exhibit inhibition at several CDKs.  Analysis of specific interactions is 
presented to identify common biding motifs that are likely to be parallel to their 
interactions with the CDKs. 
 
1.1.8.1 Staurosporine-based inhibitors 
Staurosporine is a natural product isolated from Streptomyces staurosporeus.  It is an 
ATP-competitive inhibitor with significant CDK inhibitory activity at all CDKs.  
Staurosporine38 is a large hydrophobic molecule and presents the majority of interactions 
exhibited by ATP-competitive inhibitors.  The lactam ring mimics the hydrogen bonding 
11 
interactions of adenine with an H-bond donor and H-bond acceptor.  The N-methyl 
piperidine mimics the ether of ribose, and the amine cation mimics Mg++ (Figure 6).  
Importantly, staurosporine has an additional hydrophobic region, often utilized to confer 
potency at the ATP binding region. 
 
 
 
 
 
 
 
 
Figure 6. 1) Binding mode of staurosporine. 2) Binding of staurosporine to CDK-2. Residues 
within a 4 Å radius of the staurosporine nucleus in CDK-2 are displayed.38 
 
The hydroxystaurosporine analogue UCN-01 is currently being evaluated in phase 1 
clinical trials (Figure 7). It has been also shown to induce apoptosis in malignant glioma 
cells, and in gastric and breast cancer cells.13 
 
Figure 7. The hydroxystaurosporine analogue UCN-01. 
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1.1.8.2 Purines 
This category includes olomoucine, bohemine, roscovitine, and purvalanol (Figure 8).  
These purines mimic the heterocyclic core structure of ATP but have modified 
substituents on the heteroatoms, conferring potency and selectivity.  Initially olomoucine 
was identified as an active lead compound and showed modest potency against CDK-1, 
CDK-2 and CDK-5.  Bohemine is an olomoucine analog with 6-benzylamine and 2-
amino alcohol.  The variations at 2, 6, 9-position of the adenine core have also been 
explored to examine contributions to binding.13  
Figure 8. Purine derivatives. 
 
Purvanolol A 5a and B 5b exhibit improved potency against CDK-2 compared to 
olomoucine 3 and roscovitine 6. Purvanolol B is 1000-fold more potent than olomoucine 
(IC50 = 6 nM).  Both of these compounds also exhibited a high degree of selectivity for 
CDK-1 and CDK-2 over other CDKs.  The overall geometry of the purine ring for 
purvanolol B is similar to that of compounds 3 and 4, making hydrophobic and Van der 
Waals contact with the enzyme.  The C2 side chain is bound to the ATP ribose binding 
pocket and the isopropyl group packs closely to the backbone atoms of the glycine-rich 
loop.  The improved potency of purvanolol might be due to the differences in the binding 
13 
mode such as improved packing interactions, the steric constraints by the 3-Cl 
substituent, and the reduction of conformational flexibility associated with the removal of 
the benzyl methylene groups of 3 and 438. 
Roscovitine is a potent inhibitor of CDK-1, CDK-2, CDK-5, and CDK-7 (IC50 ~ 0.5- 
0.2 mM) but is less active against CDK-4 and CDK-6 (IC50 > 100 mM).  It is an ATP-
competitive inhibitor and has been shown to bind to the ATP site.39, 40-42, 44, 45 
(R)-Roscovitine is currently under preclinical evaluation against polycystic kidney 
disease, Alzheimer’s disease, stroke, and inflammation; in phase 1 clinical trials against 
various renal diseases; in phase 2 clinical trials against nasopharyngeal cancer; and in 
phase 3 clinical trials against non-small cell lung cancer.  Significantly, the reported side 
effects are largely related to mild gastrointestinal disturbances.43   
Analysis of the interaction between roscovitine and CDK-5 reveal the following 
interactions10 (Figure 9): 
Hydrophobic interactions include the interaction of the isopropyl moiety with a 
hydrophobic cleft formed by the phenyl of Phe80, the isopropyl of Val84, and the alkyl 
portion of Lys33.  The flat adenine core is retained within a very hydrophobic pocket 
composed of a top surface (Ile10, Val18, and Phe82) and a bottom surface (Val64, 
Cys83, Leu133, and Ala143).  The ethyl side chain forms a hydrophobic interaction with 
the side chains of Gly11 and Val18.  The phenyl portion of roscovitine experiences 
hydrophobic interactions with the side chains of Phe82, Ile10, and the alkyl portion of 
Lys89. 
14 
Hydrogen bonding interactions include the H-bond donor-acceptor pair to the backbone 
amide of Cys82 (2.81 Å and 3.25 Å respectively), and the primary hydroxyl is a 
hydrogen bond donor to the backbone acyl of Gln130 (2.13 Å). 
A 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Figure 9. A) Analysis of the interactions of roscovitine in CDK-5/p25 (PDB ID 1UNL); B) Ligand 
interaction analysis of roscovitine in CDK-5/p25.10 
 
1.1.8.3 Pyrimidines  
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The pyrimidine scaffold can be viewed as a truncated purine scaffold.  2-
Aminopyrimidine retains the capacity to form the multiple hydrogen bonds observed in 
purines. Thus, donor-acceptor-donor motifs can be retained with simplified scaffold.  
NU6027 is an ATP-competitive inhibitor of both CDK-1 (Ki = 2.5 µM) and CDK-2 (Ki = 
2.5 µM)13, 37 (Figure 10).  
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Figure 10. Pyrimidine derivatives.13 
 
The 5-nitroso group of NU6027 was proposed to exhibit an internal hydrogen bond to the 
the 6-NH2 group, resulting in the remaining hydrogen of the 6-nitrogen adopting an ideal 
geometry for interactions with the hinge backbone.  Based on the x-ray crystal structure 
of NU6027 in CDK-2, the 6-NH2 interacts with the amide of Glu81.  Leu83 donates a 
hydrogen bond to N-1 NU6027 and the C-2 nitrogen proton acts as a donates hydrogen 
bond donor to the backbone carbonyl of Leu83 (Figure 11).37  
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Figure 11. A) Analysis of the x-ray structure of NU6027 in CDK-2 (PDB ID: 1E1X); B) Ligand 
interaction analysis of NU6027 in CDK-2.140 
 
1.1.8.4 Oxindoles 
This class includes the indirubin comound 10a and its analogs (Figure 12).  Indirubin, is 
a compound found as a component in traditional Chinese medicine and has been used for 
chronic myelocytic leukemia.  Synthetic or purified 10a-d inhibits CDK-1, CDK-2, 
CDK-4 and CDK-5 in an ATP-competitive manner.37  This has been confirmed by x-ray 
analysis. 
 
 
Figure 12. Oxindole derivatives.37    
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The crystal structures of 10c and 10d bound to CDK-2 are known.  The indirubin 
derivatives occupy the ATP binding site.  The lactam amide nitrogen donates hydrogen 
bond to the carbonyl group oxygen of Glu81.  Also, the carbonyl oxygen of lactam and 
NH of indole exhibits a hydrogen bond donor/acceptor pair with the backbone Leu83.  
10c and 10d have an additional interaction with Phe80, resulting in increased 
hydrophobic/hydrophobic interactions compared to ATP (Figure 13).37 
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Figure 13. A) Analysis of the x-ray structure of Indirubin 3-oxime in CDK-2 (PDB ID: 1UNH); B) 
Ligand interaction analysis of Indirubin 3-oxime in CDK-2.10 
 
1.1.8.5 Flavonoids   
Several flavonoids including quercetin, flavopiridol and 2-thioflavopiridol have shown 
inhibitory activity against several CDKs (Figure 14).  Flavopiridol exhibits growth-
inhibitory and cytotoxic activity in vitro, and growth inhibitory properties in human 
xenograft tumor models.  Several flavones are currently in phase 2 clinical trials for 
treatment of refractory myeloma, advanced gastric carcinoma, high grade non-Hodgkin’s 
and mantle cell lymphoma.  As a chemical scaffold, flavones display a broad kinase 
inhibitor profile showing inhibitory activity against multiple kinases: CDK-1, CDK-2, 
CDK-4, CDK-5, CDK-9, and CAK.13 
19 
 
Figure 14. Flavonoid inhibitors.13 
 
Flavopiridol utilizes the flavone core while presenting additional variation from a 3-
hydroxy piperidine at the 8-position at the flavones core and modification of the 2-aryl 
group.  The benzopyran ring of flavopiridol has been show to occupy the same space as 
the purine of ATP and the piperidinyl ring occupies the phosphate binding region 
associated with Mg++ binding (Figure 15).13 
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Figure 15. A) Analysis of x-ray crystal structure of Flavopyridol in CDK-9 (PDB ID: 3BLR). B) 
Ligand interaction analysis of Flavopyridol in CDK-9.141 
 
1.1.9 CDK-5 inhibitors 
As previously presented, there is a need for specific inhibitors of CDK-5.  Three broad 
activity inhibitors of CDKs with well characterized interactions with CDK-5 are 
presented in this section.  The x-ray crystal structures of CDK-5 with the following three 
inhibitors: (R)-Roscovitine, aloisine A, and Indirubin-3’-oxime (Figure 16) has been 
published.18  This provides a basis for well characterized interaction of inhibitors with the 
enzyme.  All three inhibitors contain substituted heterocyclic rings, exhibit highly 
complementary hydrogen bonding patterns with ATP-hydrogen binding patterns and 
have additional hydrophobic interactions.  Inhibitory activity of these compounds against 
CDK-5 and related kinases is shown in Table 1.46-48 
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Figure 16. Structures of (R)-roscovitine, Aloisine A, and Indirubin-3’-oxime.18 
 
Inhibitor CDK-1/cyclinB 
(µM) 
CDK-2/cyclin A,E 
(µM) 
CDK-5/p25 (µM) GSK3β (µM) 
(R)-roscovitine 0.45 0.7 0.16 220 
Aloisine A 0.15 0.12 0.2 - 
Indirubin-3’-
oxime 
0.08 - 0.1 0.022 
 
Table 1: Inhibitory activity of CDK-5 inhibitors.47-49 
 
(R)-Roscovitine is a non-specific purine-based inhibitor of CDK-1, 2, and 5. It is slightly 
more potent at CDK-5/p25 compared to CDK-1/cyclinB and CDK-2/cyclin A, E. It is 
approximately >1000 times more selective for CDK-5/p25 over GSK3β.39  
Indirubin-3’-oxime is a component of naturally occurring indigo dyes.  It is a potent 
inhibitor of CDK-5/p25, CDK-1 and GSK3 β.  It is 4.5 times more potent for GSK3β 
over CDK-5/p25. 
Aloisine A is a pyrrolo-[2,3-b]pyrazine-based inhibitor and is a potent inhibitor of CDK-
1, 2, and 5 and GSK-3α/β.  It is 1.5 times more potent for CDK-2/cyclin A,E versus 
CDK-5/p25. 
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 (R)-Roscovitine, Aloisine A, and Indirubin-3’-oxime are all ATP-competitive inhibitors. 
Ahn, et al.49 identified three more CDK-5 inhibitors through HTS with different 
mechanism of inhibition (Figure 17).49 Compound 18 displayed ATP-competitive 
inhibition; compound 19 showed ATP-competitive inhibition but was non-competitive 
with tau; compound 20 showed competitive inhibition with tau (at low tau concentration) 
but did not compete with ATP.49 
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Figure 17. Structures of CDK-5 inhibitors discovered through HTS by Ahn, et al.49 
 
Although compound 18 and 19 exhibited different kinetic mechanisms of inhibition, they 
were all proposed to interact with the ATP-binding pocket.  In this analysis, (R)-
Roscovitine, aloisine A, and Indirubin-3’-oxime, compound 18 and compound 19, were 
aligned to define the chemical space within the CDK-5 ATP-binding pocket.  All five 
inhibitors were proposed to have important hydrogen bonding interactions with the hinge 
region residue (Figure 18).  In a three-dimensional analysis, they were shown to occupy 
relatively a flat plane.  The hydrophobic contacts were generally made on both sides of 
the ATP-binding pocket while the polar interactions were made along the flat edge of the 
hydrophobic core of the heterocyclic ring. (Figure 18).49 
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Figure 18. Overlay of 5 compounds exhibiting ATP-competitive inhibition of CDK-5. Compound 
18 (blue), compound 19 (red), aloisine A (green), indirubin-3’-oxime (orange), (R)-roscovitine 
(yellow).49 
 
A review of other classes of CDK-5/p25 inhibitors are presented. 
CDK-5 inhibitors by Larsen, et al. 50 
4-Acylamino-1,3-thiazole based inhibitors were explored by Larsen, et al.50  Compound 
21 was obtained as a lead with HTS of known tyrosine protein kinase II inhibitors. 
Substitutions were explored for this scaffold.  Compound 22 was identified as having 
improved potency and selectivity for CDK-5 (Figure 19).50  
 
Figure 19. 4-acylamino-1,3-thiazole based inhibitors by Larsen, et al.50 
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SAR studies have shown that 1,1-disubstituted benzyl derivatives (for example, the 
chlorine atoms of 22 are required for inhibitory activity and selectivity at CDK-5 versus 
CDK-2.  Mono-chloro analogs of 22 exhibited 30% inhibition at 20 µM and 
unsubstituted benzyl analogs exhibited an IC50 = 55 μM.  Other phenyl derivatives were 
less potent50.  Although the replacement of the benzyl group with an aliphatic side chain 
resulted in loss of activity (IC50 = >100 μM), larger side chains (PhSCH2, 4-MeO-
PhOCH2) were tolerated.  The phenoxyamine analog 22 was more potent compared to the 
amino-morpholine analog 21 (Figure 20).  Molecular modeling analysis suggested a co-
planar arrangement of the thiazole ring and the urea moiety, with the thiazole nitrogen 
situated anti to the urea carbonyl (Figure 21).50 
 
Figure 20. SAR highlights of the 4-acylamino-1,3-thiazole based inhibitors.50 
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Figure 21. Low energy conformation of the urea side chain of the 1,3-aminothiazole 23.50 (2,6-
dichloro benzyl omitted for clarity) 
 
CDK-5 inhibitors by Helal, et al.51, 52 
Two major scaffolds have been explored by Helal, et al. 51, 52: 2-aminothiazole based 
inhibitors51 and 4-aminoimidazole based inhibitors52.  The aminothiazole inhibitor 24 was 
discovered through a HTS for CDK-5 and was used as the lead compound for 
development of a potent and moderatively selective CDK-5 inhibitor 25 (Figure 22).51  
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CDK5 IC50 = 321±18 nM
CDK2 IC50 = 318±18 nM
CDK5 IC50 = 8±1 nM
CDK2 IC50 = 96±12 nM
 
Figure 22. 2-aminothiazole inhibitors by Helal, et al.51 
 
SAR studies identified that cyclobutyl-substitution (IC50 = 25 ± 12 nM) at the C-5 
position of aminothiazole was 3 times more potent than the corresponding isopropyl 
analog (IC50 = 64 ± 12 nM).  Other groups such as cyclohexyl, methyl, and phenyl 
resulted in a marked loss of activity.  Improved potency and selectivity was observed 
with fused heteroaryl acetamide analogs. Moreover, aryl or heteroaryl ureas exhibited a 
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further improvement in activity (Figure 23).51  Possible explanations for this increase in 
potency include a contribution of both additional hydrogen bond donor/acceptor 
interactions and additional hydrophobic interactions. 
 
Figure 23. SAR of the 2-aminothiazole inhibitors.51 
 
A parallel scaffold utilizing an alternative scaffold 4-aminoimidazole was examined 
based on the observed activity of 4-aminothiazoles.  The key hydrogen bond acceptor and 
donor interactions with Cys83 in the hinge region were retained as shown below (Figure 
24).52 
 
Figure 24. 4-aminoimidazole inhibitors by Helal, et al.52 
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Similarly, SAR variations were explored for the 4-aminoimidazoles compared with the 2-
aminothiazoles.  It was observed that the 1-cyclobutyl group was the best substitution for 
4-aminoimidazoles.  Based upon molecular modeling, polar functional groups were 
explored at the C-3 position of the 1-cyclobutyl group.  These polar groups were 
proposed to have interactions with the amino side chains Lys33 and Asp144 present in 
CDK-5.  The amide group of the 3 position of the cyclobutyl ring resulted in increased 
activity. Also, the cis conformation was shown to be required for potency.  The presence 
of 1-naphthyl acetamide side chain afforded the best potency for CDK-5 inhibition 
(Figure 25).52  
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- c-Butyl and c-Propyl are preferred groups.
- Me is less active and i-Pr, c-Hexyl, benzyl
analogs are less active.
- cyclobutyl analogs with a cis conformation were more
potent than trans.
- OH, CO2Me at C-3 of c-butyl results in loss of activity,
amide increased potency.
- 2-Me-pyridine analog shows improved potency at CDK-5.
1-naphthyl analog is 10 times more
potent than the -CH2Ph analog.
 
Figure 25. SAR of the 4-aminoimidazole inhibitors.52 
 
CDK-5 inhibitors by Rzasa, et al.53 and Zhong, et al.54 
Two related scaffolds were explored: 3,4-dihydro-1H-quinazolin-2-ones (Rzasa, et al.)53 
and quinolin-2(1H)-ones (Zhong, et al.)54.  The acyclic urea 28 was used as the lead 
compound.  It was proposed that the ring-constrained quinoline or quinazoline inhibitors 
might mimic the intramolecular hydrogen bond between N1 and N3-H of the acyclic urea 
28 
28, providing a pre-organization of the inhibitor into a U-shaped binding conformation 
(Figure 26).53 
 
 
 
Figure 26. CDK-5 inhibitors by Rzasa et al53 and Zhong et al.54 
 
Initially, the SAR explored the 3,4-dihydro-1H-quinazolin-2-one derivatives.  The effect 
of different substitutions at R1, R2, R3 position of the benzene ring were examined.  
Aminothiazole side chains resulted in improved potency compared to other heteroaryl 
groups.  Potency was also affected by the position of the nitrogen atom of the pyridyl ring 
(Figure 27).53   
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Figure 27. SAR of the 3,4-dihydro-1H-quinazolin-2-one derivatives.53 
 
Alternatively, the SAR of ring-constrained quinolin-2(1H)-one scaffold was also 
explored.  The effect of different substitution at the R2, R3, R4 positions of the carbocyclic 
ring was examined.  Amino substitution at the R1 position resulted in improved potency 
over the unsubstituted analog. Arylsulfone and heteroarysulfone derivatives were more 
potent than the analogous 4-pyridyl derivative (Figure 28).54 
 
Figure 28. SAR of the quinolin-2(1H)-one derivatives.54 
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1.2 MEK-5 
1.2.1 MAPK signaling pathway 
The mitogen-activated protein kinase (MAPK) pathways are a family of related, often 
interconnected, signal-transducing pathways that are crucial for the integration of 
mitogenic signals mediated by various growth factors and other extracellular inputs. 
These pathways interpret the resultant outcome in the context of the current biological 
milieu.56-61 
The signaling sequence typically originates upon ligand binding58, 72 or in response to 
extracellular stress.  The subsequent events in the MAPK signaling pathway are unique 
and conserved since it involves a series of phosphorylation events activating the 
downstream kinases of the cascade; MEKK (mitogen-activated kinase kinase kinase) 
phosphorylates MEK (mitogen-activated kinase kinase), which in turn phosphorylates 
another kinase, ERK (extracellular signal-regulated kinase) (Figure 29).  ERKs exhibit 
multiple phosphorylation states responsible for their subcellular localization71, 77 and 
enactment of specific responses such as cell growth, proliferation, survival, and 
development.57  The localization of ERK is highly variable between cell lines and tissue 
origin. 
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Figure 29. The MAPK signaling pathway.142 
 
1.2.2 MEK: An Overview 
There are seven different MEKs known.58  Each component of a MAPK signaling 
cascade displays varying levels of substrate specificity.58  MEKs consist of D-domain at 
the N-terminus, which displays unique interaction with the complementary CD domain58 
on the C-terminus of ERKs.  The D-domain contains basic and hydrophobic residues, 
whereas the CD domain consists of acidic residues.  This D/CD interaction is a chief 
determinant of MEK-ERK specificity58, while other biochemical interactions such as 
association with scaffolding proteins69, 78, and other kinases or sub-cellular localization78 
further mediate specific outcomes for a given pathway. 
 
1.2.3 Role of MEK-5/ERK-5 pathway in cancer 
MEK-5 is a kinase in signaling pathways that allow cells to survive oxidative stress.  
Specifically MEK-5 is upregulated in response to ionizing radiation and under conditions 
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of oxygen deficiency.  Specifically, ERK-5 plays a role during the G1/S cell-cycle 
transition for EGF-induced cell proliferation via a cAMP response element (CRE)-
mediated expression of cyclin D1.80  Further studies have shown significant upregulation 
of the MEK-5/ERK-5 pathway in squamous cell carcinoma81, breast, and prostate83 
cancers.  Moreover, three recent studies examining the role of ERK-5 in breast cancer73, 
leukemia cells83, and unique activation by palytoxin or the phorbol esters84 have 
prompted re-examination of the potential role of MEK-5 as an anti-cancer therapeutic 
target.   
 
1.2.4 MEK-5 regulation 
Activators of the MEK-5/ERK-5 signaling cascade include nerve growth factor (NGF), 
endothelial growth factor (EGF), brain-derived neurotrophic growth factor (BDNF), 
oxidative stress, ionizing radiation, and the phorbol esters.66, 68, 70, 72   
 
1.2.5 MEK-5 substrate specificity 
ERK-5 is the specific substrate for MEK-5.79  ERK-5 is phosphorylated at Thr and Tyr 
residues within a Thr-Glu-Tyr (T-E-Y) activation motif. 
 
1.2.6 MEK-5 isoforms 
MEK-5 consists of two splice variants: the larger α isoform (50-kD) is highly expressed 
in liver and brain and shows differential subcellular localization, while the smaller β 
isoform (40-kD) is ubiquitously distributed and is primarily cytosolic (Figure 30).  
MEK-5α is 89 amino acids longer than MEK-5β at the N-terminus.75, 76  The differential 
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subcellular localization of MEK-5α is consistent with the large N-terminal region 
interacting with a platform protein and mediating subcellular localization.  In addition, 
MEK-5α also contains a phox and Bem1p (PB1) domain required for the binding and 
interaction with other kinases, MEKK2 and MEKK3. 
MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVLDVIGQVLPEATTTA
FEYEDEDGDRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPLQIFPRACKPPGERNIH
GLKVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQMNEQDIRYRDTLGHGNG
GTVYKAYHVPSGKILAVKVILLDITLELQKQIMSELEILYKCDSSYIIGFYGAFFVENR
ISICTEFMDGGSLDVYRKMPEHVLGRIAVAVVKGLTYLWSLKILHRDVKPSNMLVNTRG
QVKLCDFGVSTQLVNSIAKTYVGTNAYMAPERISGEQYGIHSDVWSLGISFMELALGRF
PYPQIQKNQGSLMPLQLLQCIVDEDSPVLPVGEFSEPFVHFITQCMRKQPKERPAPEEL
MGHPFIVQFNDGNAAVVSMWVCRALEERRSQQGPP  
 
MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVLDVIGQVLPEATTTA
FEYEDEDGDRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPLQIFPRACKPPGERNIH
GLKVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQMNEQDIRYRDTLGHGNG
GTVYKAYHVPSGKILAVKVILLDITLELQKQIMSELEILYKCDSSYIIGFYGAFFVENR
ISICTEFMDGGSLDVYRKMPEHVLGRIAVAVVKGLTYLWSLKILHRDVKPSNMLVNTRG
QVKLCDFGVSTQLVNSIAKTYVGTNAYMAPERISGEQYGIHSDVWSLGISFMEIQKNQG
SLMPLQLLQCIVDEDSPVLPVGEFSEPFVHFITQCMRKQPKERPAPEELMGHPFIVQFN
DGNAAVVSMWVCRALEERRSQQGPP 
Figure 30. Protein sequence of MEK-5α and MEK-5β. 
 
1.2.7 ERK: an overview 
There are eight different ERKs known143.  The consensus phosphorylation motif for ERK 
substrates is [Ser/Thr]-Pro. ERK substrate specificity requirements are a Pro residue at +1 
position relative to the substrate phosphorylation residue and aliphatic residue at the 2- 
position.  
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ERK substrate specificity and affinity for ERKs results are mediated by docking 
interactions.  There are two major types of docking interactions present between 
substrates and the complementary substrate groove on the kinase.  
The first major docking site on the substrates is the D-domain (D-site, δ-domain, DEJL 
domain), which consists of two or three basic residues upstream of a Leu-x-Leu motif 
with a group of hydrophobic residues.  The corresponding ERK includes acidic and 
hydrophobic regions complementary to the substrate D-site.  
The second major docking site present in ERK substrates is the DEF site (docking site for 
ERK FXF, also called the F-site).  DEF sites are generally characterized as an [Phe/Tyr]-
x-[Phe/Tyr]-Pro sequence, typically located between 6 and 20 amino acid downstream 
from the C-terminal to the phosphorylation site.  The DEF interaction site of ERK 
consists of a hydrophobic pocket adjacent to the active site cleft.  The accessibility of this 
hydrophobic pocket of the DEF site to docking site requires activation of ERK by the 
MEK.  Phosphorylation of ERK triggers a conformational rearrangement of the activation 
loop, aligns residues important for catalysis, forms the phosphate acceptor binding site, 
and exposes the DEF site.  Substrates are the transcription factors Elk-1, c-Fos, c-Myc, 
and JunD.  In addition, DEF sites mediate interactions with ERK regulators, including 
MKP- phosphatase and nucleophorins that are likely to be involved in the nuclear 
transport of the kinase.  
 
1.2.8 ERK-5:  Structure and molecular characteristics 
ERK-5, also known as Big mitogen-activated protein kinase 1, BMK1 is a 100-kD 
protein, containing 816 amino acids. It consists of the N-terminal region containing the 
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kinase domain, two proline-rich domains (PR1 and PR2), nuclear localization signal 
(NLS), and autophosphorylation sites present at the C-terminal region (Figure 31). The 
autophosphorylation of C-terminal region contributes to increased transcriptional activity 
of ERK-5. There is 66-67% of sequence similarity with the kinase domain of ERK-1/2 
extending to the T-E-Y (Thr-Glu-Tyr) motif of the activation loop.77  
 
Figure 31. Structure of the ERK-5. 
 
1.2.9 ERK-5 substrates 
Phospho-ERK-5 derived from MEK-5 mediated phosphorylation is upregulated in 
multiple tumor types and may confer an anti-apoptotic effect in these tumors: MEK-5 
activity is upregulated in breast cancer73, metastatic prostate cancer82, and is also 
involved in proliferation of human mesolithoma cells83.  MEK-5 is both upregulated in 
tumor cells and activated by mitogens including the phorbol esters84. 
ERK-5 substrates include the MEF2 family members (MEF2A, C, and D), and the Ets-
like transcription factor Sap 1a.  Other substrates include transcription factors, such as c-
Myc, NF-kB, c-Fos, and Fra-1 as well as the serum and glucocorticoid-inducible kinase 
(SGK).71, 77 
 
1.2.10 ERK-5 nucleocytoplasmic transport77 
ERK-5 has a bipartite nuclear localization signal (NLS) in its carboxy-terminal region.  In 
resting cells, the intramolecular interaction between the amino-terminal and the carboxy-
36 
terminal halves form a region responsible for a CRM1-dependent nuclear export signal 
(NES).  Under non-stimulating conditions, NES activity is stronger than NLS activity, 
resulting in retention of ERK-5 in the cytoplasm.  On stimulation, ERK-5 undergoes 
activating phosphorylation, and the interaction between the N-terminal and the C-
terminal halves is disrupted, resulting in the loss of NES activity.  ERK-5 then 
translocates to the nucleus (Figure 32).  
 
 
Figure 32. Mechanism of ERK-5 translocation into the nucleus.77 
 
1.2.11 MEK inhibitors 89-92 
Inhibition of MEK-5 might have potential as an anti-cancer target.  Yet, only a single 
selective MEK-5 inhibitor has been identified, BIX02189, an indolinone-6-carboxamide 
(Figure 38, page 41).  The development of new scaffolds and new inhibitors should 
permit a better characterization of the functional role of the enzyme both in vitro and in 
vivo.  Variation is anticipated to arise from different chemical properties for each unique 
compound as well as from each unique compounds profile of kinase selectivity.  But 
most importantly, it has been demonstrated that there are multiple ways to inhibit MEKs: 
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at the ATP binding site, at the ATP site with a type II (DFG-out) conformation, or at an 
allosteric site proximal to the ATP-associated magnesium atom. 
 
1.2.11.1  Flavones 
The flavone PD 098059 is a known MEK-1/2 and 5 inhibitor77.  The first MEK-1 and 
MEK-2 inhibitor, PD98059 77, 79 was identified in an in vitro screen for inhibitors of ERK 
activation87 (Figure 33).  It also shows inhibitory activity against MEK-5.  Some studies 
have shown PD98059 to be a non-competitive inhibitor of ATP, while others have shown 
it to be involved in activation of a cAMP-activated protein kinase mechanism.  The exact 
mechanism of inhibition for 31 has not yet been fully elucidated. 
 
Figure 33. Flavones as MEK inhibitors.77, 79 
 
A structurally related but different flavone, flavopiridol, is a well-known ATP-
competitive inhibitor, mostly at CDK-related kinases. Flavopiridol exhibits growth-
inhibitory and cytotoxic activity in vitro, and has shown growth inhibition of human 
xenograft tumors in mouse models of human tumors. 
There are several x-ray crystal structures with flavopyridol bound to a kinase; no such 
structure exists for PD 098059. 
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1.2.11.2  Succinonitrile-based inhibitors 
UO126 binds selectively to MEK-1 and MEK-2 with IC50 of 0.07±0.02 µM and 
0.06±0.02 µM respectively.86  It exhibits non-competitive inhibition with respect to ATP 
or ERK, thus it might bind to an allosteric site on MEK. It consists of three isomers: Z,Z; 
Z,E; and EE isomers (Figure 34). The Z,Z-isomer of UO126 exclusively exhibits MEK 
inhibitory activity.  Different substitutions have been examined on the phenyl ring.  An 
electron-donating group at the C-2 or C-4 position of the phenyl ring showed 3-10 fold 
increase in activity.  Cyclized derivatives were less potent than the parent UO126. 
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Figure 34. Succinonitrile-based inhibitors of MEK.86 
 
1.2.11.3  Diphenylamines 
An x-ray crystal structure, 1S9J, of the diphenylamine MEK-1/2 inhibitor PD318088 
bound to MEK-1 is known.  CI-1040 was designed as a MEK-1/2 inhibitor for treatment 
of cancer (Figure 35).  It was the first MEK inhibitor that progressed into clinical trials.  
SAR were explored for the diphenylamine scaffold.  Analysis of the x-ray crystal 
structure of MEK-1 with PD318088 showed that the B-ring mainly occupies a 
hydrophobic pocket formed by Met143, Ile141, Phe209, and Leu118 remote from the 
ATP-binding site.  Second, an important induced electrostatic interaction is formed 
between the backbone carbonyl oxygen of Val127 and the 4-iodide atom on the B-ring in 
the kinase hinge region.   The A-ring occupies small hydrophobic pocket and 4-fluoro of 
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A-ring forms H-bond interaction with the backbone amide of Ser212. The hydrogen 
bonding interaction occurs between the oxygen atoms of hydroxamate side chain and the 
protonated amine side chain of Lys97.  The oxygen atoms of hydroxamate side chain are 
involved in hydrogen bond interaction and the terminal hydroxyl group interacts with the 
terminal phosphate group of ATP. 60, 65, 67 
CI-1040 showed better activity in preclinical models of human colon cancer, but was 
unstable in humans, and consequently was withdrawn from clinical trials.87, 88  
PD0325901 showed improved potency and stability compared to CI-1040, and 
consequently progressed into clinical trials (Figure 35). PD0325901 is currently being 
tested against melanoma, non-small lung cancer and cancers of the breast and colon87.  
Both of these compounds exhibit non-competitive ATP competitive inhibition.88 
 
 
Figure 35. Diphenylamine based MEK inhibitors.87, 88 
 
1.2.11.4  Pyridone inhibitors 
Pyridone based inhibitors159  were developed using pharmacophore model. Substitution at 
the C-5 position of the pyridine A-ring influenced cellular activity significantly.  The 
presence of an A-ring H-bond acceptor was important for activity, as the compound 38 
containing the 2-methoxy pyridine moiety was inactive against MEK.  The primary H-
bond interaction occurs between the carbonyl oxygen of the pyridone and a backbone 
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amide NH group.  Substitution on the C-4 position of B-ring did not influence direct 
enzymatic or cellular potency (Figure 36).  
 
Figure 36. Pyridone-based inhibitors of MEK.159 
 
Alternative A-ring templates were explored that led to the discovery of AZD6244 which 
has progressed into clinical trials.  It is being examined against melanoma, pancreatic 
cancer and non-small lung cancers.  It also exhibits non ATP-competitive inhibition of 
MEK-1/2 (Figure 37). 
 
Figure 37. AZD6244 – MEK inhibitor in clinical trials. 
 
1.2.11.5  Indolinone inhibitors 
Specific MEK-5 inhibitors were reported by Boehringer Ingelheim85, discovered through 
high throughput screening85 (Figure 38).  BIX02188 and BIX02189 showed inhibition of 
MEK-5 catalytic activity in dose dependent manner with an IC50 4.3 and 1.5 nM, 
respectively.  The mechanism of inhibition is not known, but high-throughput ATP 
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surrogate screening assays (kinome scan) are consistent with these compounds having an 
ATP-competitive mechanism of inhibition. 
 
Figure 38. Indolinone-based selective MEK-5 inhibitors. 
 
1.2.11.6  Other classes of MEK inhibitors 
Other chemical classes are also being explored as MEK inhibitors, such as coumarin-
based compounds88 (G8935, G0328), pyrrolopyridazines 45, and imido-substituted 2-
chloro-1,4-naphthoquinones 46 (Figure 39). 
 
Figure 39. Other classes of MEK inhibitors. 
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The x-ray crystal structure of PD0325901 with MEK-1 (PDB code 1S9J, Figure 40) has 
provided insight into the specific nature of its MEK inhibition.  Selective MEK-5 
inhibitors would provide a useful tool for understanding the role of MEK-5/ERK-5 
pathway, and well characterized ATP-site or non ATP-site inhibitors would permit an 
analysis of which strategy would be the best method of inhibition in vivo. 
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Figure 40. X-ray crystal structure of PD0325901 with MEK-1 (PDB code 1S9J) and Ligand 
interaction  analysis of PD0325901 in MEK-1. 
 
1.3 Tubulysin 
Tubulin is the major protein comprising the mitotic spindles and plays an important role 
in cell growth, division, and differentiation. This helps in proliferation and survival of 
44 
cancer cells.98 Tubulin-interacting agents such as tubulysin disrupt microtubule 
dynamics, blocking mitosis resulting in cell death and are currently used clinically as 
anti-cancer therapeutic agents.109 
 In neurodegenerative diseases oxidative stress activates CDK-5/p25 resulting in 
hyperphosphorylation of tau18, dissociation from microtubules, formation of 
neurofibrillary tangles, and possible acceleration of the neurodegenerative progression 
observed in Alzheimer’s disease. 
 
1.3.1 Microtubules: An Overview 
Microtubules are long, filamentous, tube-shaped protein polymers that are the key 
structural components of the cytoskeleton.  They are vital for all aspects of a cell’s life 
including development, maintenance of cell shape, and division.  They also function in 
the transport of vesicles, mitochondria, organelles, and other subcellular components 
within the cell.  Microtubules are composed of α-tubulin and β-tubulin heterodimers that 
have dimensions of 4 nm × 5 nm × 8 nm.93  These heterodimers can be arranged to form 
hollow filamentous tubes known as microtubules.  Microtubules are highly dynamic 
assemblies and its dynamics are tightly regulated both spatially and temporally.  Tubulin 
monomers consist of multiple isoforms within the α- or β- designations and exhibit 
extensive post-translational modification including glutamoylation, glycation, 
phosphorylation, acetylation, and tyrosylation.93, 94 
 
1.3.2 Polymerization dynamics of microtubules 
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Polymerization of microtubules occurs via a nucleation, then elongation mechanism.  
Slow formation of a short microtubule “nucleus” is followed by rapid elongation of this 
nascent microtubule possibly at both ends by reversible, non-covalent addition of new 
GTP-containing tubulin heterodimers (Figure 41).  They exhibit complex polymerization 
dynamics that use energy provided from the hydrolysis of the bound GTP to GDP to form 
the microtubule structure.95 
Microtubules show two major types of non-equilibrium dynamics – “dynamic instability” 
and “treadmilling.”  
 
 
 
 
 
Figure 41. Polymerization of microtubules.95 
 
The first major dynamic behavior of microtubules is dynamic instability.  In dynamic 
instability, microtubule ends alternate between phases of elongation or shortening.  The 
plus end of the microtubule grows and shortens more rapidly than the minus end.  This 
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end has exposed β-tubulin monomers.  Microtubules can undergo long periods of stability 
or rapid lengthening shortening.  Dynamic instability is characterized by four main 
variables: the rate of microtubule growth, the rate of shortening, the frequency of 
transition from growth to dynamic shortening (catastrophe), and frequency of transition 
from shortening to dynamic growth (rescue).95 
The second major dynamic behavior is called “treadmilling” represented as growth at one 
microtubule end and balanced shortening at the opposite end.  Treadmilling involves a 
cyclic recovery of tubulin subunits from the minus end of the microtubule to the plus end 
and is driven by concentration differences in the subunits at each microtubule end.95 
Polymerization dynamics of microtubules can be driven by gain or loss of a GTP cap 
(Figure 42). The GTP cap is a short region of attenuated activity with tubulin-GTP or 
tubulin-GDP-inorganic phosphate (Pi) capping residues.  Assembly of free heterodimer 
tubulin-GTP to dimers associated with microtubules hydrolyse GTP to GDP and Pi.  The 
presence of a GTP or GDP-Pi cap stabilizes the microtubule and attenuates dynamic 
modification.  Loss of the GTP cap results in depolymerization.  Microtubule dynamics 
are regulated by various mechanisms in the cells, including tubulin isotype expression, 
post-translational modification of tubulin, microtubule-associate proteins and 
microtubule-interacting proteins.96 
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Figure 42. Polymerization dynamics and GTP cap.95 
 
1.3.3 Crucial role of microtubule dynamics in mitosis 
Mitosis in most cells progresses rapidly and dynamic microtubules comprise the mitotic 
spindle which is essential for all stages of cell division97, 98 (Figure 43).  As such each of 
the four major phases of mitosis utilizes microtubule dynamics.  First, during interphase 
the cellular microtubule network disassembles at the onset of mitosis and reforms as the 
mitotic spindle.  Spindle microtubule dynamics are 4–100 times more active than 
microtubules during the interphase. Attachment of the chromosomes by their 
kinetochores99 to the mitotic spindles is the second phase: spindle prometaphase.  The 
third phase, congression, aligns chromosomes at the mid plate of the mitotic spindle.100  
The last phase (anaphase and telophase)99 separates the chromosomes toward opposing 
ends of the cell by shortening the spindle arms.  Thus, microtubules have several unique 
dynamic features that are crucial to successful mitosis and cell division. 
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Figure 43. Human osteosarcoma cells in different stages of the cell cycle with and without 
addition of antimitotic drugs. Microtubules are shown in red, chromosomes in blue and 
kinetochores in green. a) The prometaphase shows the absence of nuclear envelope, condensed 
chromosomes, and dynamic microtubules forming contact with chromosomes. b) Congression 
and alignment of the chromosomes at the equator forming metaphase plate occurs in metaphase. 
c) The anaphase is characterized by the separation of duplicated chromosoms, followed by their 
movement towards the spindle poles to form the two daughter cells. d) In telophase, the 
separated chromosomes have reached the spindle poles and the cell is dividing to form two 
daughter cells. e) In the presence of 10 nM paclitaxel, some chromosomes remain at the spindle 
poles and have not congressed to the metaphase plate. f) Similarly, in the presence of 50 nM 
vinflunine, some chromosomes remain at the spindle poles.95 
 
1.3.4 Antimitotic drugs and their mechanism of tubulin interaction 
Antimitotic agents can inhibit cell-proliferation by modifying microtubule polymerization 
dynamics (Table 2)102.  Microtubule-targeted antimitotic drugs are primarily classified 
into two main groups.  The first major group is microtubule-destabilizing agents.  These 
inhibit microtubule polymerization and are represented by the Vinca alkaloids 
(vinblastine, vincristine, vinorelbine, vindesine, and vinflunine), the cryptophycins, the 
halichondrins, estramustine, colchicines, and the combretastatins.  The second major 
group is microtubule-stabilizing agents. These stimulate microtubule polymerization and 
are represented by the taxanes, epothilones, discodermolide, eleutherobins, sarcodictyins, 
laulimalide, rhazinalam, and certain steroids or polyisoprenyl benzophenones (Figure 
44). 
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Binding 
domains 
Drugs Therapeutic uses 
Vinca 
Domain 
Vinblastine  Hodgkin’s disease, testicular germ cell cancer 
Vincristine Leukemia, lymphomas 
 Vinorelbine Solid tumors, lymphomas, lung  cancer 
Vinflunine Bladder, non-small cell lung cancer, breast cancer 
Dolastatins  Vascular targeting agents 
Hemiasterlins  
Colchicine 
Domain 
Colchicine Non-neoplastic diseases (gout, familial Mediterranean 
fever), also actinic keratoses 
Combretastatins  Vascular -disrupting agents 
2-Methoxyestradiol Multiple myeloma, glioblastoma multiforme carcinoid, 
prostate, breast 
Methoxybenzene-sulfonamide  Solid tumors, vascular-disrupting agents 
Diketopiperazine Vascular-disrupting agent 
Taxane 
Site 
Paclitaxel and analogs  Ovarian, breast, lung tumors, Kaposi’s sarcoma; trials 
with  numerous other tumors 
Docetaxel Prostate, brain, breast,  and lung tumors 
Epothilone  Taxol-resistant tumors 
Discodermolide Synergistic with taxanes 
Other 
Binding 
Sites 
Estramustine Prostate, often in combination 
Arsenic trioxide Vascular-disruptive agent 
Noscapine Leukemia, lymphoma 
 
Table 2. Microtubule-interfering drugs and their therapeutic uses.102 
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Figure 44. Discrete binding sites for tubulin binding antimitotic agents.95 
 
Vinca alkaloids: Vinblastine show binding to the β-subunit of tubulin dimers at a 
discrete region termed the Vinca-binding domain.103  Vinblastine depolymerizes 
microtubules and disrupts mitotic spindles at high concentration. However, there is no 
depolymerization at low concentration, yet it still inhibits mitosis at low concentrations 
inducing apoptosis. 
Paclitaxel and related drugs: Paclitaxel102 binds to the β-subunit of the microtubule 
dimer. Binding of paclitaxel on the inner surface of the microtubule results in 
stabilization and consequently increases polymerization and growth of the microtubule.  
Tumor sensitivity and resistance 
The inherent resistance to chemotherapy with antimitotic drugs can result from over-
expression of a class of membrane bound transporter proteins known as ABC-
transporters (ATP-dependent drug efflux pumps or ATP-binding cassettes).  These 
membrane pumps reduce drug levels in the cell and can give rise to the multidrug 
resistance (MDR) phenotype.  One of these transport proteins are the P-glycoproteins, a 
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product of the human MDR1 gene.  Other mechanisms of MDR include over-expression 
of key proteins inhibiting apoptosis, or post-translational modification of tubulin or 
expression of different tubulin isotypes, for example the β3 tubulin monomer.102 
1.3.5 Tubulysins: an overview 
Tubulysin interferes with the dynamics of tubulin and has been shown to reduce tumor 
growth at sub-nanomolar levels.  Tubulysin inhibits tubulin polymerization and induces 
apoptosis by inducing cell cycle arrest in the G2/M phase of cell division.105 
 
1.3.5.1 Isolation and structure of tubulysins 
 The tubulysin family of compounds was first discovered by the Höfle research group at 
the Gesellschaft für Biotechnologische Forschung (GBF) in DüBeldorf.104  Tubulysins 
are peptide based antimitotic agents with novel γ-amino acids, originally isolated from 
unrelated species of myxobacteria: Archangium gephyra and Angiococcus disciformis.105  
Tubulysins are inactive against bacteria, have minimal activity against fungi, but notably 
exhibit good cytostatic activity against mammalian cancer cell lines.  Tubulysins are 
linear tetrapeptides consisting of a sequence of N-methyl pipecolic acid (Mep), isoleucine 
(Ile), tubuvaline (Tuv), and a C-terminal tubutyrosine (Tut) or a C-terminal 
tubuphenylalanine (Tup) residue (Figure 45).   Tubulysins A, B, C, G, and I contain a p-
hydroxyphenyl residue and were isolated from A. gephyra. Tubulysins D, E, F, and H are 
phenyl (Tup) variants isolated from A. disciformis.  
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Figure 45. Structure of tubulysins.105 
 
The structure elucidation and absolute configuration of the tubulysins utilized NMR 
analysis, chemical degradation, and comparison with known amino acids, and X-ray 
crystal structure determination for tubulysin A.105  The 5-acetoxy residue in Tuv is 
common to all tubulysins, but absent in pretubulysin.106-108  The N-acyloxymethyl 
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substituent varies in each specific compound.  The N-acyloxymethyl substituent is an 
N,O-acetal and that liberates formaldehyde upon treatment with acid.  Comparison of the 
x-ray crystal structure of tubulysin A (Figure 46) with the structure elucidation via NMR 
methods (e.g., NOE) (Figure 47) identified that rotation about the thiazole ring exists, yet 
the N and C termini are retained in a similar conformation.105 
Figure 46. Stereoview of the crystal structure of tubulysin A (ORTEP plot, hydrogen atoms 
added).105 
 
Figure 47. Conformation of tubulysin A in [D
6
] DMSO, based on the crystal structure, NOE 
correlations, and vicinal proton coupling constants. Ac = acetyl.105 
 
1.3.5.2 Biological evaluation and mechanism of action 
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Initial biological studies of tubulysins were carried out by the Höfle research group.105  
They identified that tubulysins were more cytotoxic than vinblastine, and displayed an 
activity comparable to dolastatin 10; with an IC50 in the subnanomolar range.  A 
correlation was noticed between cellular activity and the lipophilicity of the tubulysin 
form being tested.  Difference in cellular activity was postulated to arise from preferential 
uptake of the more lipophilic tubulysins from the medium by the cells or from direct 
interaction with tubulin. 
The Reichenbach group studied the mechanism of action for the most abundant tubulysin: 
tubulysin A.109  A summary of the findings is shown below:  
a. In cell culture analysis, tubulysin A led to the depletion of microtubules within the 
cells, which was not inhibited by epothilone B or paclitaxel (microtubule 
stabilizing agents). Tubulysin A induced cell accumulation in the G2/M transition 
of the cell cycle and induced apoptosis.  These results suggest that tubulysin A 
interferes with microtubule dynamics, and this anti-mitotic effect may induce 
apoptosis. 
b. The in vitro assay of tubulysin A showed that it inhibits tubulin polymerization, 
which was comparable to phomopsin A and more efficient than vinblastine. 
c. Binding competition experiments showed that tubulysin A non-competitively 
inhibits the binding of vinblastine to tubulin. 
d. Electron microscopy investigations identified oligomeric tubulin aggregates, 
formation of the rings, and the generation of pinwheel-like structures in the 
presence of MAPs.18, 19 
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Dömling’s group at Morphochem AG studied the in vivo biological activity of tubulysin 
A, focusing on its potency in MDR cell lines, selectivity over normal cells, metabolic 
stability, antiangiogenic activity, and in vivo efficacy.112 
a. In the NCI 60-human cell line screen, tubulysin A showed a distinct pattern for 
total growth inhibition (TGI) for a panel of melanoma, leukemia, and prostrate 
cancers suggesting specificity for certain tumor cells. 
b. Tubulysin A (GI
50 
0.059 ± 0.03 nM) showed high cytotoxicity against the HL-60 
cell line as compared to paclitaxel (GI
50 
1.95 ± 1.04 nM) and vinblastine (GI
50 
0.94 ± 0.51 nM). Moreover, comparable activity against HCT-116 (a non-MDR 
resistant cell line with very low Pgp expresstion) and HCT-15 (a cell line with 
very high Pgp expresstion) cells sugested tubulysin A is not a substrate for Pgp. 
c. A 10-fold difference for the induction of apoptosis in the cancer cell line (HL-60) 
versus the normal cell line (HUVEC) was observed in presence of tubulysin A.  
Moreover, tubulysin A showed a low potential for interaction with the three major 
CYPs (CYP1A2, 3A4 and 2D6). 
d. In the hollow fiber assay, tubulysin A inhibited cell growth in 33% of the 12 
cancer cell lines tested. 
In conclusion, both in vitro and in vivo assays suggest that tubulysin A is a potent anti-
proliferative agent and may find applications as an anticancer agent. 
 
1.3.5.3 Known Structure Activity Relationship of tubulysins 
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Tubulysin analogs have been synthesized by several groups.107, 113-116  A summary and 
critical analysis of known findings is presented below: 
a. Different cell lines and experimental conditions were used by each group. 
b. Different compounds were used as standards for the assays. 
c. Cellular assays and in vitro tubulin depolymerization assays do not always show 
the same trend within a given series of compounds or partial data was presented 
(The Ellman group did not do an in vitro tubulin depolymerization assay).  In 
general the activity in the cell-based assay is more sensitive to structural 
modification; lipophilic compounds tend to be more potent in these assays.  The 
in vitro tubulin depolymerization assay is less affected by lipophilic variation.  
One possible explanation given was that the lipophilicity may contribute to 
cellular uptake properties. 
d. Only Ellman’s group developed a total synthesis of tubylysin D with the N,O-
acetal substitution.   Ellman’s analogs are only one point variations based on 
tubulysin D.  Wipf’s analogs all have an N14-methyl substituent.  Fecik’s group 
identified that only the epimer of the 7-acetate is inactive.  This suggests a modest 
favorable interaction for the correct epimer and a strong disfavorable interaction 
for the wrong epimer, particularly for the acetate ester compared to the hydroxyl. 
A summary of modifications carried out by each group is presented discussed below 
(Figure 48): 
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- gem-dimethyl is less active.
B.) - More hydrophobic acyl hemiaminals
are more potent.
- Acyl hemiaminal is not required for activity
(removal of acyl heminal results in 20-fold
loss of activity).
C.) - Not required for activity.
- 7-epimer is 5-fold less active.A.) - Amino acid must be present.
- Cyclic piperidine can be replaced with
acyclic dimethyl valine.
 
Figure 48: Fragment SAR summary of tubulysin and its analogs. (R1 and R2 defined in Figue 45, 
Page 52). 
 
FRAGMENT A 
Replacement of the N-methyl piperidine with a simple tertiary amine, as demonstrated by 
all three groups, is well tolerated.  N,N-dimethyl glycine, a simplified and low molecular 
weight analog was shown to be equipotent to tubulysin D.114  Further, a tertiary basic 
amine and D-configuration or achiral glycine is necessary for activity.   
FRAGMENT B 
Replacement of the N,O-acetal group is desired as it is chemically unstable, difficult to 
synthesize and unstable in biological systems.  N-methyl substitution for the acyl 
hemiaminal results in a 20-fold drop of activity as compared to tubulysin D.114  
Unsubstituted analogs, tubulysin U and V, synthesized by Dömling, are less active than 
tubulysin A – I; but are within the nanomolar range exhibited by taxol and epothilones.106  
Fecik’s group showed that tubulysin U (Figure 45, Page 52) is potent against 1A9 and 
MCF-7 cell lines.108   
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FRAGMENT C 
Replacement of the acetal with a hydroxyl group showed a minimal decrease in activity 
compared to tubulysin D.  However, the hydroxyl analog (tubulysin V, R2 = H) is 1000-
fold less potent than tubulysin U (R2 = Ac) in vitro. 107  Although  the 7- epi-tubulysin V 
is less potent against 1A9 and MCF-7 cell lines, both epimers were equivalent in the 
tubulin depolymerization assay. 
FRAGMENT D 
Ellman and Fecik studied modifications at different modifications at Tup portion of 
tubulysin.  Most modifications resulted in minimal drop in activity compared to tubulysin 
D114 (Figure 49). Minimally, an α-methyl group is necessary for activity. 
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Figure 49. Modifications of Tup portion of tubulysin by Ellman.114 
 
The goal of this thesis is not to synthesize tubulysins; tubulysin contains a chemically 
labile N,O-acetal group and requires complex synthesis while simplified analogs of 
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tubulysin might be more synthetically accessible, more chemically stable, and still retain 
potency. 
Pretubulysin 
Recently a related tubulysin, pretubulysin118, lacking the chemically labile N,O-acetal and 
the stereogenic 7- acetate group was identified and found to be only 5 times less potent 
than tubulysin D in HL-60 cell line (Figure 50). This suggests that the N,O-acetal group 
is not required for activity clearing the way for exploring simple stable analogs from 
pretubulysin. 
 
Figure 50. Structure of pretubulysin118.
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Chapter 2 
 
Chemical Literature Review 
 
2.1 Benzimidazoles 
2.1.1 Benzimidazole core: An overview 
Numerous reviews of benzimidazoles exist.144-150  The most comprehensive review is by 
Grimmett151.  1H-Benzimidazole (47) is a planar, bicyclic molecule with a benzene ring 
fused at the 4- and 5-atoms of imidazole.  Their biological activity has also been 
reviewed.149, 150  It exists as a pair of tautomers 47 and 48 (Scheme 1).  N-alkylation 
effectively fixes the tautomeric equilibrium and as a result differentiates the 4/7 and 5/6 
positions of the substituents on the 6-membered carbocyclic ring.  
 
Scheme 1. Benzimidazole numbering and tautomerism. 
 
2.1.2 Physical properties 
Benzimidazoles are generally high-melting solids (1H-benzimidazole mp 170oC.151  The 
N-substituted benzimidazoles have lower melting and boiling points due to the fewer 
61 
resonance forms accessible than for the 1 NH equivalents.  Benzimidazoles have lower 
water solubility compared to imidazoles due to the carbocyclic ring.  Benzimidazoles 
have high thermal stability, high aromatic stability, and are resistant to acids, bases, heat, 
oxidation and reduction.151 
Benzimidazoles with an annular NH exhibit fast protoropic tautomerism.  The exchange 
is so fast that only one species is observable on the NMR timescale at ordinary 
temperatures; 4(7)- and 5(6)- substituted benzimidazoles appear to be a single compound 
rather than a tautomeric mixture until the NH proton is replaced by an alkyl or other 
group. 
Benzimidazoles are amphoteric, forming salts with both acids and bases.  The protonated 
charged benzimidazole 49 loses a proton to generate the uncharged species 47 (Scheme 
2).  Unsubstiuted benzimidazole has a pKa = 5.53 for the equilibrium between 49 and 47.  
This weak basicity correlates with low nucleophilicity.  Substitution on the 5-membered 
ring have a greater effect than substitution on the 6-membered carbocyclic ring.  
Electron-donating substituents raise the pKa and basicity of the ring nitrogen (2-Me 
benzimidazole, pKa = 6.19; 4-Me benzimidazole, pKa = 5.67) while electron-
withdrawing substituents lower the pKa and the basicity of the ring nitrogen (4-nitro 
benzimidazole, pKa = 3.33).    The second deprotonation occurs at pKa of 13.22 and is 
relevant only for benzimidazoles with an exchangeable NH proton.  Thus the 
benzimidazole cores presented in these studies is not anticipated to be protonated at 
physiological pH.  This is consistent with the proposed role of the 3-nitrogen activity as a 
proton-acceptor (lone-pair donor). 
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Scheme 2. Protonation and deprotonation of benzimidazoles. 
 
2.1.3 Synthesis of benzimidazoles 
Different approaches have been used for the synthesis of benzimidazoles: ring closure 
reactions, ring transformation, aromatization from partially reuced systems and 
substituent modification on the preformed benzimidazole. Ring transformation and 
aromatization reactions are not common for the synthesis of benzimidazoles.151 
 
2.1.3.1 Ring-closure reactions150, 151 
Ring formation is the most versatile method for the synthesis of benzimidazoles, and is 
commonly employed.  The most common ring formation is from a precursor diamine, 
which can also be generated in situ from an ortho-nitro aniline. The 2-carbon of the 
benzimidazole ring is most commonly derived from a carboxylic acid, acid chloride, or 
ester.  Subsequent dehydration typically under acidic conditions generates the fully 
aromatized benzimidazole ring system (Scheme 3) 
 
Scheme 3. Synthesis of benzimidazole by formation of 1-2 and 2-3 bonds.151 
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2.1.3.2 Substituent modification reactions150, 151 
Nucleophilic aromatic substitutions occur at 2-position.  Thus, the benzimidazoles can 
easily undergo 2-amination reactions.  The electrophilic substitution occurs most readily 
in the benzene ring, commonly in the 5(6)-position.  Typically, a mixture of products 
resulted.  However, the substituents already present in the molecule can modify the usual 
substitution orientation.  The substrates are more reactive if they are present as anions 
(either as deprotonated on nitrogen by a base, or as C-lithio compounds, for example 
deprotonation of 1 N-methyl benzimidazole occurs exclusively at the 2-carbon). 
 
2.1.3.3 Synthesis of benzimidazoles with variations at 1, 4, 6-positions 
Variations at the 1, 4, and 6 positions of benzimidazole were the desired SAR points 
based on the (R)-Roscovitine core. Different synthetic strategies are presented in this 
section. 
 
N-1 Substituted benzimidazoles 
The synthesis of N-1-substituted 2-trichloromethylbenzimidazoles was reported by 
Holen, et al.152 (Scheme 4).  The reaction of N-Substituted diaminoarene 54 and methyl 
trichloroacetimidate 55 using protic solvent gave benzimidazole 56.  Unfortunately, this 
precursor is symmetric.  Utilization of this strategy would generate two regioisomeric 
structures: both the 4,6-disubstituted system and the 5,7-disubstituted system. 
 
Scheme 4. Synthesis of 1-methyl-2-(trichloromethyl)-1H-benzo[d]imidazole.152 
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The synthesis of N-1 substituted benzimidazole 59 using N-substituted diaminoarene 58 
and formic acid and ethyl ortho-formate was reported by Leonard, et al.153 (Scheme 5).  
N-substituted diaminoarene 58 was obtained by reduction of the compound 57 with 
Raney Nickel in DMF and ammonia.  Interestingly, the orientation was provided during 
the nitration to form compound 57.  Unfortunately, this strategy would not give the 
desired substitutent pattern. 
Scheme 5. Reaction of N-substituted diaminoarene with formic acid.153 
 
Another strategy for the synthesis of N-1 substituted benzimidazoles was reported by 
Suschitzky, et al.154 (Scheme 6).  Acylation of 60 with acetic anhydride followed by 
heating with phosphoric acid gave 1,2-disubstituted benzimidazole 62.  The symmetrical 
nature of 60 led to a single product, our desired system required a capacity for 
desymmetrization. 
 
Scheme 6. Synthesis of 1,2-disubstituted benzimidazole 62.154 
 
1,4,6-trisubstituted benzimidazoles  
The synthesis of properly tri-substituted 1,4,6-benzimidazoles120 utilized in this thesis 
followed a strategy published previously by our group (Scheme 7).  Modifications to this 
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approach are presented in the chemical discussion portion of this thesis.  The success of 
this strategy was based on the observation that the meta-amine of 64 was more 
nucleophilic than the ortho-amine of 64.  This effect is a combination of  both resonance 
and electroinductive effects. Regioselectivity for the reductive alkylation was 
confirmed120 by x-ray crystallographic analysis on the product 66. 
 
Scheme 7. Synthesis of 1,4,6-trisubstituted benzimidazole 66.120 
 
 
2.2 Diphenylamines 
Multiple synthetic methods exist for the formation of the diphenylamine compounds 
122a-122g.  Traditional methods include coupling of an amine with an aryl chloride 
either by direct proton abstraction from the aniline followed by nucleophilic attack into 
the halogen-bearing ring resulting in the loss of the halogen, or by in situ formation of an 
aryl cuprate via an Ullmann coupling strategy155 (Scheme 8), or by more modern 
palladium catalyzed Buchwald coupling strategies156 (Scheme 9). 
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Scheme 8. Synthesis of diphenylamines by Ullmann Coupling.155 
 
Scheme 9. Synthesis of diphenylamines using Buchwald Coupling.156 
 
Our series of compounds was designed based on a prior SAR addressing MEK-1 active 
compounds and utilized strategies shown to be effective for this class of compounds.  The 
significantly electron-deficient carboxyl-bearing ring has been utilized as the electrophile 
and the aniline anion has been prepared as either the lithium or sodium anion130 (Scheme 
10). 
 
Scheme 10. Synthesis of diphenylamine 75.130 
 
The Davis group130 analyzed the practical utility of the lithium cation to direct the 
regioselective addition of the aniline anion into the electrophilic aniline ring and 
identified that the lithium anion preferentially added to the ortho- position (relative to the 
carboxylic acid). The lithium cation was presented as important for controlling 
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regioselective attack and directing the aniline anion preferentially to the position ortho to 
the carboxylic acid.  Coordination of the lithium cation with the carboxyl group and the 
leaving group were postulated as facilitating both attack and elimination, resulting in 
preferential ortho substitution.130 
 
2.3 Tubulysins 
Various approaches have been used for the total synthesis of tubulysins.114, 116, 136, 157  The 
syntheses of tubulysin-related structures by the Ellman114, Fecik116, Wipf136 groups have 
utilized a carboxyl to amine assembly strategy with sequential assembly of each peptide 
bond from the right to left.  Our focus is on modifying the amine of the Tuv portion and 
as such we would prefer a more convergent synthesis according to the following 
disconnection (Scheme 11).   
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Scheme 11. Disconnection approach for synthesis of pretubulysin analogs. 
 
This strategy includes late-stage addition of side-chain variants with alkylation fragment 
D, utilization of racemic N-methyl pipecolinic acid with subsequent isolation from the 
diasteremeric mixture of the dipeptide formed from (S)-Ile, simplification of the Tuv 
portion to pre-tubuvaline, and a 1,3-relay of chirality to generate the Tup fragment using 
modification of the Wipf protocol.  This thesis describes early studies on the synthesis of 
the dipeptide A and a repeat of the synthesis of the Tup fragment C.  This repeat of the 
synthesis provided two significant contributions: (1) 5 g of essential synthetic 
intermediate C; (2) validation of the synthetic protocol. 
A synopsis of the known synthetic strategies of the Tup portion is presented. 
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Synthesis by Höfle, et al.157  
The γ-amino ester 77 was synthesized from the α-amino alcohol using Swern oxidation 
followed by the Wittig reaction.  After catalytic reduction, Evan’s oxazolidinone 
chemistry was used to install the methyl group with the correct stereochemistry (Scheme 
12). 
BocHN CH2OH
1. swern oxidation
2. Wittig reaction BocHN
OEt
O
BocHN
N
O
O
O
BocHN
OCH2CH2TMS
O
76 77
78 79  
Scheme 12. Synthesis of Tup portion by Höfle, et al.157 
 
This strategy requires a full stoichiometric equivalent of chiral auxiliary on a previously 
chiral substrate. 
Synthesis by Wipf136 
In Wipf’s synthesis, the diastereomers were obtained in the ratio of 3:1, which were 
converted to alcohol and then isolated as the TBS silyl ether (Scheme 13).  Assignment 
of the stereochemistry was conducted to know compound 82. 
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Scheme 13. Synthesis of Tup portion by Wipf.136 
 
The Fecik116 and Ellman114 groups followed Wipf’s strategy136 for their assembly of 88. 
The Friestad group158 assembled the γ-amino acid structure using a Mn3+ mediated free 
radical Mannich reaction utilizing a stoichiometric chiral precursor 86 to give a 
diastereomeric ratio > 98:2 when condensed with the chiral iodide 87 (Scheme 14). 
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Scheme 14. Synthesis of γ-amino acid structure using a Mn3+-mediated free-radical Mannich 
reaction.158 
 
Notably, this strategy required the 2-methyl to be installed in enantiopure form prior to 
condensation with the chiral oxazolidine.  Given the goal of one-point variants from 
pretubulysin, we chose to follow the Wipf protocol with appropriate variations employed 
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to facilitate the synthesis. Notably we were able to isolate the acid 154a in enantiopure 
form and obtain an x-ray crystal of this compound. 
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Chapter 3 
 
Statement of the Problem 
 
3.1 CDK-5 
Goal of the research: 
To synthesize novel potent and selective inhibitors of CDK-5 and to explore a new 
scaffold that would retain the hydrogen-bonding interactions displayed by (R)-
Roscovitine with CDK-5 while optimizing hydrophobic interactions to increase potency 
and selectivity for CDK-5 over CDK-2 or related kinases. 
Hypothesis: 
Structural variation from the purine scaffold of (R)-Roscovitine to a benzimidazole 
scaffold could retain essential H-bonding patterns identified in the X-ray structure of 
Roscovitine/CDK-5/p25 and permit exploration of interactions unique to the surface of 
the enzyme CDK-5 versus CDK-2.  C-6 variations could explore the solvent-exposed 
ribose binding pocket and C-4 variations could explore the region of CDK-5/p25 known 
to interact with the benzyl moiety of Roscovitine. 
Specific goals:  
To synthesize and test a series of compounds designed on structure-assisted and Topliss 
analysis to explore the utility of variations at the 4-and 6-positions of the benzimidazole 
ring. 
1. Target compounds of the C6-O linked benzimidazole series. 
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The C6-O linked benzimidazole series was designed to replace the exocyclic C2-NH-2-
butan-1-ol moiety of roscovitine and to explore the ribose-binding portion of the ATP-
binding pocket of CDK-5.  
Analysis of the interaction between roscovitine and CDK-5 reveal the following 
interactions (Figure 51): 
Hydrophobic interactions including the interaction of the isopropyl moiety with a 
hydrophobic cleft formed by the phenyl of Phe80, the isopropyl of Val84, and the alkyl 
portion of Lys33.  The flat adenine core is retained within a very hydrophobic pocket 
composed of a top surface (Ile10, Val18, and Phe82) and a bottom surface (Val64, 
Cys83, Leu133, and Ala143).  The ethyl side chain forms a hydrophobic interaction with 
the side chains of Gly11 and Val18.  The benzyl portion of roscovitine experiences 
hydrophobic interactions with the side chains of Phe82, Ile10, and the alkyl portion of 
Lys89. 
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Hydrogen bonding interactions include the H-bond donor-acceptor pair to the backbone 
amide of Cys82 (2.81 Å and 3.25 Å respectively), and the primary hydroxyl acts as a 
hydrogen bond donor to the backbone acyl of Gln130 (2.13 Å). 
 
 
 
Figure 51. Analysis of the interaction between roscovitine and CDK-5 (PDB ID: 1UNL). 
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This suggests that replacement of purine with benzimidazole and the exocylic NH at C-2 
with O (Figure 52) would not only retain the key H-bonding pattern but might result in 
increased selectivity as the exocyclic NH at C-2 forms an important H-bond with Glu131 
of CDK-2.   
These compounds were constructed in MOE and docked using MOEdock into the 
putative ATP binding site of CDK-5 (1UNL). These conformations were initially brought 
to a local energy minimum (MMF94) and then the receptor/ligand complex was brought 
to an overall local energy minima retaining the backbone conformation of 1UNL (Amber 
98). The ether analog (94a) bound to CDK-5/p25 is shown in Figure 52. The terminal 
hydroxyl group of ether analog is shown interacting with Asp86 (Mg++ binding region of 
the polar ribose / triphosphate domain). 
 
 
Figure 52. Interaction of ether analog 94a with CDK-5/p25. 
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2. Target compounds of the C4-benzamide and phenylacetamide benzimidazoles. 
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The C4-benzamide and phenylacetamide series were based on very potent and selective 
benzamide and phenylacetamide variations explored by the Helal group using the 2-
aminothiazole scaffold.  The phenyl acetamide moiety was suggested as interacting in the 
same region as the benzyl of roscovitine.  We anticipated that incorporation of the 
benzamide or phenylacyl variation at C4 position of the benzimidazole core would be 
synthetically tractable while retaining the proposed hydrogen bond and hydrophobic 
interactions from the Helal series.  Factors encouraging this strategy included that the 
orientation of the amide in its enzyme-free low-energy conformation. This conformation 
was very similar to the orientation presented during docking the compound in to the 
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active site of CDK-5.  This suggested that the benzamides might bind in a preferred low 
energy conformation.  Furthermore, the synthetic tractability was favorable for evaluating 
any secondary contributions toward activity. 
The benzamide is shown docked into MOE (Figure 53).  The benzamide was generated 
with MOE's ligand generator with several rotational isomers arising from the benzamide. 
The lowest energy compound, shown was docked using MOE dock and then scored using 
the London dG protocol.  Representative interactions are shown below. 
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Figure 53. Ligand interaction map of 4-benzamide in CDK-5/p25 model derived from 
1UHL. 
 
Results: 
The C6-O linked benzimidazoles were either less potent than roscovitine or inactive.  Of 
the compounds prepared in this series, only the 2-(butane-1,2-diol ether) displayed 
appreciable activity.  The absolute requirement for an hydrogen bond donor four heavy 
atoms away from the benzimidazole core is consistent with binding at the proposed site, 
but clearly more analysis of the scoring function is required.  The C4-benzamides and 
phenylacetamides were inactive in the isolated CDK-5 assay. 
 
3.2 MEK-5 
 
Goal of the Research: 
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To develop new scaffolds and inhibitors to permit a better characterization of the 
functional role of MEK-5 both in vitro and in vivo. 
 
Hypothesis: 
MEK-5 is a selective activator of ERK-5 and does not activate any other MAPK.  MEK-5 
is upregulated in tumor cells and activated by mitogens including the phorbol esters and 
inhibition of this enzyme might have potential as an anti-cancer target.  The use of a 
variety of medicinal chemistry strategies both at the ATP site and a proposed allosteric 
site on MEK-5 could assist in developing selective and potent in vivo inhibitors of MEK-
5. 
Variation is anticipated to arise from different chemical properties for each unique 
compound as well as from each unique compounds profile of kinase selectivity.  But 
most importantly, it has been demonstrated that there are multiple ways to inhibit MEKs: 
at the ATP-binding site, at the ATP site with a type II (DFG-out) confirmation, or at an 
allosteric site proximal to the ATP-associated magnesium atom. 
Specific goals: 
The chemical categories examined included compounds from the following chemical 
classes:  benzimidazoles, diphenylamines, flavones, and ortho-carboxyamides. 
As mentioned previously, each class of compounds is anticipated to have different 
physical/chemical properties and may well display unique mechanisms for the inhibition 
of MEK-5.  Although it is not known at this time, one manner of inhibiting MEK-5 
(ATP-competitive, ATP-uncompetitive) may be a more useful strategy in vivo than 
another type of inhibition. 
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1. Target compounds of the benzimidazole series 
 
 
Rationale: 
For the benzimidazole series, this strategy was a calculated guess. CDK and MEK are 
both Ser/Thr kinases and there are marked similarities in the ATP-binding region.  
Clearly both categories bind ATP and phosphorylate the substrate peptidyl serine.  Also 
known MEK-1/2 and 5 inhibitors were originally derived from CDK-2 inhibitors.  
Comparison of the active sites indicate similar auxiliary hydrophobic binding regions as 
well.  Side chain variations at the C-6 position of the benzimidazole were different than 
the trends identified for CDK-5 and were proposed to mimic phosphate triester side chain 
of ATP.  This strategy had previously been successfully employed for the development of 
the tyrosine receptor kinase inhibitors such as erlotinib, gefitinib, and EKB569. 
 
2. Target compounds of the diphenylamine series 
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Rationale: 
For the diphenylamine series, these compounds were based on clear literature 
precedence.  New compounds were proposed as MEK-5 allosteric inhibitors derived from 
the known MEK-1/2 inhibitor PD318088 and our homology model.  These compounds 
explore the glycine-rich loop and its interaction with the Mg++ binding portion of the 
ATP-binding pocket. 
 
3. Target compounds of the flavone series 
 
Rationale: 
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For the flavones, this was based on the idea of hybrid structures.  The flavone PD 098059 
is a known MEK-1/2 and 5 inhibitor.  A structurally related but different flavone, 
flavopiridol, is a well-known ATP-competitive inhibitor (Figure 1).  Hybrid structures of 
the flavones PD 098059 and flavopiridol were proposed as MEK-5 inhibitors. 
O
O
NH2
O
O
OH
HO
O
N
H OH
Cl
Flavopiridol
PD 098059
 
Figure 1: Lead compounds. 
 
4. Target compounds of the ortho-carboxyamide series 
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Rationale: 
For the ortho-carboxyamides, these compounds were based on the MEK-1 structure of 
1S9J in the allosteric site of MEK.  These compounds were proposed to assess the quality 
of the initial homology model.  Similar side chains were used between the ortho-
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carboxyamide and diphenylamine series to compare the two scaffolds and test the validity 
of the initial homology model.  These and subsequent compounds (not presented) explore 
the homology model validity by targeting unique amino acid interactions specific for 
MEK-5 contrasted with MEK-1 as proposed by the homology model. 
Results: 
For the design and synthesis of MEK-5 inhibitors, medicinal chemistry strategies 
included: an initial lead and analog design, modification of known MEK-1/2 inhibitors 
including both allosteric and ATP-site inhibitors, and computer-assisted design based on 
a homology model. 
Compound 119b was identified as a selective inhibitor of MEK-5 mediated 
phosphorylation of ERK-5 in HEK cells. The diphenylamine, flavones and ortho-
carboxyamide compounds synthesized exhibited non-selective inhibition of ERK-1/ 2, 
and 5 phosphorylation.  A second iteration of compounds is underway (not presented). 
 
3.3 Tubulysins 
 
Goal of the Research: 
To synthesize compounds that will permit an analysis of structural variations from 
pretubulysin that can retain the desired properties of tubulysin (anti-tumor properties and 
tubulin depolymerization) and reduce the undesired metabolic instabilities of the parent 
molecule. 
Hypothesis: 
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Tubulysin interferes with the dynamics of tubulin and has been shown to reduce tumor 
growth at sub-nanomolar levels.  Pretubulysin, lacking the chemically labile N,O-acetal 
and the stereogenic 7- acetate group was identified and found to be only 5 times less 
potent than tubulysin D.  Alkyl and amide substitutions for the N,O acylhemiaminal are 
proposed that might provide retained potency, less chemical instability, and greater 
structural simplicity. 
Specific goals: 
To reach this goal, practical synthesis of the component parts was required for assembly:  
1. Establishment of an efficient synthesis of the Mep-Ile diastereomer dipeptide 
fragment. 
 
2. Establishment of an efficient synthesis of the Tup fragment. 
 
 
Results: 
Simple, reliable and large scale synthesis of Mep-Ile dipeptide (3 g), and Tup (5.2 g) 
portions of Tubulysin was achieved. 
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Chapter 4 
 
Chemical Discussion 
 
4.1 CDK-5 
4.1.1 Benzimidazole core 
Synthesis of the benzimidazole core began with commercially available 4-methoxy-2,6-
dinitroaniline 63, which was converted to compound 64 by mono reduction of the nitro 
group by ammonium sulfide (Zinnin reduction)119.  Reductive alkylation of 64 with 
sodium triformylborohydride followed by cyclization in presence of concentrated 
hydrochloric acid and formic acid gave 1-isopropyl benzimidazole 66 (Scheme 15).  A 
crystal structure of 66 confirmed that desired regioisomer was isolated120.  Although this 
procedure gave the desired product, the isolated yield was relatively low (50%).  
NO2
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Scheme 15. Initial synthesis of 1-isopropyl benzimidazole 66. 
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A modification of the reductive alkylation of 64 then cyclization to 66 (Scheme 16) 
which utilized commercially available sodium triacetoxyborohydride and trace amounts 
of butylated hydroxytoluene (BHT) provided a reliable synthesis of 66 with improved 
yield.  The role of BHT is to suppress undesired radical oxidation of 65 prior to 
cyclization. Once the benzimidazole core of 66 was formed, the compound was stable. 
 
Scheme 16. Modified synthesis of 1-isopropyl benzimidazole 66. 
 
1-Cyclopentyl benzimidazole 90 was synthesized in an analogous manner (Scheme 17).  
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Scheme 17. Synthesis of 1-cyclopentyl benzimidazole 90. 
 
4.1.2 C6-O linked benzimidazoles 
Deprotection of the 6-methoxy group of benzimidazole 66 with 48% HBr (aq) under 
microwave conditions (300 Watt, 120 oC, 2.5 h) gave 6-hydroxy benzimidazole 91 which 
was used as the precursor for a divergent SAR strategy that included Mitsunobu coupling 
(Scheme 18) or could be used to give the corresponding 6-triflate presented elsewhere122.  
 
Scheme 18. Synthesis of 6-hydroxy benzimidazole 91. 
 
6-Hydroxy benzimidazole 91 was utilized for Mitsunobu coupling with various alcohols 
to form the C6-O linked benzimidazoles 92a-92d (Scheme 19).  Addition of diisopropyl 
azodicarboxylate (DIAD) in two portions gave better yield.  A probable reason is the 
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instability of the DIAD of generated electrophile in the reaction mixture. Addition in two 
portions permitted complete consumption of first portion of DIAD before second portion 
was added effectively prolonging the half-life of the generated electrophile.  This strategy 
provided an improved yield.  Isolation of the Mitsunobu coupling product was 
problematic; the product co-eluted with triphenylphosphine oxide.  Consequently, the 
crude product was carried on directly to the catalytic hydrogenation step and then 
characterization was conducted on the more readily isolated reduced product.  This 
strategy was employed for both the 1-isopropyl series (Scheme 19) and the 1-cyclopentyl 
series (Scheme 20).  
 
Scheme 19. Synthesis of intermediate 92a-92d by Mitsunobu coupling. 
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Scheme 20. Synthesis of intermediate 92e by Mitsunobu coupling. 
 
Reduction of the 4-nitro group to the corresponding 4-amine with in situ deprotection of 
the TBDMS protective group with concentrated hydrochloric acid gave 93a,e.  
Subsequent reductive alkylation with commercially available substituted benzaldehydes 
gave compounds 94a,e,f (Scheme 21). 
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Scheme 21. Synthesis of 94a,e,f. 
 
Some of the alcohols required for Mitsunobu coupling were not commercially available 
and were prepared as described below.  Amino alcohol 96 was prepared from 
commercially available racemic epoxide 95 in one step with N,N-dimethylamine for a 
yield of 88% (Scheme 22).124 
91 
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Scheme 22. Synthesis of 96. 
 
Alcohol 98 was synthesized from the commercially available 4-hydroxymethyl piperidine 
97 via the Eschweiler Clarke alkylation123 in 99% yield (Scheme 23). 
 
Scheme 23. Synthesis of 98. 
 
Initially, the protection strategy for the primary alcohol employed TMSCl to give the 
TMS ether.  But low yields and problematic isolation of product recommended 
modification of the protective group.  The more stable TBDMS group was used for 
protection of the primary alcohol121.  This protective group was hydrolytically more 
stable and provided improved yield (Scheme 24). 
 
 
 
Scheme 24. TBDMS protection of alcohol 99. 
Reagents Solvent Reaction Conditions Yield/Comments 
TMSCl, TEA DCM 12 h, Room temp. 20% yield, impure product. 
TBDMSCl, Imidazole DMF 12 h, Room temp. 60% yield 
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Catalytic hydrogenation of 92b,c,d to 93b,c,d proceeded smoothly. The reductive 
alkylation of 93b,c gave 94b,c in acceptable yield (Scheme 25).   
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Scheme 25. Synthesis of 94b,c. 
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Alcohols carrying an N-Boc protected amine were deprotected in the final reductive 
alkylation step.  Compound 93d underwent reductive alkylation followed by deprotection 
of the Boc group to give 94d (Scheme 26). 
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Scheme 26. Synthesis of 94d. 
 
Initially, 1-methylpiperidine alcohol 98 was used for Mitsunobu coupling in an attempt to 
prepare 92g (Scheme 27).  However, isolation of 92g was not successful due to 
problematic chromatographic isolation.  
 
Scheme 27. Mitsunobu coupling of 91 with 98. 
 
A different strategy was used for synthesis of 94g (Scheme 28).  Deprotection of the Boc 
group of 92d followed by N-methylation by the Eschweiler Clarke methylation gave 93g 
effectively. Catalytic reduction of the nitro group then reductive alkylation gave 94g. 
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Scheme 28. Synthesis of 94g. 
 
4.1.3 C-4 benzamides 
The benzimidazole 91 underwent Mitsunobu coupling followed by catalytic 
hydrogenation to give the 6-O linked benzimidazole 103.  Unlike synthesis of compound 
93a (Scheme 19, 21; Page 88, 90), the TBDMS group was retained to avoid ester 
formation in presence of benzoyl chlorides (Scheme 29).  
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Scheme 29. Synthesis of benzimidazole 103. 
 
Initially, several methods were surveyed for acylation of the benzimidazole 103.  Classic 
Schotten-Baumann coupling125 in the presence of potassium carbonate was not 
successful, and starting material was recovered (Scheme 30).  
 
Scheme 30. Amide coupling using Schotten -Baumann reaction conditions. 
 
Acylation with the acid chloride in presence of catalytic DMAP gave a mixture of both 
the desired monobenzamide 104a, along with the undesired dibenzamide 105 (Scheme 
31).  This acylation strategy represented too aggressive of an acylation system. 
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Scheme 31. Amide coupling in presence of catalytic DMAP. 
 
Coupling of 103 with one equivalent of the acid chloride in presence of triethylamine in 
THF gave benzamides 104a-104p with a minor amount of dibenzoylation product.  
Deprotection of the TBDMS group with concentrated hydrochloric acid to unmask the 
corresponding hydroxyl group gave compounds 105a-105p as the hydrochloride salts 
(Scheme 32).  The side product, TBS-OH, could be triturated away from the ammonium 
hydrochloride salt with hexanes. 
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Scheme 32. Synthesis of compounds 105a-105p. 
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Compound 105q was synthesized in analogous manner using naphthoyl chloride 
(Scheme 33). 
 
Scheme 33. Synthesis of compound 105q. 
 
The nitro-benzamides, 105h-105j were subjected to catalytic hydrogenation with 
palladium on carbon and 50 psi hydrogen to reduce the nitro group to the corresponding 
amine, which was then isolated as the hydrochloride salt, 105r-105t (Scheme 34). Both 
the nitro and amine compounds were envisioned as being useful for the benzamide SAR 
studies. 
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Scheme 34. Synthesis of compounds 105r - 105t. 
 
4.1.4 C-4 phenylacetamides 
Initially, coupling strategies to give the phenylacetamides 108a, 108b included 
triethylamine as the base (Scheme 35).  This reaction was not successful; 103 was 
recovered, yet the acid chloride was consumed.  The most probable reason was the 
generation of a ketene from phenylacetyl chloride without subsequent aromatic amine 
acylation. 
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Scheme 35. Initial method for synthesis of phenylacetamide 108a.  
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To avoid ketene formation, acylation with phenylacetyl chloride and a weaker base, solid 
sodium bicarbonate, gave the phenylacetamides 108a, 108b cleanly without ketene 
formation. Deprotection of the TBDMS group gave compounds 109a, 109b (Scheme 36).  
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Scheme 36. Synthesis of phenylacetamides 109a, 109b. 
 
Synthesis of compound 108a, o-fluoro phenylacetyl chloride 107b was achieved from its 
corresponding o-fluoro phenyl acetic acid 110 with oxalyl chloride and catalytic 
dimethylformamide in dichloromethane (Scheme 37). 
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Scheme 37. Synthesis of o-fluoro-phenylacetyl chloride 107b. 
 
4.2 MEK-5 
4.2.1 C6-O alkoxy substitution 
Two different strategies were examined and ultimately method B was used for the 
synthesis of the required C6-O alkoxy benzimidazoles. 
Method A (Scheme 38): TBDMS protection of 6-hydroxy-benzimidazole 91 gave the 
protected aryl silyl ether 111.  Catalytic hydrogenation of 111 reduced the nitro group to 
the corresponding amine 112 which further underwent reductive alkylation to give 
compound 113.  Deprotection of the TBDMS group with hydrochloric acid/ethanol gave 
114 as corresponding hydrochloride salt.  Mitsunobu coupling was tried on compound 
114 with several alcohols as shown in Table 3.  Alcohol 100b was used because it 
underwent Mitsunobu coupling previously with the 6-hydroxy benzimidazole 91.  
However, this reaction was not successful in the presence of a 4-benzyl amino group.  
This strategy was tried initially as it was easier to prepare different substitutions on the 
phenol from a single common precursor, 114, to give the target compounds in a single 
step.  All the reactions upto compound 114 were simple, reliable and high yielding with 
the exception of the Mitsunobu coupling.  This step was regretfully, problematic. 
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Scheme 38. C6-O alkoxy substitution by Method A. 
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Table 3. Mitsunobu coupling of 114 with different alcohols. 
 
Method B (Scheme 39): Alternatively, a modification of this strategy was used with 4-
nitro-6-hydroxy benzimidazole 91 as the substrate for the Mitsunobu coupling followed 
by catalytic hydrogenation to give 118a-h.  A likely reason for the success of this strategy 
is that the electron withdrawing effect of the nitro group increased the acidity of the 
phenol.  It is well established that increasing the acidity of the phenolic group facilitates 
Mitsunobu coupling126.  Reductive alkylation then gave 119a-h.  This strategy worked 
very well and reactions gave higher yields but this strategy required three steps for 
synthesis of each target compound because the synthetic point of variation occurred 
sooner.  As a result multiple parallel reductive benzylations were required.  Compounds 
119a,c were prepared as the more easily isolated oxalate salts for characterization 
purposes.  Compound 119h was synthesized as its hydrochloride salt.  
 
Mitsunobu coupling 
alcohol Solvent Result 
  
THF 
No reaction, starting 
material recovered 
  
DMF 
No reaction, starting 
material recovered 
n-butanol THF No reaction, starting material recovered 
n-butanol DMF No reaction, starting material recovered 
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Scheme 39. Synthesis of compounds 119a-d.  
 
4.2.2 C6-O alkyl substitution 
Initially, Mitsunobu coupling was tried for precursor 91 with different alcohols.  
However, good yields were not always obtained.  Alkylation was also tried with 
NaHMDS as the base but gave equally low yields (Scheme 40).  Alternatively, alkylation 
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of 91 with different alkyl iodides utilizing sodium hydride as the base and N,N-
dimethylformamide as the solvent gave 117e-h with acceptable yields (Scheme 41).  
Isolation of the C-4 nitro benzimidazoles 117e-h was possible.  This contrasts to the 
Mitsunobu coupling strategy where the crude product was carried on to the next step due 
to difficulty with isolation; compounds from this route required isolation and 
characterization after catalytic hydrogenation.  These simple alkylation reactions proved 
quite reliable.  Compounds 117e-h underwent catalytic hydrogenation and then reductive 
alkylation to give compounds 119e-h.  
 
 
Precursor Reagents Solvent Reaction Conditions Yield 
Ethanol Ph3P, DIAD DMF Room temp. 5% yield 
Propanol Ph3P, DIAD DMF Room temp. 7% yield 
CH3CH2I NaHMDS THF Room temp. 15% yield 
CH3CH2CH2I NaHMDS THF Room temp. 20% yield 
 
Scheme 40: C6-O coupling of 91 with alcohols and alkyl iodides. 
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Scheme 41. Synthesis of 119e-h. 
 
4.2.3 Diphenylamines 
Literature precedent had conducted an extensive analysis of the appropriate base for this 
conversion and the use of lithium amide as the base was crucial to successful synthesis of 
this series of compounds.127-130 
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Diphenylamine 75 has been synthesized in the literature130 by coupling aniline 73 with 
compound 74 using lithium amide as the base (Scheme 42).  The lithium cation was 
presented as important for controlling regioselective attack and directing the aniline anion 
preferentially to the position ortho to the carboxylic acid.  Coordination of the lithium 
cation with the carboxyl group and the leaving group were postulated as facilitating both 
attack and elimination, resulting in preferential ortho substitution. 131, 132   The 
diphenylamine 75 was used as a precursor in the synthesis for all amido-diphenylamines.  
 
Scheme 42. Synthesis of diphenylamine 75. 
 
Initially, several methods were examined for amide coupling with carboxy-
diphenylamine 75 (Scheme 43).  Different amines and different reagents were used, but 
carbo-diimide or substituted-triazine amide couplings were unsuccessful. 
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Precursor 
amine 
Reagents Solvent Reaction 
Conditions 
Comments 
NH3 EDCI, DMAP EtOH 25 oC, 12 h No reaction, starting 
material recovered. 
 EDCI, DMAP EtOH 25 oC, 12 h No reaction, starting 
material recovered. 
NH3 
 
          , NMP THF 25 oC, 12 h No reaction, starting 
material recovered. 
            , NMP THF 25 oC, 12 h No reaction, starting 
material recovered. 
 
Scheme 43. Summary of methods used for amide formation. 
 
Ultimately conversion of the ortho-carboxy-diphenylamine 75 to the more reactive acid 
chloride 120, then attack by the amine was found to work and gave acceptable yields (55-
70%).  The acid chloride was generated in situ, and used directly for amide coupling 
(Scheme 44).  The amides 122a-d were obtained with a 60-70% yield.  A possible 
explanation for the lack of reactivity of 75 in traditional amide couplings was the severe 
electron deficiency of the aromatic carboxy group due to the electron withdrawing 
fluorine atoms.  This clearly would have hindered acyl activation.  Fortunately, this same 
effect facilitates nucleophilic attack by the amine if the carboxylic acid has been 
activated, so once the acid chloride was formed, nucleophilic attack by the amine was 
facile.   
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Scheme 44. Synthesis of 122a-d. 
 
Other amides 122e-g were synthesized by coupling of the acid chloride 120 with different 
amines 124a-c (Scheme 45).  Amine scaffolds with oxygen-bearing groups with 
exchangeable protons required transient protection with TMSCl (Scheme 46).  In situ 
deprotection of the TMS groups with citric acid/MeOH directly gave compounds 122e-g. 
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Scheme 45. Synthesis of 122e-g. 
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Scheme 46. Synthesis of 124a-c. 
 
4.2.4 Flavones 
Two different strategies were used for the synthesis of flavones.  Method A employed 
traditional LiHMDS condensation with a carbamate protective group strategy.  Method B 
utilized a phase-transfer catalyst condensation to the β-diketone and an aromatic nitro 
group as a latentiated aniline moiety. 
Method A (Scheme 47): First, the amino group of compound 125 was protected with 
CBZCl, followed by conversion of carboxylic acid to acid chloride 126.  Then, the 
lithium dianion intermediate 128 was generated with the commercially available 
hydroxyacetophenone 127 and 2 equivalents of 1M LiHMDS in THF according to a 
protocol similar to Cushman133.  Condensation of the dianion 128 with the acid chloride 
126, afforded the β-diketone intermediate 129 after Baker-Venkataraman rearrangement.  
Intermediate 129 was used directly and cyclized to the flavone 130 (11% yield for two 
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steps).  Yields compared favorably with prior literature133 yields.  Finally, deprotection of 
the CBZ group under 1 atm hydrogen and in the presence of catalytic Pd-C, afforded the 
flavone 31 in 42% yield.  
 
Scheme 47. Synthesis of flavone 31 by Method A. 
 
Protective groups other than CBZCl groups were examined, but in all examined cases 
deprotection was problematic (Scheme 48).  
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Protective group Formation Attempted deprotection Result 
 Na2CO3, THF, 
 
 
1.)  Potassium tert-butoxide, 
potassium hydroxide, 
water/THF, 100 oC. 
2.)  LiOH, water/THF, 100 oC. 
 
No deprotection, 
starting material 
recovered. 
 
 
 
Triethylamine, 
DCM, 
 LiOH, water/THF, 100 
oC. 
No deprotection, 
starting material 
recovered. 
 
Scheme 48. Protecting group strategies for amino flavone. 
 
Method B (Scheme 49): The utility of a phase transfer catalyst variant134 of the 
condensation, then Baker-Venkataraman rearrangement was examined.  
Hydroxyacetophenones 131a, 131b were coupled to the acid chloride 136 using 
tetrabutylammonium hydrogen sulfate as the phase-transfer catalyst with a two-phase 
system of aqueous potassium carbonate and toluene, to afford the β-diketone 
intermediates 132a, 132b, respectively.  These intermediates 132a, 132b were used 
directly without purification, analogous to prior cyclization, to give flavones 133a and 
133b.  Reduction of the nitro group to the corresponding amine gave compounds 134a 
and 134b.  This revised method was far simpler and far more reliable than Method A.   
Significantly, use of precursor 136 eliminated the necessity for a protective group.  This 
modified procedure, Method B used 3 steps contrasted to 5 steps for Method A. Method 
B also gave a better yield; 30% conversion from starting material contrasted to 3% 
conversion with Method A. 
 
O
126b
Cl O
O
Cl
O
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Scheme 49. Synthesis of 133a,b and 134a,b by Method B. 
 
Acid chloride 136 was conveniently formed from treatment of the commercially available 
carboxylic acid 135 with oxalyl chloride and catalytic dimethylformamide (Scheme 
50)135. 
NO2
O
OH
O
, DMF, DCM
0 oC - 25 oC, 4 h
NO2
O
Cl
O
O
O
Cl
Cl
135 136  
Scheme 50. Synthesis of acid chloride 136. 
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Flavone 140 was synthesized using Method B.  Commercially available 
hydroxyacetophenone 137 was coupled to the commercially available acid chloride 138, 
followed by cyclization to afford flavone 140 (Scheme 51).  The yield of this compound 
was slightly higher owing to the hydrophobic nature of the product which facilitated 
isolation. 
CH3
O
OH
Cl
Cl
O
OH
O O Cl
O
O
Clconc H2SO4,
90-95 oC, 3 h
137
139
140, 50%
, K2CO3
H2O/toluene, 60 oC, 3.5 h
N(C4H9)4.HSO4+
138
(2 steps)
OH
O
 
Scheme 51. Synthesis of 140. 
 
4.2.5 Ortho-carboxy-amides 
Given the adventurous nature of the design and postulated activity for these ortho-
carboxy-amides, a simple direct synthesis was imperative.  Treatment of commercially 
available phthalic anhydride 141 with selected amines gave compounds 142a-d (Scheme 
52).  The reaction was carried out at 25 oC using catalytic DMAP to afford an excellent 
yield of the desired ortho-carboxy-amides (73-80%). 
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Scheme 52. Synthesis of 142a-d. 
 
4.3 Tubulysin 
4.3.1 Mep fragment  
Two different strategies were explored and ultimately method B was used for the 
synthesis of (+/-)Mep fragment of tubulysin.  
Method A (Scheme 53): First, the carboxyl group of piperidine-2-carboxylic acid 143 
was protected as the tert-butyl ester to give compound 144.  Then the N-methylated 
compound 145 was generated using microwave-assisted Eschweiler Clarke reaction123.  
Finally, deprotection of tert-butyl ester using 4M hydrochloric acid/dioxane gave 
compound 146.  However, this strategy utilized 3 steps and low yield was obtained.  The 
probable reason for low yield might be the partial deprotection of tert-butyl ester under 
microwave conditions.  
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 Scheme 53. Synthesis of compound 146 using Method A. 
 
Method B (Scheme 54): Alternatively, the piperidine-2-carboxylic acid 143 was directly 
subjected to the microwave assisted Eschweiler Clarke reaction123 to give compound 146.  
The modified strategy, method B, showed that prior protection as tert-butyl ester was not 
necessary for synthesis of compound 146 and employing this strategy actually lowered 
the overall yield.  As a result, method B provided a simple, reliable and high yielding 
(92%) procedure with the capacity of preparing (+/-)Mep 146 at a 6.5 g scale. 
N
H
OH
O
H OH
O
H H
O
, microwave (300 W), 120 oC, 2 min
HCl, EtOH
N
OH
O
a.
b.
143
146, 92%
.HCl
 
Scheme 54. Synthesis of compound 146 using Method B. 
 
4.3.2 Ile fragment 
The carboxyl group of L-isoleucine 147 was protected as tert-butyl ester in an analogous 
manner (Scheme 55).  The protection of carboxylic acid was required prior to dipeptide 
coupling.  
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Scheme 55. Synthesis of compound 148. 
  
4.3.3 Dipeptide 
Synthesis of the diastereomer dipeptide 149 from of (+/-) Mep 146 and L-(S)-isoleucine 
tert-butyl ester 148 was shown to be achievable on a gram scale.  The reliability of this 
synthesis was demonstrated by a successful repeat by undergraduate student at an 
identical scale with similar yields (Scheme 56).               
N
OH
O
H2N O
O
N
H
N
O
O
O
+
DCC, DMAP, HOBt, DCM
12 h, 23 oC
146 148
149, 60%
.HCl
Scheme 56. Synthesis of dipeptide 149. 
 
4.3.4 Tup portion 
The synthesis begins with commercially available 80.  Initially, compound 80 was 
synthesized from L-phenylalanine, which was reduced to the corresponding amino 
alcohol by borane generated in situ with sodium borohydride and iodine, followed by Boc 
protection of the amino group.  The alcohol 80 was oxidized to the corresponding 
aldehyde, 151 with a Tempo/sodium hypochlorite oxidation.  This aldehyde 151 was 
directly used in a Wittig olefination with commercially available 152 to give compound 
81.  Ester deprotection to compound 81 was followed by catalytic hydrogenation to 
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afford compound 153 as a mixture of diastereomers.  Recrystallization from 1:1 
hexane/ether gave desired compound 154a (Scheme 57).  
In the Wipf protocol136, catalytic hydrogenation of the ester 81, afforded two 
diastereomers 154a,b in 3:1 ratio, but they were inseperable with by silica gel 
chromatography.  Shuyan Yi122, developed a strategy that utilized saponification to 153, 
reduction to 154a/154b and finally recrystallization to give a single compound 154a.  The 
probable reason for the selectivity is that hydrogenation occurs on the most accessible 
face of the alkene.  The absolute configuration of 154a was confirmed by x-ray 
crystallographic analysis.  Compound 154b could not be identified by 1H NMR. Chiral 
HPLC is pending. Thus, large scale synthesis of Tup portion (5.2 g) was achieved with 
this procedure in a reliable manner. 
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H2N OH
O
a. NaBH4, I2, THF, 0 oC, 15 min
b. Boc2O, DMAP, 23 oC, 40 min
BocHN
OH
80, 40%150
Tempo, NaOCl, NaHCO3
NaBr, H2O/CH2Cl2, 0 oC, 2 h CH2Cl2, 23 oC, 12 h
Ph3P
EtO
O
BocHN
H
O
151
152
BocHN
O
O
81, 55%
H2/Pd-C, EtOHNaOH, EtOH
23 oC, 12 h
BocHN
O
OH
153, 99%
+
BocHN
OH
O
BocHN
OH
O
154a
154b
recrystallization
154a, 53%
BocHN
OH
O
23 oC, 24 h
 
Scheme 57. Synthesis of compound 154a. 
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Chapter 5 
 
Experimental 
 
All solvents and reagents were used as received unless noted otherwise.  Tetrahydrofuran 
(THF) was distilled from Na-benzophenone ketyl radical under a blanket of argon prior 
to use.  All reactions were conducted in dry glassware and under an atmosphere of argon 
unless otherwise noted.  Melting points were determined on a MelTemp apparatus and 
are uncorrected.  All proton NMR spectra were obtained with an 500 MHz Oxford 
spectrospin cryostat, controlled by a Bruker Avance system, and were acquired using 
Bruker Topsin 2.0 acquisition software.  Acquired FIDs were analyzed using MestReC 
3.2.  Elemental analyses were conducted by Atlantic Microlabs and are ± 0.4 of 
theoretical.  All HRMS mass spectral analyses were conducted at Duquesne University 
with a nano ESI chip cube TOF HRMS and are ± 0.004 of theoretical.  All 1H NMR 
spectra are reported as ppm relative to TMS and as an internal standard.  Coupling values 
are reported in Hertz. 
2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol (93a).  A dry one-
necked flask was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (91; 334.0 
mg, 1.5 mmol), 1-(tert-butyldimethylsilyloxy)butan-2-ol (817.5 mg, 4.0 mmol), Ph3P 
(985.0 mg, 3.8 mmol), and 4 mL of anhydrous DMF.  This solution was cooled to 0 oC. 
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Neat DIAD (0.4 mL, 2.8 mmol) was added with slow dropwise addition.  The solution 
was stirred for 30 min at 0 oC, the ice-bath was removed, and the reaction was stirred for 
an additional 2 h at 23 oC.  The reaction was then cooled to 0 oC and an additional 
quantity of DIAD (0.4 mL, 2.8 mmol) was added in one portion at 0 oC.  The reaction 
was stirred for 30 min at 0 oC, then at 23 oC for 12 h. The reaction mixture taken up into 
10 mL of EA and 10 mL K2CO3 (aq, sat).  The mixture was extracted three times each 
with 10 mL portions of EA and then the combined organic extracts were washed with 
NaCl (aq, sat) and dried over Na2SO4.  The extract was decanted and the solvent was 
removed under reduced pressure to afford 3.5 g of crude product.  The crude material was 
dissolved into 75 mL of EtOH and added to a Parr hydrogenation vessel previously 
charged with Pd/C (10% w/w, 150.1 mg).  After 3 vacuum/purge cycles with H2, the 
vessel was charged to 50 psi with H2 and shaken for 5 h.  The mixture was filtered 
through a pad of Celite and then washed with an additional 25 mL of EtOH.  A 10 mL 
portion of conc HCl was added to the 100 mL of resultant filtrate at 0 oC.  This mixture 
was stirred at 23 oC for 12 h.  The solvent was removed under reduced pressure and the 
crude oil (4.1 g) taken up into 50 mL of 1 N HCl (aq) (pH = 1) and washed three times 
each with 10 mL portions of EA, neutralized and adjusted with 6 N NaOH (aq) to a pH of 
10.  The mixture was then extracted three times with 15 mL portions of Et2O, washed 
with NaCl (aq, sat) and dried over Na2SO4.  The organic phase was decanted and the 
solvent was removed under reduced pressure to give 264.6 mg (67%) of a pale brown, 
hygroscopic solid.  mp: 35.5 - 36.9 oC.  SiO2 TLC Rf 0.44 (CH2Cl2/5% CH3OH/0.1% 
NH4OH).   1H NMR (CDCl3): δ 7.75 (s, 1 H), 6.36 (d, J = 2.0 Hz, 1 H), 6.23 (d, J = 2.0 
Hz, 1 H), 4.45 (m, 1 H), 4.36 (s, 2 H, NH2), 4.26 (m, 2 H), 3.47 (m, 1 H), 2.08 (s, 1 H, 
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OH) 1.66 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H). Anal Calcd for 
C14H21N3O2.1H2O: C, 59.77; H, 8.24; N, 14.94. Found: 59.91; H, 7.93; N, 14.64. 
2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (94a).  2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(93a; 80.0 mg, 0.3 mmol) and solid NaBH(OAc)3 (650.0 mg, 3.0 mmol) were added to 
2.5 mL of DCE.  Benzaldehyde (36 µL, 1.2 mmol) was added in one portion and the 
mixture was stirred for 12 h.  The reaction mixture was quenched with the addition of 1 
mL of NaHCO3 (aq, sat) and stirred for 10 min.  The mixture was taken up into 5% 
K2CO3 (aq) and then extracted three times with 15 mL portions of Et2O. The combined 
organic extracts were washed with 10 mL of NaCl (aq, sat) and then dried over Na2SO4. 
The extract was decanted and the solvent was removed under reduced pressure.  The 
crude material was isolated on SiO2 and eluted with hexane/EA.  The HCl salt was 
synthesized using 2 mL of ethereal HCl, followed by recrystallization from EA.  46.1 mg 
(40%) of a white solid was obtained.  mp: 148.7 - 149 oC.  SiO2 TLC Rf 0.5 (CH2Cl2/5% 
CH3OH/0.1% NH4OH). 1H NMR (CDCl3): δ 8.79 (s, 1 H), 7.69 (s, 1 H, NH), 7.41 (d, J = 
7.6 Hz, 2 H), 7.31 (d, J = 7.2 Hz, 2 H), 7.28 (m, 1 H), 6.26 (d, J = 2.0 Hz, 1 H), 6.07 (d, J 
= 2.0 Hz, 1 H), 4.63 (m, 1 H), 4.54 (s, 1 H), 4.14 (m, 2 H), 3.70 (m, 1 H), 2.69 (s, 1H,  
NH) 1.66 (d, J = 6.8 Hz, 6 H), 1.57 (m, 2 H), 0.86 (t, J = 7.6 Hz, 3 H). Anal Calcd for 
C21H28ClN3O2.1/8H2O: C, 64.32; H, 7.26; N, 10.71. Found: 64.27; H, 7.30; N, 10.61. 
2-(4-amino-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol (93e).  A dry one-
necked flask was charged with 1-cyclopentyl-4-nitro1H-benzo[d]imidazol-6-ol (91a; 
334.0 mg, 1.35 mmol), 1-(tert-butyldimethylsilyloxy)butan-2-ol (817.5 mg, 4.0 mmol), 
Ph3P (985.0 mg, 3.8 mmol), and 4 mL of anhydrous DMF.  This solution was cooled to 0 
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oC. Neat DIAD (0.4 mL, 2.8 mmol) was added with slow dropwise addition.  The 
solution was stirred for 30 min at 0 oC, the ice-bath was removed, and the reaction was 
stirred for an additional 2 h at 23 oC.  The reaction was then cooled to 0 oC and an 
additional quantity of DIAD (0.4 mL, 2.8 mmol) was added in one portion at 0 oC. The 
reaction was stirred for 30 min at 0 oC, and then at 23 oC for 12 h. The reaction mixture 
taken up into 10 mL of EA and 10 mL K2CO3 (aq, sat) was added.  The mixture was 
extracted three times with 10 mL portions of EA and the combined organic extracts were 
washed with NaCl (aq, sat) and dried over Na2SO4.  The extract was decanted and the 
solvent was removed under reduced pressure.  The crude material was dissolved into 75 
mL of EtOH and added to a Parr hydrogenation vessel previously charged with Pd/C 
(10% w/w, 162.7 mg).  After 3 vacuum/purge cycles with H2, the vessel was charged to 
50 psi with H2 and shaken for 5 h.  The mixture was filtered through a pad of Celite and 
then washed with an additional 25 mL of EtOH.  A 10 mL portion of conc HCl was 
added to the 100 mL of resultant filtrate at 0 oC. This mixture was stirred at 23 oC for 12 
h.  The solvent was removed under reduced pressure and the crude oil (4.3 g) taken up 
into a 50 mL volume of 1 N HCl (aq) (pH = 1) and washed three times with 10 mL 
portions of EA, neutralized and adjusted with 6 N NaOH (aq) to a pH of 10. This mixture 
was then extracted three times with 15 mL portions of Et2O, and washed with NaCl (aq, 
sat) and dried over Na2SO4.  The organic phase was decanted and the solvent was 
removed under reduced pressure to give 195.3 mg (50%) of a pale brown, hygroscopic 
solid.  mp: 29.7 - 31.1 oC.  SiO2 TLC Rf 0.51 (CH2Cl2/5% CH3OH/0.1% NH4OH). 1H 
NMR (CDCl3): δ 7.72 (s, 1 H), 6.37 (d, J = 2.0 Hz, 1 H), 6.24 (d, J = 2.0 Hz, 1 H), 4.57 
(m, 1 H), 5.36 (s, 2 H, NH2), 4.26 (m, 2 H), 3.81 (m, 1 H), 2.29 (s, 1H, OH), 2.21 (m, 2 
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H), 2.08 (m, 2 H), 1.81 (m, 2 H), 1.79 (m, 2 H), 1.70 (m, 2 H), 1.68 (d, J = 6.8 Hz, 6 H), 
0.98 (t, J = 7.6 Hz, 3 H). Anal Calcd for C16H23N3O2.H2O: C, 66.41; H, 8.01; N, 14.52. 
Found: 66.22; H, 8.15; N, 14.30. 
2-(4-(benzylamino)-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (94e).  2-(4-amino-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butan-1-
ol (93e; 90.0  mg, 0.3 mmol) and solid NaBH(OAc)3 (650.0 mg, 3.0 mmol) were added to 
5 mL of DCE.  Benzaldehyde (36.5µL, 1.2 mmol) was added in one portion and the 
mixture was stirred for 12 h.  The reaction mixture was quenched with the addition of 1 
mL of saturated NaHCO3 and stirred for 10 min.  The mixture was taken up into 5% 
aqueous solution of K2CO3 and then extracted three times with 15 mL portions of Et2O.  
The combined organic extracts were washed with NaCl (aq, sat) and then dried over 
Na2SO4.  The extract was decanted and the solvent was removed under reduced pressure.  
The crude material was isolated on SiO2 and eluted with hexane/EA.  The HCl salt was 
synthesized with the addition of 2 mL of ethereal HCl, followed by recrystallization from 
EA and EtOH.  66.8 mg (50%) of a white solid was obtained.  mp: 187.5 oC.  SiO2 TLC 
Rf 0.57 (CH2Cl2/5% CH3OH/0.1% NH4OH). 1H NMR (CDCl3): δ 8.71 (s, 1 H), 8.01 (d, J 
= 7.6 Hz, 2 H), 7.62 (s, 1 H, NH), 7.56 (m, 1H), 7.52 (m, 2 H), 7.41 (d, J = 7.2 Hz, 2 H), 
7.31 (d, J = 7.2 Hz, 2 H), 7.28 (m, 1 H), 6.28 (d, J = 2.0 Hz, 1 H), 6.07 (d, J = 2.0 Hz, 2 
H), 4.74 (m, 1 H), 4.54 (s, 1 H), 4.17 (m, 2 H), 3.71 (m, 1 H), 2.33 (m, 2 H), 2.31 (m, 2 
H), 2.04 (m, 2 H), 2.02 (m, 2 H), 1.62 (d, J = 6.8 Hz, 6 H), 1.59 (m, 2 H), 0.88 (t, J = 7.6 
Hz, 3 H). Anal Calcd for C23H30ClN3O2: C, 66.14; H, 7.27; N, 10.10. Found: 66.14; H, 
7.30; N, 10.15. 
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2-(4-(3-chlorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (94f).  2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
(93a; 100 mg, 0.38 mmol) and solid NaBH(OAc)3 (650.0 mg, 3.0 mmol) were added to 5 
mL of DCE.  m-Chlorobenzaldehyde (47 µL, 1.2 mmol) was added in one portion and the 
mixture was stirred for 12 h at 23 oC.  The reaction mixture was quenched with the 
addition of 1 mL of NaHCO3 (aq, sat) and stirred for 10 min.  The mixture was taken up 
into 5% K2CO3 (aq) and extracted three times with 15 mL portions of Et2O.  The 
combined organic extracts were washed with NaCl (aq, sat) and then dried over Na2SO4. 
The extract was decanted and the solvent was removed under reduced pressure. The 
crude material was isolated on SiO2 and eluted with Et2O.  The HCl salt was synthesized 
using 2 mL of ethereal HCl, followed by recrystallization from EA and EtOH.  72.0 mg 
(40%) of a white solid was obtained.  mp: 94.2 - 93.0 oC.  SiO2 TLC Rf 0.52 (CH2Cl2/5% 
CH3OH/0.1% NH4OH). 1H NMR (CDCl3): δ 7.73 (s, 1 H), 7.41 (s, 1 H), 7.26 (m, 1 H), 
7.25 (d, J = 7.2 Hz, 1 H), 7.23 (d, J = 2.0 Hz, 1 H), 6.30 (d, J = 2.0 Hz, 1 H), 5.99 (s, 1 
H), 5.38 (s, 1 H, NH), 4.45 (s, 1 H), 4.20 (m, 1 H), 3.80 (m, 2 H), 3.73 (m, 1 H), 2. 04 (s, 
1 H, OH), 1.58 (m, 2 H), 1.56 (d, J = 6.8 Hz, 6 H), 0.93 (t, J = 7.6 Hz, 3 H). Anal Calcd 
for C21H27Cl2N3O2.2/3 H2O: C, 57.80; H, 6.54; N, 9.63. Found: 57.59; H, 6.61; N, 9.35. 
1-isopropyl-6-((1-methylpiperidin-4-yl)methoxy)-4-nitro-1H-benzo[d]imidazole 
(92g).  A dry one-neck flask was charged with 1-isopropyl-4-nitro1H-benzo[d]imidazol-
6-ol (91; 334.0 mg, 1.5 mmol), tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate 
(861.2 mg, 4.0 mmol), Ph3P (985.0 g, 3.8 mmol), and 4 mL of anhydrous DMF.  This 
solution was cooled to 0 oC.  Neat DIAD (0.4 mL, 2.8 mmol) was added with slow 
dropwise addition.  The solution was stirred for 30 min at 0 oC, the ice-bath was 
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removed, and the reaction was stirred for an additional 2 h at 23 oC.  The reaction was 
then cooled to 0 oC and an additional quantity of DIAD (0.4 mL, 2.8 mmol) was added in 
one portion at 0 oC.  The reaction was stirred for 30 min at 0 oC, then at 23 oC 12 h.  The 
reaction mixture taken up into 10 mL of EA and 10 mL K2CO3 (aq, sat).  This mixture 
was extracted three times each with 10 mL of portions of EA and then the combined 
organic extracts were washed with NaCl (aq, sat) and dried over Na2SO4.  The extract 
was decanted and the solvent was removed under reduced pressure.  The crude was 
dissolved into 30 mL of EtOH and 3 mL of conc HCl was added dropwise at 0 oC.  The 
reaction was stirred at 23 oC until the reaction was complete as determined by TLC.  The 
solvent was removed under reduced pressure and resulting solid was dissolved into 50 
mL of 1 N HCl (aq) and washed three times with 10 mL portions of EA, neutralized and 
adjusted with 6 N NaOH (aq) to a pH of 10 and extracted three times with 15 mL 
portions of CHCl3.  The combined organic extracts were washed with NaCl (aq, sat) and 
then dried over Na2SO4.  The organic phase was decanted and the solvent was removed 
under reduced pressure.  The crude yellow solid (100 mg, 0.38 mmol) obtained was 
dissolved in 0.7 mL of formic acid, 1 mL of 38% aqueous formaldehyde, and subjected to 
250 watt microwave irradiation to a temperature of 120 oC for 5.5 min.  After cooling the 
solvent was removed and the resultant yellow oil taken up into 10 mL K2CO3 (aq, sat) 
and 10 mL EA.  This was extracted three times with 10 mL portions of EA, washed with 
NaCl (aq, sat) and then dried over Na2SO4.  The extract was decanted and the solvent was 
removed under reduced pressure to give 150.2 (30%) of a brown solid.  mp: 205 - 211 oC.  
SiO2 TLC Rf 0.31 (CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR (CDCl3): δ 8.42 (s, 1 
H), 7.77 (d, J = 2.0 Hz, 1 H), 7.23 (d, J = 2.0 Hz, 1 H), 4.64 (m, 1 H), 3.98 (d, J = 5.6 Hz, 
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2 H), 3.61 (d, J = 10.0 Hz,1 H), 2.74 (s, 3 H), 2.68 (m, 2 H), 2.06 (m, 2 H), 1.95 (m, 2 H), 
1.65 (d, J = 6.8 Hz, 6 H), 1.26 (m, 2 H). Anal Calcd for C17H24N4O3: C, 61.43; H, 7.28; 
N, 16.86. Found: 61.45; H, 7.21; N, 16.58. 
1-isopropyl-6-((1-methylpiperidin-4-yl)methoxy)-1H-benzo[d]imidazol-4-amine 
(93g).  The 1-isopropyl-6-((1-methylpiperidin-4-yl)methoxy)-4-nitro-1H-
benzo[d]imidazole (92g; 148.3 mg, 0.4 mmol) was dissolved into 75 mL of EtOH and 
added to a Parr hydrogenation vessel previously charged with Pd/C (10% w/w, 8.1 mg).  
After 3 vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 and 
shaken for 5 h.  The mixture was filtered through a pad of Celite and then washed with an 
additional 25 mL of EtOH. A 10 mL portion of conc HCl was added to resultant filtrate at 
0 oC.  This mixture was stirred at 23 oC until the reaction was complete as determined by 
TLC.  The solvent was removed under reduced pressure.  The resultant solid was 
dissolved into 10 mL K2CO3 (aq, sat) and extracted three times with 10 mL portions of 
Et2O.  The combined organic extracts were washed three times with NaCl (aq, sat) and 
then dried over Na2SO4.  The organic phase was decanted and the solvent was removed 
under reduced pressure to give 76.7 mg (51.1%) of a yellow, hygroscopic solid.  mp: 37.0 
- 38.5 oC.  SiO2 TLC Rf 0.22 (CH2Cl2/5% CH3OH/0.1% NH4OH). 1H NMR (CDCl3): δ 
7.73 (s, 1 H), 6.23 (d, J = 2.0 Hz, 1 H), 6.17 (d, J = 2.0 Hz, 1 H), 4.64 (m, 1 H), 3.98 (d, J 
= 5.6 Hz, 2 H), 3.61 (d, J = 10.0 Hz,1 H), 2.74 (s, 3 H), 2.68 (m, 2 H), 2.06 (m, 2 H), 1.95 
(m, 2 H), 1.65 (d, J = 6.8 Hz, 6 H), 1.26 (m, 2 H). Anal Calcd for C17H26N4O: C, 67.52; 
H, 8.67; N, 18.53. Found: 67.45; H, 8.41; N, 18.58. 
N-benzyl-1-isopropyl-6-((1-methylpiperidin-4-yl)methoxy)-1H-benzo[d]imidazol-4-
amine hydrochloride (94g).  1-isopropyl-6-((1-methylpiperidin-4-yl)methoxy)-1H-
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benzo[d]imidazol-4-amine (93g; 63.7 mg, 0.16 mmol) and solid NaBH(OAc)3 (650.0 mg, 
3.0 mmol) were added to 5 mL of DCE. Benzaldehyde (18 µL, 1.2 mmol) was added in 
one portion and the mixture was stirred for 12 h. The reaction mixture was quenched with 
the addition of 1 mL of NaHCO3 (aq, sat) and stirred for 10 min.  The mixture was taken 
up into 5% K2CO3 (aq) and then extracted three times with 15 mL portions of Et2O.  The 
combined organic extracts were washed with 10 mL of NaCl (aq, sat) and then dried over 
Na2SO4.  The extract was decanted and the solvent was removed under reduced pressure.  
The crude material was isolated on SiO2 and eluted with EA.  The HCl salt was prepared 
from 2 mL of ethereal HCl to give 38.1 mg (46%) of a white hygroscopic solid. mp: 92.1 
- 92.7 oC.  SiO2 TLC Rf 0.39 (CH2Cl2/5% CH3OH/0.1% NH4OH). 1H NMR (MeOD-d4): 
δ 9.26 (s, 1 H), 7.51(s, 1H, NH) 7.42 (q, 2 H), 7.35 (d, J = 7.2 Hz, 2 H), 7.28 (q, 1 H), 
6.66 (d, J = 2.0 Hz, 1 H), 6.25 (d, J = 2.0 Hz, 1 H), 4.48 (m, 1 H), 3.95 (s, 1 H), 3.43 (d, 2 
H), 3.30 (m, 1 H), 3.01 (m, 2 H),  2.88 (s, 3 H), 2.14 (m, 2 H), 2.13 (m, 2 H), 1.58 (d, 6 
H), 1.28 (m, 2 H). Anal Calcd for C24H34Cl2N4O.4 H2O: C, 53.63; H, 7.88; N, 10.42. 
Found: 53.31; H, 7.59; N, 10.31. 
N-benzyl-1-isopropyl-6-(1-methylpiperidin-4-yloxy)-1H-benzo[d]imidazol-4-amine 
hydrochloride (94b).  A dry one-necked flask was charged with 1-isopropyl-4-nitro1H-
benzo[d]imidazol-6-ol (91; 334.0 mg, 1.5 mmol), 1-methylpiperidin-4-ol (468.6 mg, 4.0 
mmol), Ph3P (985.0 mg, 3.8 mmol), and 4 mL of anhydrous DMF.  This solution was 
cooled to 0 oC. Neat DIAD (0.4 mL, 2.8 mmol) was added with slow dropwise addition.  
The solution was stirred for 30 min at 0 oC, the ice-bath was removed, and the reaction 
was stirred for an additional 2 h at 23 oC.  The reaction was then cooled to 0 oC and an 
additional quantity of DIAD (0.4 mL, 2.8 mmol) was added in one portion at 0 oC.  The 
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reaction was stirred for 30 min at 0 oC, then at 23 oC for 12 h.  This reaction mixture was 
then taken up into a mixture of 10 mL of EA and 10 mL of K2CO3 (aq, sat).  This mixture 
was extracted three times with 10 mL portions of EA and the combined organic extracts 
were washed with NaCl (aq, sat) and dried over Na2SO4.  The extract was decanted and 
the solvent was removed under reduced pressure.  The crude material was dissolved into 
75 mL of EtOH and added to a Parr hydrogenation vessel previously charged with Pd/C 
(10% w/w, 120.3 mg).  After 3 vacuum/purge cycles with H2, the vessel was charged to 
50 psi with H2 and shaken for 5 h.  The mixture was filtered through a pad of Celite and 
then washed with an additional 25 mL of EtOH.  A 10 mL portion of conc HCl was 
added to the resulting filtrate at 0 oC.  The mixture was stirred at 23 oC until the reaction 
was complete as determined by TLC.  The solvent was removed under reduced pressure.  
The crude oil was taken up into 50 mL of 1 N HCl (aq) (pH = 1) and washed three times 
with 10 mL portions of EA, neutralized and adjusted with 6 N NaOH (aq) to a pH of 10 
and extracted three times with 15 mL portions of Et2O.  The combined ether layers were 
washed with NaCl (aq, sat) and dried over Na2SO4.  The organic phase was decanted and 
the solvent was removed under reduced pressure.  The crude product was directly carried 
to next step. 1H NMR (CDCl3): δ 7.68 (s, 1 H), 6.66 (d, J = 2.0 Hz, 1 H), 6.25 (d, J = 2.0 
Hz, 1 H), 4.48 (m, 1 H), 3.95 (s, 1 H), 3.30 (m, 1 H), 3.01 (m, 2 H),  2.88 (s, 3 H), 2.14 
(m, 2 H), 2.13 (m, 2 H), 1.58 (d, J = 6.8 Hz, 6 H), 1.28 (m, 2 H).  
The crude material (50 mg) and solid NaBH(OAc)3 (650.0 mg, 3.0 mmol) were added to 
2 mL of DCE. Benzaldehyde (39 µL, 1.2 mmol) was added in one portion and the 
mixture was stirred for 12 h.  The reaction mixture was quenched with the addition of 1 
mL of NaHCO3 (aq, sat) and stirred for 10 min.  The mixture was taken up into 5% 
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K2CO3 (aq) and then extracted three times with 15 mL portions of Et2O.  The combined 
organic extracts were washed with NaCl (aq, sat) and then dried over Na2SO4.  The 
extract was decanted and the solvent was removed under reduced pressure.  The crude 
material was isolated on SiO2 and eluted with EA/5% TEA.  The HCl salt was prepared 
from 2 mL of ethereal HCl. 13.1 mg (20%) of a white, hygroscopic solid was obtained.  
mp: 97.0 - 98.3 oC.  SiO2 TLC Rf 0.42 (CH2Cl2/5% CH3OH/0.1% NH4OH). 1H NMR 
(MeOD-d4): δ 9.26 (s, 1 H), 7.51 (s, 1H, NH) 7.42 (q, 2 H), 7.35 (d, J = 7.2 Hz, 2 H), 
7.28 (q, 1 H), 6.66 (d, J = 2.0 Hz, 1 H), 6.25 (d, J = 2.0 Hz, 1 H), 4.48 (m, 1 H), 3.95 (s, 1 
H), 3.30 (m, 1 H), 3.01 (m, 2 H),  2.88 (s, 3 H), 2.14 (m, 2 H), 2.13 (m, 2 H), 1.58 (d, J = 
6.8 Hz, 6 H), 1.28 (m, 2 H). Anal Calcd for C23H32Cl2N4O.1 H2O: C, 55.47; H, 7.70; N, 
10.70. Found: 55.22; H, 7.52; N, 10.91. 
tert-butyl 4-((4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-
yloxy)methyl)piperidine-1-carboxylate (93d).  A dry one-necked flask was charged 
with 1-isopropyl-4-nitro1H-benzo[d]imidazol-6-ol (91; 334.0 mg, 1.5 mmol), tert-butyl 
4-(hydroxymethyl)piperidine-1-carboxylate (861.1 mg, 4.0 mmol), Ph3P (985.0 mg, 3.8 
mmol), and 4 mL of anhydrous DMF.  This solution was cooled to 0 oC. Neat DIAD (0.4 
mL, 2.8 mmol) was added with slow dropwise addition.  The solution was stirred for 30 
min at 0 oC, the ice-bath was removed, and the reaction was stirred for an additional 2 h 
at 23 oC.  The reaction was then cooled to 0 oC and an additional quantity of DIAD (0.4 
mL, 2.8 mmol) was added in one portion at 0 oC.  The reaction was stirred for 30 min at 0 
oC, then at 23 oC for 12 h.  The reaction mixture taken up into 10 mL of EA and 10 mL 
K2CO3 (aq, sat) was added.  This mixture was extracted three times with 10 mL portions 
of EA and the combined organic extracts were washed with 10 mL of NaCl (aq, sat) and 
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dried over Na2SO4. The extract was decanted and the solvent was removed under reduced 
pressure.  The crude material was dissolved into 75 mL of EtOH and added to a Parr 
hydrogenation vessel previously charged with Pd/C (10% w/w, 145.7 mg).  After 3 
vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 and shaken for 5 
h.  The mixture was filtered through a pad of Celite and then washed with an additional 
25 mL of EtOH.  A 10 mL portion of conc HCl was added to the resulting filtrate at 0 oC. 
The reaction was stirred at 23 oC until the reaction was complete as determined by TLC.  
The solvent was removed under reduced pressure.  The crude oil was taken up into 50 
mL of 1 N HCl (aq) (pH = 1) and washed with EA, neutralized and adjusted with 6 N 
NaOH (aq), and then extracted three times with 15 mL portions of Et2O.  The combined 
Et2O layers were washed with NaCl (aq, sat) and dried over Na2SO4.  The organic phase 
was decanted and the solvent was removed under reduced pressure.  The crude product 
was carried directly to next step. 1H NMR (CDCl3): δ 7.61 (s, 1 H), 6.18 (d, J = 2.0 Hz, 1 
H), 6.02 (d, J = 2.0 Hz, 1 H), 5.27 (s, 1 H, NH), 4.47 (s, 1 H), 4.14 (m, 1 H), 3.78 (d, 2 
H), 2.71 (m, 1 H), 1.70 (m, 2 H), 1.80 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 1.46 (s, 9 H), 
1.30 (m, 2 H), 1.25 (m, 2 H). 
The crude material (83.3 mg) and solid NaBH(OAc)3 (650.0 mg, 3.0 mmol) were added 
to 5 mL of DCE.  Benzaldehyde (24 µL, 1.2 mmol) was added in one portion and the 
mixture was stirred for 12 h.  The reaction mixture was quenched with the addition of 1 
mL of NaHCO3 (aq, sat) and stirred for 10 min.  The mixture was taken up into 5% 
K2CO3 (aq) and then extracted three times with 15 mL portions of Et2O.  The combined 
organic extracts were washed with NaCl (aq, sat) and then dried over Na2SO4.  The 
extract was decanted and the solvent was removed under reduced pressure.  The crude 
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material was isolated on SiO2 and eluted with hexane/EA. 72.1 mg (10%) of a white 
solid, hygroscopic was obtained.  mp: 81.1 - 81.5 oC.  SiO2 TLC Rf 0.57 (CH2Cl2/5% 
CH3OH/0.1% NH4OH). 1H NMR (CDCl3): δ 7.61 (s, 1 H), 7.41 (d, J = 7.6 Hz, 2 H), 7.31 
(d, J = 7.2 Hz, 2 H), 7.28 (q, 1 H), 6.18 (d, J = 2.0 Hz, 1 H), 6.02 (d, J = 2.0 Hz, 1 H), 
5.27 (s, 1 H, NH), 4.47 (s, 1 H), 4.14 (m, 1 H), 3.78 (d, 2 H), 2.71 (m, 1 H), 1.70 (m, 2 
H), 1.80 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 1.46 (s, 9 H), 1.30 (m, 2 H), 1.25 (m, 2 H). 
Anal Calcd for C28H38Cl4N3O.1 H2O: C, 67.71; H, 8.12; N, 11.28. Found: 68.09; H, 7.77; 
N, 11.26. 
N-benzyl-1-isopropyl-6-(piperidin-4-ylmethoxy)-1H-benzo[d]imidazol-4-amine 
hydrochloride (94d).  tert-butyl 4-((4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-
6-yloxy)methyl)piperidine-1-carboxylate (93d; 71.1 mg, 0.15 mmol) was dissolved in 50 
mL EtOH and 5 mL of conc HCl was added at 0 oC.  The reaction was stirred at 23 oC for 
12 h.  The solvent was removed under reduced pressure.  Recrystallization from MeOH 
afforded 60 mg (83%) of a white solid.  mp: 218 - 220 oC.  1H NMR (MeOD-d4): δ 9.26 
(s, 1 H), 7.51(s, 1 H, NH) 7.42 (q, 2 H), 7.35 (d, J = 7.2 Hz,  2 H), 7.28 (q, 1 H), 6.66 (d, 
J = 2.0 Hz, 1 H), 6.42 (s, 1 H, NH),  6.25 (d, J = 2.0 Hz, 1 H), 4.48 (m, 1 H), 3.95 (s, 1 
H), 3.43 (s, 2 H), 3.30 (m, 1 H), 3.01 (m, 2 H), 2.14 (m, 2 H), 2.13 (m, 2 H), 1.58 (d, J = 
6.8 Hz, 6 H), 1.28 (m, 2 H). Anal Calcd for C23H32Cl2N4O.2.5H2O: C, 55.64; H, 7.51; N, 
11.21. Found: 55.40; H, 7.38; N, 11.26. 
N-benzyl-6-(1-(dimethylamino)butan-2-yloxy)-1-isopropyl-1H-benzo[d]imidazol-4-
amine hydrochloride (94c).  A dry one-necked flask was charged with 1-isopropyl-4-
nitro1H-benzo[d]imidazol-6-ol (91; 334.0 mg, 1.5 mmol), 1-(dimethylamino)butan-2-ol 
(468.6 mg, 4.0 mmol), Ph3P (985.0 mg, 3.8 mmol), and 4 mL of anhydrous DMF.  This 
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solution was cooled to 0 oC.  Neat DIAD (0.4 mL, 2.8 mmol) was added with slow 
dropwise addition.  The solution was stirred for 30 min at 0 oC, the ice-bath was 
removed, and the reaction was stirred for an additional 2 h at 23 oC.  The reaction was 
then cooled to 0 oC and an additional quantity of DIAD (0.4 mL, 2.8 mmol) was added in 
one portion at 0 oC.  The reaction was stirred for 30 min at 0 oC, then at 23 oC for 12 h.  
The reaction mixture taken up into 10 mL of EA and 10 mL of K2CO3 (aq, sat).  It was 
extracted three times with 10 mL portions of EA and the combined organic extracts were 
washed with 10 mL of NaCl (aq, sat) and then dried over Na2SO4.  The extract was 
decanted and the solvent was removed under reduced pressure.  The HCl salt was 
prepared with the addition of 2 mL of ethereal HCl.  This crude material was carried on 
directly in 75 mL of EtOH and was added to a Parr hydrogenation vessel previously 
charged with Pd/C (10% w/w, 91.3 mg).  After 3 vacuum/purge cycles with H2, the 
vessel was charged to 50 psi with H2 and shaken for 5 h.  The mixture was filtered 
through a pad of Celite and then washed with an additional 25 mL of EtOH.  A 10 mL 
portion of conc HCl was added to the filtrate at 0 oC.  The reaction was stirred at 23 oC 
for 12 h.  The solvent was removed under reduced pressure.  The crude oil was taken up 
into 50 mL of 1 N HCl (aq) (pH = 1) and washed three times with 10 mL portions of EA, 
neutralized and adjusted with 6 N NaOH (aq) to a pH of 10 and then extracted three times 
with 15 mL portions of Et2O.  The combined Et2O layers were washed with NaCl (aq, 
sat) and dried over Na2SO4.  The organic phase was decanted and the solvent was 
removed under reduced pressure.  The crude product was carried directly to the next step.  
1H  NMR (CDCl3): δ 8.31 (s, 1 H), 6.83 (d, J = 2.0 Hz, 1 H), 6.44 (d, J = 2.0 Hz, 1 H), 
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6.42 (s, 1 H, NH), 4.44 (m, 1 H), 4.52 (s, 1 H),  2.92 (s, 6 H), 3.62 (m, 1 H), 1.70 (m, 2 
H), 1.68 (d, J = 6.8 Hz, 6 H), 1.20 (m, 2 H), 1.11 (t, J = 7.6 Hz, 1 H). 
6-(1-(dimethylamino)butan-2-yloxy)-1-isopropyl-1H-benzo[d]imidazol-4-amine (84.0  
mg, 0.39 mmol) and solid NaBH(OAc)3 (650.0 mg, 3.0 mmol) were added to 2.5 mL of 
DCE. Benzaldehyde (31 µL, 1.2 mmol) was added in one portion and the mixture was 
stirred for 12 h. The reaction mixture was quenched with the addition of 1 mL of 
NaHCO3 (aq, sat) and stirred for 10 min.  The mixture was taken up into 5% K2CO3 (aq) 
and then extracted three times with 15 mL of Et2O.  The combined organic extracts were 
washed with NaCl (aq, sat) and then dried over Na2SO4.  The extract was decanted and 
the solvent was removed under reduced pressure. The crude material was isolated on 
SiO2 and eluted with hexane/EA.  The HCl salt was prepared with dropwise addition of 2 
mL of ethereal HCl to give a white, hygroscopic solid.  mp: 88.2 - 89.5 oC.  SiO2 TLC Rf 
0.47 (CH2Cl2/5% CH3OH/0.1% NH4OH). 1H NMR (MeOD-d4): δ 9.31 (s, 1 H), 7.42 (q, 
2 H), 7.35 (d, J = 7.2 Hz, 2 H), 7.29 (q, 1 H), 6.83 (d, J = 2.0 Hz, 1 H), 6.44 (d, J = 2.0 
Hz, 1 H), 6.42 (s, 1 H, NH), 4.44 (m, 1 H), 4.52 (s, 1 H),  2.92 (s, 6 H), 3.62 (m, 1 H), 
1.70 (m, 2 H), 1.68 (d, J = 6.8 Hz, 6 H), 1.20 (m, 2 H), 1.11 (t, J = 7.6 Hz, 1 H). Anal 
Calcd for C23H34Cl2N4O.2.5H2O: C, 55.42; H, 7.89; N, 11.24. Found: 55.38; H, 7.62; N, 
11.15. 
1-cyclopentyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (90).  A 250 mL flask was 
flame dried under stream of argon and permitted to cool to room temp.  The flask was 
charged with 50 mL of anhydrous THF and NaBH4 (454.5 mg, 12.0 mmol).  Formic acid 
(1.8 mL, 12.0 mmol) was added slowly over 5 min maintaining an internal temperature of 
0 oC.  The reaction mixture was stirred for 15 min and a clear colorless suspension 
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resulted. 5-Methoxy-3-nitrobenzene-1,2-diamine (64; 1.0 g, 5.5 mmol) was added 
followed by addition of cyclopentanone (2.4 mL, 2.31 moles).  The reaction was stirred at 
25 oC for 20 h.  The reaction mixture was concentrated under vacuum and the crude 
product was dissolved in 50 mL of formic acid and 5 mL of conc HCl.  BHT (20 mg, 
0.09 mmol) was added and reaction refluxed for 15 min.  The reaction mixture was 
concentrated under vacuum and the crude solid was suspended in 50 mL of ice cold 
water.  The aqueous layer was basified with 50% NaOH and extracted three times with 
25 mL portions of DCE.  The organic extracts were concentrated under vacuum and 
crude product was isolated on SiO2 using hexane/EA.  The product was recrystallized 
from hexane and EA.  600 mg (60%) of yellow crystalline solid was obtained.  mp:  92.5 
- 93.1oC. SiO2 TLC Rf 0.46 (CH2Cl2/5% CH3OH/0.1% NH4OH). 1H NMR (CDCl3): δ 
7.72 (s, 1 H), 6.37 (d, J = 2.0 Hz, 1 H), 6.24 (d, J = 2.0 Hz, 1 H), 3.92 (s, 3 H), 3.81 (m, 1 
H), 2.21 (m, 2 H), 2.08 (m, 2 H), 1.79 (m, 2 H), 1.70 (m, 2 H).  Anal. Calcd160 for 
C13H15N3O3: C, 59.76; H, 5.79; N, 16.08; O, 18.37.   Found: C,59.88; H, 5.84; N, 16.27. 
1-isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (66).  A 250 mL flask was flame 
dried under stream of argon and permitted to cool to room temp.  The flask was charged 
with 5-methoxy-3-nitrobenzene-1,2-diamine (64; 2.0056 g, 10.9 mmol), NaBH(OAc)3 
(7.0211 g, 32.7 mmol), acetone (4.1 mL, 54.5 mmol), formic acid (1.2 mL, 54.5 mmol), 
and 50 mL of anhydrous THF.  The reaction was stirred at 25 oC for 6 h.  The reaction 
mixture was concentrated under vacuum and the crude product was dissolved into 12 mL 
of formic acid and 35 mL of conc HCl.  BHT (20 mg, 0.09 mmol) was added and 
reaction was brought to reflux for 15 min.  The reaction mixture was concentrated under 
vacuum and the crude solid was suspended into 50 mL of ice cold water.  The aqueous 
137 
layer was basified with 50% NaOH and extracted three times with 40 mL portions of 
DCE.  The organic extracts were concentrated under vacuum and crude product was 
isolated on SiO2 using hexane/EA.  The product was recrystallized from hexane and EA 
to give 1.98 g (78%) of a yellow crystalline solid. mp: 126.3 - 126.9 oC (lit120 mp: 126 - 
127 oC)  1H NMR (CDCl3): δ 7.72 (s, 1 H), 6.37 (d, J = 2.0 Hz, 1 H), 6.24 (d, J = 2.0 Hz, 
1 H), 5.4 (m, 1 H), 3.92 (s, 3 H), 1.57 (d, J = 6.8 Hz, 6 H). 
1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (90).  A microwave reactor tube was 
charged with 1-isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (64; 3.6 g, 15.3 
mmol) and 40 mL of 48% HBr.  The reaction was carried under 300 watt microwave 
irradiation maintaining the temperature at 120 oC for 2.5 h min.  After cooling, the 
solvent was removed under reduced pressure.  The crude product was dissolved into H2O, 
followed by addition of solid NaHCO3.  The precipitated solid was collected and dried 
under high vacuum (150mm Hg).  3.1 g (93%) of yellow solid was obtained.  1H NMR 
(CDCl3): δ 7.72 (s, 1 H), 6.37 (d, J = 2.0 Hz, 1 H), 6.24 (d, J = 2.0 Hz, 1 H), 5.4 (m, 1 H), 
1.57 (d, J = 6.8 Hz, 6 H).  Anal. Calcd160 for C10H11N3O3: C, 54.29; H, 5.01; N, 19.00;   
Found: C, 51.84; H, 4.73; N, 18.07 plus 0.131 HBr. 
1-((tert-butyldimethylsilyl)oxy)butan-2-ol (100b).  A 250 mL round bottom flask was 
charged with butane-1,2-diol (10.1 g, 110.9 mmol). 80 mL of DMF was added followed 
by addition of imidazole (18.8 g, 277.0 mmol ).  tert-butyldimethylsilyl chloride (23.2 g, 
166.4 mmol) was added slowly to the reaction mixture with stirring.  The reaction 
mixture was stirred for 10 h at 23 oC.  The reaction mixture was diluted with DCM and 
washed three times with 100 mL portions of H2O, three times with 20 mL portions of 
NaCl (aq, sat) and then dried over MgSO4.  The organic layer was filtered and then 
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concentrated under reduced pressure.  The crude oil (45.8 g) obtained was purified using 
SiO2. 22.6 g (60%) of colourless oil was obtained.  bp: 250.2 oC (lit121 248 - 249 oC).  
SiO2 TLC Rf 0.4 (20:1 hexane:EA). 1H NMR (CDCl3): δ 3.62 (m, 1 H), 3.54 (m, 1 H), 
3.40 (m, 1 H), 2.45 (s, 1 H), 1.42 (m, 2 H), 1.02 (t, J = 7.6 Hz, 3 H), 0.88 (s, 9 H), 0.06 (s, 
6 H). 
1-(dimethylamino)butan-2-ol (96).  An oven dried 250 mL round bottom flask was 
cooled under argon and charged with dimethylamine.  The reaction mixture was cooled to 
-78 oC and n-BuLi was added slowly over 15 min.  The reaction was permitted to warm 
to 23 oC and then stirred at 23 oC for 1 h.  The reaction mixture was cooled to -78 oC and 
2-ethyloxirane was added slowly, and the reaction mixture stirred for additional 12 h at 
23 oC.  A mixture of 3:1 NH4OH: NH4Cl was added and extracted three times with 15 
mL portions of Et2O, washed three times with 10 mL portions of NaCl (aq, sat), and then 
dried over Na2SO4.  The extract was decanted off and then removed under reduced 
pressure to give 1.23 g (88%) of brownish-yellow oil. bp: 149.8 - 151.1 oC (lit124 152  -
153 oC).  1H NMR (CDCl3): δ 3.46 (m, 1 H), 2.51 (m, 2 H), 2.31 (s, 6 H), 1.51 (m, 2 H), 
0.95 (t, 3 H). 
6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-
4-amine (103).  A dry 250 mL one-necked flask was charged with 1-isopropyl-4-nitro-
1H-benzo[d]imidazol-6-ol (91; 1.0 g, 4.52 mmol), 1-(tert-butyldimethylsilyloxy)butan-2-
ol (100b; 2.2 g, 11.3 mmol), Ph3P (2.9 g, 11.3 mmol), and 7 mL of anhydrous DMF. This 
solution was cooled to 0 oC.  Neat DIAD (1.3 mL, 6.78 mmol) was added with slow 
dropwise addition over 15 min.  The solution was stirred for 30 min at 0 oC, the ice-bath 
was removed, and then the reaction was stirred for an additional 2 h at 23 oC.  The 
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reaction was cooled to 0 oC and an additional quantity of DIAD (0.9 mL, 4.52 mmol) was 
added at 0 oC in one portion.  The reaction was stirred for 30 min at 0 oC, then at 23 oC 
for 12 h.  The reaction mixture was poured into 100 mL of EA and 20 mL of K2CO3 (aq, 
sat).  This mixture was extracted three times with 30 mL portions of EA and the 
combined organic extracts were washed with NaCl (aq, sat) and dried over Na2SO4.  The 
extract was decanted off and the solvent was removed under reduced pressure.  The crude 
material was dissolved into 100 mL of EtOH and added to a Parr hydrogenation vessel 
previously charged with Pd/C (10% w/w, 302.1 mg).  After 3 vacuum/purge cycles with 
H2, the vessel was charged to 50 psi with H2 and shaken for 12 h on a Parr hydrogenation 
apparatus.  The reaction mixture was filtered through a pad of Celite, and then washed 
with an additional 100 mL of EtOH.  The solvent was removed from the filtrate under 
reduced pressure.  The crude product (4.4 g) was isolated on SiO2 using hexane/EA 
followed by recrystallization from EA/hexane to give 1.19 g (62%) of a white crystalline 
solid.  mp: 102.1 - 103.0 oC.  SiO2 TLC Rf 0.47 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H 
NMR (CDCl3): δ 7.75 (s, 1 H), 6.36 (d, J = 2.0 Hz,1 H), 6.23 (d, J = 2.0 Hz, 1 H), 4.45 
(m, 1 H), 4.36 (s, 2 H, NH2), 4.26 (m, 2 H), 3.47 (m, 1 H), 1.66 (m, 2 H), 1.57 (d, J = 6.8 
Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.89 (s, 9 H), 0.06 (s, 6 H).  Anal Calcd for 
C20H35N3O2Si: C, 63.62; H, 9.34; N, 11.13. Found: C, 63.62; H, 9.34; N, 11.13. 
General Procedure A: C-4 benzamides (104a-104p):  A dry 25 mL round bottom flask 
was charged with 6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-amine, (103; 0.40 mmol), and 1 mL of anhydrous THF. TEA (0.72 
mmol) was added to the reaction followed by addition of the appropriate acid chloride 
(0.52 mmol).  The reaction was stirred for 12 h at 23 oC.  The reaction was quenched with 
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1mL of NaHCO3 (aq, sat) and stirred for 5 min.  This crude reaction mixture was 
extracted three times with 15 mL portions of Et2O, washed with 10 mL of NaCl (aq, sat), 
and then dried over Na2SO4.  The organic phase was decanted off and the solvent was 
removed under vacuum.  The product was isolated on SiO2 with typical yields of 45-70%. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)benzamide (104a).  Compound 104a was synthesized using 
procedure A with 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-amine (103; 150.2 mg, 0.40 mmol), benzoyl chloride (34 µL, 0.44 
mmol), TEA (0.1 mL, 0.72 mmol), and 1.5 mL of anhydrous THF. 100.3 mg (53%) of 
brown hygroscopic solid was obtained.  mp: 45.7 - 46.9 oC.  SiO2 TLC Rf 0.44 
(CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 8.19 (s, 1 H), 8.01 (d, J = 7.2 
Hz, 2 H), 7.56 (m, 2 H), 7.52 (m, 1 H), 6.36 (d, J = 2.0 Hz, 1 H), 6.23 (d, J = 2.0 Hz, 1 
H), 4.45 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 1.66 (m, 2 H), 1.57 (d, 
J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.89 (s, 9 H), 0.06 (s, 6 H).  Anal Calcd for 
C27H39N3O3Si: C, 67.32; H, 8.16; N, 8.72. Found: C, 67.64; H, 8.06; N, 8.72. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-chlorobenzamide (104b).  Compound 104b was synthesized 
with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-amine (103; 150.2 mg, 0.40 mmol), 2-chloro benzoyl chloride 
(66 µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1 mL of anhydrous THF. 90 mg 
(44%) of brown hygroscopic solid was obtained.  mp: 42.1 - 43.5 oC.  SiO2 TLC Rf 0.47 
(CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR (CDCl3): δ 8.19 (s, 1 H), 7.78 (m, 1H), 
7.47 (m, 1 H), 7.45 (m, 1 H), 7.38 (m, 1 H), 6.36 (d, J = 2.0 Hz, 1 H), 6.23 (d, J = 2.0 Hz, 
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1 H), 4.45 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 1.66 (m, 2 H), 1.57 
(d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.89 (s, 9 H), 0.06 (s, 6 H).  Anal Calcd for 
C27H38ClN3O3Si: C, 62.83; H, 7.42; N, 8.14. Found: C, 63.03; H, 7.44; N, 7.94. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-chlorobenzamide (104c). Compound 104c was synthesized 
with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-amine (103; 150.0 mg, 0.40 mmol), 3-chlorobenzoyl chloride (67 
µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1.2 mL of anhydrous THF. 126.4 mg 
(61.6%) of brown hygroscopic solid was obtained.  mp: 35.4 - 36.0 oC.  SiO2 TLC Rf 
0.41 (CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR (CDCl3): δ 8.19 (s, 1 H), 7.85 (s, 
1H), 7.81 (m, 1 H), 7.54 (m, 1 H), 7.43 (d, J = 7.6 Hz, 1 H), 6.38 (d, J = 2.0 Hz, 1 H), 
6.21 (d, J = 2.0 Hz, 1 H), 4.45 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 
1.66 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.90 (s, 9 H), 0.06 (s, 6 
H).  Anal Calcd for C27H38ClN3O3Si.1/3H2O: C, 62.11; H, 7.46; N, 8.05. Found: C, 
62.34; H, 7.37; N, 7.81. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-chlorobenzamide (104d).  Compound 104d was synthesized 
with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-amine (103; 150.1 mg, 0.40 mmol), 4-chlorobenzoyl chloride (67 
µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1 mL of anhydrous THF.  102.2 mg 
(50%) of brown hygroscopic solid was obtained.  mp: 42.1 - 42.9 oC.  SiO2 TLC Rf 0.48 
(CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR (CDCl3): δ 8.19 (s, 1 H), 7.95 (d, J = 8.4 
Hz, 2 H), 7.47 (d, J = 8.4 Hz, 2 H), 6.38 (d, J = 2.0 Hz, 1 H), 6.21 (d, J = 2.0 Hz, 1 H), 
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4.45 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 1.66 (m, 2 H), 1.57 (d, J = 
6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H) 0.90 (s, 9 H), 0.06 (s, 6 H). Anal Calcd for 
C27H38ClN3O3Si.1/3H2O: C, 62.11; H, 7.46; N, 8.05. Found: C, 62.12; H, 7.46; N, 7.98. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-fluororobenzamide (104e).  Compound 104e was synthesized 
using procedure A with 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-amine (103; 150.2 mg, 0.40 mmol), 2-fluorobenzoyl chloride (61 
µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1.2 mL of anhydrous THF.  74.6 mg 
(38%) of brown hygroscopic solid was obtained.  mp: 40.1 - 41.9 oC.  SiO2 TLC Rf 0.42 
(CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 9.67 (s, 1 H), 8.19 (d, J = 2.0 
Hz, 1 H), 7.47 (m, 1 H), 7.51 (m, 1 H), 7.33 (m, 1 H), 6.41 (d, J = 2.0 Hz, 1 H), 6.23 (d, J 
= 2.0 Hz, 1 H), 4.45 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 1.66 (m, 2 
H), 1.57 (d, J = 6.8 Hz, 6 H), 0.92 (t, J = 7.6 Hz, 3 H), 0.87 (s, 9 H), 0.06 (s, 6 H).  Anal 
Calcd for C27H38FN3O3Si: C, 64.90; H, 7.67; N, 8.41. Found: C, 64.92; H, 7.68; N, 8.13. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-fluororobenzamide (104f).  Compound 104f was synthesized 
with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-amine (103; 150.1 mg, 0.40 mmol), 3-fluorobenzoyl chloride (61 
µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1 mL of anhydrous THF. 116.0 mg 
(58.4%) of brown hygroscopic solid was obtained.  mp: 32.9 - 33.3 oC.  SiO2 TLC Rf 
0.43 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 8.21 (s, 1 H), 7.79 (s, 1 
H), 7.69 (m, 1 H), 7.47 (m, 1 H), 7.26 (d, J = 7.6 Hz, 1 H), 6.39 (d, J = 2.0 Hz, 1 H), 6.21 
(d, J = 2.0 Hz, 1 H), 4.45 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 1.66 
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(m, 2 H), 1.58 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.93 (s, 9 H), 0.06 (s, 6 H).  
Anal Calcd for C27H38FN3O3Si.1/3H2O: C, 64.13; H, 7.71; N, 8.31. Found: C, 64.30; H, 
7.51; N, 8.36. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-fluororobenzamide (104g).  Compound 104g was 
synthesized with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-
1-isopropyl-1H-benzo[d]imidazol-4-amine (103; 150.1 mg, 0.40 mmol), 4-fluorobenzoyl 
chloride (61 µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1.2 mL of anhydrous THF. 
113.4 mg (57.1%) of brown hygroscopic solid was obtained.  mp: 92.1 - 93.5 oC.  SiO2 
TLC Rf 0.51 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 9.02 (s, 1 H), 
7.02 (d, J = 8.4 Hz, 2 H), 7.47 (d, J = 8.4 Hz, 2 H), 7.18 (d, J = 2.0 Hz, 1 H), 6.45 (d, J = 
2.0 Hz, 1 H), 4.52 (m, 1 H), 4.38 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 1.66 (m, 2 
H), 1.56 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.90 (s, 9 H), 0.06 (s, 6 H).  Anal 
Calcd for C27H38FN3O3Si.1H2O: C, 62.64; H, 7.79; N, 8.12. Found: C, 62.87; H, 7.82; N, 
8.04. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-nitrobenzamide (104h).  Compound 104h was synthesized 
with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-amine (103; 200.2 mg, 0.50 mmol), 2-nitrobenzoyl chloride 
(118.1 mg, 0.64 mmol), TEA (0.15 mL, 1.06 mmol), and 1.5 mL of anhydrous THF.  
210.2 mg (75.2%) of yellow solid was obtained.  mp: 72.9 - 73.5 oC.  SiO2 TLC Rf 0.52 
(CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 9.04 (s, 1 H), 8.12 (m, 1 H), 
8.08 (m, 1 H), 7.67 (m, 1 H), 7.65 (d, J = 4.0 Hz, 1 H), 7.23 (d, J = 2.0 Hz, 1 H), 6.83 (d, 
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J = 2.0 Hz, 1 H), 4.46 (m, 1 H), 4.34 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 1.67 (m, 
2 H), 1.56 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.88 (s, 9 H), 0.06 (s, 6 H).  Anal 
Calcd for C27H38N4O5Si: C, 61.57; H, 7.27; N, 10.64. Found: C, 61.46; H, 7.09; N, 10.41. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-nitrobenzamide (104i). Compound 104i was synthesized with 
procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-amine (103; 201.1 mg, 0.50 mmol), 3-nitrobenzoyl chloride (117.1 
mg, 0.64 mmol), TEA (0.15 mL, 1.06 mmol), and 1.5 mL of anhydrous THF. 190.0 mg 
(68.1%) of yellow solid was obtained.  mp: 99.3 - 100.8 oC.  SiO2 TLC Rf 0.49 
(CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 8.92 (s, 1 H), 8.57 (s, 1 H), 
8.43 (m, 1 H), 8.40 (m, 1 H), 8.31 (d, J = 7.6 Hz, 1 H), 8.15 (d, J = 2.0 Hz, 1 H), 7.72 (d, 
J = 2.0 Hz, 1 H), 4.46 (m, 1 H), 4.35 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 1.66 (m, 
2 H), 1.57 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.93 (s, 9 H), 0.06 (s, 6 H).  Anal 
Calcd for C27H38N4O5Si.1/2H2O: C, 60.53; H, 7.34; N, 10.46. Found: C, 60.29; H, 7.39; 
N, 10.56. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-nitrobenzamide (104j).  Compound 104j was synthesized 
with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-amine (103; 200.2 mg, 0.50 mmol), 4-nitrobenzoyl chloride 
(118.2, 0.64 mmol), TEA (0.15 mL, 1.06 mmol), and 1.5 mL of anhydrous THF.  190.1 
mg (68.1%) of yellow solid was obtained.  mp: 133.2 - 133.9 oC.  SiO2 TLC Rf 0.54 
(CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 9.29 (s, 1 H), 8.37 (d, J = 8.4 
Hz, 2 H), 8.20 (d, J = 8.4 Hz,2 H), 8.18 (d, J = 2.0 Hz,1 H), 7.88 (d, J = 2.0 Hz, 1 H), 
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4.52 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.45 (m, 1 H), 1.66 (m, 2 H), 1.56 (d, J = 
6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz,3 H), 0.90 (s, 9 H), 0.06 (s, 6 H).  Anal Calcd for 
C27H38N4O5Si.1H2O: C, 59.53; H, 7.43; N, 10.29. Found: C, 59.46; H, 7.18; N, 10.21. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-methylbenzamide (104k).  Compound 104k was synthesized 
with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-amine (103; 150.1 mg, 0.40 mmol), 2-methylbenzoyl chloride 
(69 µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1 mL of anhydrous THF.  98.3 mg 
(50%) of brown hygroscopic solid was obtained.  mp: 32.2 - 33.5 oC.  SiO2 TLC Rf 0.39 
(CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 8.67 (s, 1 H), 8.19 (m, 1 H), 
7.58 (m, 1 H), 7.56 (m, 1 H), 7.35 (d, J = 4.0 Hz, 1 H), 7.25 (d, J = 2.0 Hz, 1 H), 6.73 (d, 
J = 2.0 Hz, 1 H), 4.45 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 2.52 (s, 3 
H), 1.67 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz,3 H), 0.89 (s, 9 H), 0.06 
(s, 6 H).  Anal Calcd for C28H41N3O3Si: C, 67.84; H, 8.34; N, 8.48. Found: C, 67.69; H, 
8.23; N, 8.32. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-methylbenzamide (104l).  Compound 104l was synthesized 
with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-amine (103; 150.2 mg, 0.40 mmol), 3-methylbenzoyl chloride 
(60 µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1 mL of anhydrous THF. 84.0 mg 
(42.6%) of brown hygroscopic solid was obtained.  mp: 33.5 - 33.7 oC.  SiO2 TLC Rf 
0.41 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 9.07 (s, 1 H), 8.20 (s, 1 
H), 7.81 (m, 1 H), 7.37 (m, 1 H), 7.26 (d, J = 7.6 Hz,1 H), 7.15 (d, J = 2.0 Hz, 1 H), 6.74 
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(d, J = 2.0 Hz, 1 H), 4.43 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 2.47 
(s, 3 H),  1.66 (m, 2 H), 1.57 (d, J = 6.8 Hz,6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.91 (s, 9 H), 
0.06 (s, 6 H).  Anal Calcd for C28H41N3O3Si: C, 67.84; H, 8.34; N, 8.48. Found: C, 67.80; 
H, 8.29; N, 8.31. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-methylbenzamide (104m).  Compound 104m was 
synthesized with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-
1-isopropyl-1H-benzo[d]imidazol-4-amine (103; 150.2 mg, 0.40 mmol), 4-methylbenzoyl 
chloride (69 µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1 mL of anhydrous THF.  
74.6 mg (37.8%) of brown hygroscopic solid was obtained.  mp: 36.3 - 37.1 oC.  SiO2 
TLC Rf 0.45 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 9.06 (s, 1 H), 
8.19 (d, J = 8.4 Hz, 2 H), 7.91 (d, J = 8.4 Hz, 2 H), 7.18 (d, J = 2.0 Hz, 1 H), 6.45 (d, J = 
2.0 Hz, 1 H), 4.52 (m, 1 H), 4.38 (s, 2 H, NH), 4.26 (m, 2 H), 3.47 (m, 1 H), 2.44 (s, 3 H), 
1.66 (m, 2 H), 1.56 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.90 (s, 9 H), 0.06 (s, 6 
H).  Anal Calcd for C28H41N3O3Si.1/4H2O: C, 67.23; H, 8.36; N, 8.40. Found: C, 67.30; 
H, 8.32; N, 8.40. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-methoxybenzamide (104n).  Compound 104n was 
synthesized with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-
1-isopropyl-1H-benzo[d]imidazol-4-amine (103; 150.4 mg, 0.40 mmol), 2-
methoxybenzoyl chloride (69 µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1 mL of 
anhydrous THF. 117.0 mg (57.6%) of brown hygroscopic solid was obtained.  mp: 40.5 - 
41.8 oC.  SiO2 TLC Rf 0.44 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 
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8.32 (s, 1 H), 8.26 (d, J = 4.0 Hz, 1 H), 7.82 (m, 1 H), 7.52 (m, 1 H), 7.47 (m, 1 H), 7.15 
(d, J = 2.0 Hz, 1 H), 6.83 (d, J = 2.0 Hz, 1 H), 4.45 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 
2 H), 4.06 (s, 3 H), 3.47 (m, 1 H), 1.67 (m, 2 H), 1.56 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 
Hz, 3 H), 0.88 (s, 9 H), 0.06 (s, 6 H).  Anal Calcd for C28H41N3O4Si: C, 65.72; H, 8.08; 
N, 8.21. Found: C, 65.82; H, 8.00; N, 8.05. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-methoxybenzamide (104o).  Compound 104o was 
synthesized with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-
1-isopropyl-1H-benzo[d]imidazol-4-amine (103; 150.2 mg, 0.40 mmol), 3-
methoxybenzoyl chloride (69 µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1 mL of 
anhydrous THF.  90.0 mg (44.3%) of brown hygroscopic solid was obtained.  mp: 34.0 - 
35.7 oC. SiO2 TLC Rf 0.41 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 
8.19 (s, 1 H), 7.81 (s, 1 H), 7.57 (m, 1 H), 7.54 (m, 1 H), 7.26 (d, J = 7.6 Hz, 1 H), 7.11 
(d, J = 2.0 Hz, 1 H), 6.83 (d, J = 2.0 Hz, 1 H), 4.47 (m, 1 H), 4.32 (s, 2 H, NH), 4.26 (m, 
2 H), 3.89 (s, 3 H), 3.47 (m, 1 H), 1.66 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 
Hz,3 H),  0.91 (s, 9 H), 0.06 (s, 6 H). Anal Calcd for C28H41N3O4Si: C, 65.72; H, 8.08; N, 
8.21. Found: C, 65.96; H, 8.22; N, 8.35. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-methoxybenzamide (104p).  Compound 104p was 
synthesized with procedure A from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-
1-isopropyl-1H-benzo[d]imidazol-4-amine (103; 150.2 mg, 0.40 mmol), 4-
methoxybenzoyl chloride (67 µL, 0.52 mmol), TEA (0.1 mL, 0.72 mmol), and 1.2 mL of 
anhydrous THF. 110.1 mg (54.1%) of brown hygroscopic solid was obtained.  mp: 31.9 - 
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33.0 oC.  SiO2 TLC Rf 0.47 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 
8.19 (s, 1 H), 8.17 (d, J = 8.4 Hz, 2 H), 7.98 (d, J = 8.4 Hz, 2 H), 7.62 (d, J = 2.0 Hz, 1 
H), 7.27 (d, J = 2.0 Hz, 1 H), 4.58 (m, 1 H), 4.32 (s, 2 H, NH), 4.25 (m, 2 H), 3.90 (s, 3 
H), 3.47 (m, 1 H), 1.64 (m, 2 H), 1.56 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.91 
(s, 9 H), 0.06 (s, 6 H).  Anal Calcd for C28H41N3O4Si.1/17H2O: C, 65.59; H, 8.08; N, 
8.22. Found: C, 65.26; H, 8.19; N, 8.51. 
General Procedure B: C-4 benzamides (TBDMS deprotection) (105a-105p):  N-(6-
((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-yl) 
benzamides, 104a-104p were dissolved in to 5 mL of EtOH. 0.5 mL of conc HCl was 
added and the reaction was stirred for 12 h at 23 oC.  The solvent was removed under 
reduced pressure.  The crude solid product was triturated three times with 5 mL portions 
of hexane retaining the solid as the product to afford compounds 105a-105p with typical 
yields of 90-98%. 
N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-yl)benzamide 
hydrochloride (105a).  Compound 105a was synthesized with procedure B from N-(6-
((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide (104a; 110.0 mg, 0.23 mmol), 0.5 mL of conc HCl, and 5 mL of EtOH.  
80.0 mg (95.3%) of a white solid was obtained.  mp: 182.1 - 183.9 oC.  SiO2 TLC Rf 0.41 
(CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4) δ 9.38 (s, 1 H), 8.07 (m, 2 
H), 7.64 (m, 2 H), 7.59 (m, 1 H), 7.54 (d, J = 2.0 Hz, 1 H), 7.30 (d, J = 2.0 Hz, 1 H), 5.03 
(m, 1 H), 4.95 (s, 2 H, NH), 3.77 (m, 2 H), 3.31 (m, 1 H), 2.08 (s, 1 H, OH), 1.80 (m, 2 
H), 1.71 (d, J = 6.8 Hz, 6 H), 1.03 (t, J = 7.6 Hz, 3 H). Anal Calcd for 
C21H26ClN3O3.1H2O: C, 59.78; H, 6.69; N, 9.95. Found: C, 59.95; H, 6.32; N, 9.72. 
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2-chloro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105b).  Compound 105b was synthesized with procedure 
B from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-chlorobenzamide (104b; 110.0 mg, 0.21 mmol), 0.6 mL of 
conc HCl, and 6 mL of EtOH.  77.1 mg (90%) of a white solid was obtained. mp: 187.9 - 
189.0 oC.  SiO2 TLC Rf 0.44 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): 
δ 9.39 (s, 1 H), 7.73 (m, 1 H), 7.56 (m, 1 H), 7.41 (m, 1 H), 7.36 (d, J = 4.0 Hz, 1 H), 
7.28 (d, J = 2.0 Hz, 1 H), 7.23 (d, J = 2.0 Hz, 1 H), 5.04 (m, 1 H), 4.49 (s, 2 H, NH), 3.78 
(m, 2 H), 3.76 (m, 1 H), 1.83 (s, 1 H, OH), 1.81 (m, 2 H), 1.77 (d, J = 6.8 Hz, 6 H), 1.06 
(t, J = 7.6 Hz, 3 H).  Anal Calcd for C21H25Cl2N3O3.1/2H2O: C, 56.38; H, 5.86; N, 9.39. 
Found: C, 56.23; H, 5.72; N, 9.04. 
3-chloro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105c).  Compound 105c was synthesized using procedure 
B with N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-chlorobenzamide (104c; 110.0 mg, 0.21 mmol), 0.6 mL of conc 
HCl, and 6 mL of EtOH.  79.0 mg (92%) of a white solid was obtained. mp: 165.9 - 
166.5 oC.  SiO2 TLC Rf 0.37 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): 
δ 9.42 (s, 1 H), 8.09 (s, 1H), 8.02 (m, 1H), 7.66 (m, 1H), 7.58 (d, J = 7.6 Hz, 1 H), 7.43 
(d, J = 2.0 Hz, 1 H), 7.28 (d, J = 2.0 Hz, 1 H), 5.04 (m, 1 H), 4.89 (s, 2 H, NH), 3.78 (m, 
2 H), 3.47 (m, 1 H), 1.85 (s, 1 H, OH), 1.78 (m, 2 H), 1.76 (d, J = 6.8 Hz, 6 H), 1.01(t, J 
= 7.6 Hz, 3 H). Anal Calcd for C21H25Cl2N3O3.1/2H2O: C, 56.38; H, 5.86; N, 9.39. 
Found: C, 56.66; H, 5.78; N, 9.38. 
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4-chloro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105d).  Compound 105d was synthesized with procedure 
B from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-chlorobenzamide  (104d; 98.1 mg, 0.19 mmol), 0.6 mL of conc 
HCl, and 6 mL of EtOH. 69.4 mg (91%) of a white solid was obtained. mp: 238.9 - 240.2 
oC.  SiO2 TLC Rf 0.44 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): δ 
9.41 (s, 1 H), 8.06 (d, J = 8.4 Hz, 2 H), 7.57 (d, J = 8.4 Hz, 2 H), 7.42 (d, J = 2.0 Hz, 1 
H), 7.28 (d, J = 2.0 Hz, 1 H), 5.05 (m, 1 H), 4.89 (s, 2 H, NH), 3.77 (m, 2 H), 3.45 (m, 1 
H), 1.81 (s, 1 H, OH), 1.79 (m, 2 H), 1.76 (d, J = 6.8 Hz, 6 H), 1.05 (t, J = 7.6 Hz, 3 H).  
Anal Calcd for C21H25Cl2N3O3: C, 57.54; H, 5.75; N, 9.59. Found: C, 57.52; H, 5.81; N, 
9.49. 
2-fluoro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105e).  Compound 105e was synthesized with procedure 
B from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-fluorobenzamide (104e; 94.3 mg, 0.19 mmol), 0.6 mL of conc 
HCl, and 6 mL of EtOH.  60.1 mg (82.6%) of a white solid was obtained. mp: 125.2 - 
126.9 oC.  SiO2 TLC Rf 0.37 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): 
δ 9.39 (s, 1 H), 7.92 (m, 1 H), 7.63 (m, 1 H), 7.40 (m, 1 H), 7.34 (d, J = 4.0 Hz, 1 H), 
7.31 (d, J = 2.0 Hz, 1 H), 7.28 (d, J = 2.0 Hz, 1 H), 5.04 (m, 1 H), 4.48 (s, 2 H, NH), 3.76 
(m, 2 H), 3.31 (m, 1 H), 1.79 (s, 1 H, OH), 1.78 (m, 2 H), 1.72 (d, J = 6.8 Hz, 6 H), 1.01 
(t, J = 7.6 Hz, 3 H). Anal Calcd for C21H25ClFN3O3.1H2O: C, 57.34; H, 6.19; N, 9.55. 
Found: C, 57.34; H, 5.95; N, 9.24. 
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3-fluoro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105f).  Compound 105f was synthesized with procedure B 
from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-fluorobenzamide (104f; 103.0 mg, 0.21 mmol), 0.6 mL of conc 
HCl, and 6 mL of EtOH.  72.6 mg (94.2%) of a white solid was obtained. mp: 130.4 - 
131.6 oC.  SiO2 TLC Rf 0.39 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): 
δ 9.42 (s, 1 H), 7.92 (s, 1H), 7.82 (m, 1 H), 7.61 (m, 1 H), 7.44 (d, J = 7.6 Hz, 1 H), 7.43 
(d, J = 2.0 Hz, 1 H), 7.31 (d, J = 2.0 Hz, 1 H), 5.04 (m, 1 H), 4.81 (s, 2 H, NH), 3.79 (m, 
2 H), 3.45 (m, 1 H), 1.82 (s, 1 H, OH), 1.78 (m, 2 H), 1.77 (d, J = 6.8 Hz, 6 H), 1.03 (t, J 
= 7.6 Hz, 3 H). Anal Calcd for C21H25ClFN3O3.1H2O: C, 57.34; H, 6.19; N, 9.55. Found: 
C, 57.26; H, 6.05; N, 9.36. 
4-fluoro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105g).  Compound 105g was synthesized with procedure 
B from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-fluorobenzamide (104g; 100.0 mg, 0.20 mmol), 0.6 mL of conc 
HCl, and 6 mL of EtOH.  77.1 mg (90%) of a white solid was obtained. mp: 205.3 - 
206.7 oC.  SiO2 TLC Rf 0.47 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): 
δ 9.41 (s, 1 H), 8.16 (d, J = 8.4 Hz, 2 H), 8.14 (d, J = 8.4 Hz, 2 H), 7.43 (d, J = 2.0 Hz, 1 
H), 7.32 (d, J = 2.0 Hz, 1 H), 5.05 (m, 1 H), 4.51 (s, 2 H, NH), 3.80 (m, 2 H), 3.63 (m, 1 
H), 1.75 (s, 1 H, OH), 1.74 (m, 2 H), 1.73 (d, J = 6.8 Hz, 6 H), 1.05 (t, J = 7.6 Hz, 3 H). 
Anal Calcd for C21H25ClFN3O3.2/3H2O: C, 58.13; H, 6.12; N, 9.68. Found: C, 57.89; H, 
5.93; N, 9.57. 
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2-nitro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105h).  Compound 105h was synthesized with procedure 
B from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-nitrobenzamide (104h; 180.0 mg, 0.34 mmol), 1 mL of conc 
HCl, and 10 mL of EtOH.  139.0 mg (98.6%) of a yellow solid was obtained.  mp: 144.1 
- 145.3 oC.  SiO2 TLC Rf 0.48 (CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR (MeOD-
d4): δ 9.41 (s, 1 H), 7.74 (m, 1 H), 7.58 (m, 1 H), 7.43 (m, 1 H), 7.32 (d, J = 4.0 Hz, 1 H), 
7.28 (d, J = 2.0 Hz, 1 H), 7.23 (d, J = 2.0 Hz, 1 H), 5.04 (m, 1 H), 4.49 (s, 2 H, NH), 3.78 
(m, 2 H), 3.76 (m, 1 H), 1.83 (s, 1 H, OH), 1.83 (m, 2 H), 1.77 (d, J = 6.8 Hz, 6 H), 1.07 
(t, J = 7.6 Hz, 3 H).  Anal Calcd for C21H25ClN4O5.H2O: C, 54.02; H, 5.83; N, 9.59. 
Found: C, 54.12; H, 5.72; N, 9.34. 
3-nitro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105i).  Compound 105i was synthesized with procedure B 
from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-nitrobenzamide (104i; 160.0 mg, 0.30 mmol), 1 mL of conc 
HCl, and 10 mL of EtOH. 122.1 mg (97.4%) of a yellow solid was obtained.  mp: 95.9 - 
97.0 oC.  SiO2 TLC Rf 0.45 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): 
δ 9.44 (s, 1 H), 8.95 (s, 1H), 8.51 (m, 1H), 8.47 (m, 1H), 7.85 (d, J = 7.6 Hz, 1 H), 7.45 
(d, J = 2.0 Hz, 1 H), 7.31 (d, J = 2.0 Hz, 1 H), 5.04 (m, 1 H), 4.81 (s, 2 H, NH), 3.79 (m, 
2 H), 3.45 (m, 1 H), 1.82 (s, 1 H, OH), 1.78 (m, 2 H), 1.77 (d, J = 6.8 Hz, 6 H), 1.02 (t, J 
= 7.6 Hz, 3 H).  Anal Calcd for C21H25ClN4O5.2/3H2O: C, 54.72; H, 5.76; N, 12.16. 
Found: C, 54.89; H, 5.70; N, 12.03. 
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4-nitro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105j).  Compound 105j was synthesized with procedure B 
from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-nitrobenzamide (104j; 140.0 mg, 0.27 mmol), 1.2 mL of conc 
HCl, and 12 mL of EtOH. 105.0 mg (96.3%) of a white solid was obtained.  mp: 231.4 - 
232.0 oC.  SiO2 TLC Rf 0.50 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): 
δ 9.43 (s, 1 H), 8.42 (d, J = 8.4 Hz, 2 H), 8.28 (d, J = 8.4 Hz, 2 H), 7.44 (d, J = 2.0 Hz, 1 
H), 7.31 (d, J = 2.0 Hz, 1 H), 5.03 (m, 1 H), 4.50 (s, 2 H, NH), 3.78 (m, 2 H), 3.35 (m, 1 
H), 1.74 (s, 1 H, OH), 1.74 (m, 2 H), 1.73 (d, J = 6.8 Hz, 6 H), 1.05 (t, J = 7.6 Hz, 3 H). 
Anal Calcd for C21H25ClN4O5: C, 56.19; H, 5.61; N, 12.48. Found: C, 55.97; H, 5.58; N, 
12.30. 
2-methyl-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105k).  Compound 105k was synthesized with procedure 
B from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-methylbenzamide (104k; 74.3 mg, 0.15 mmol), 0.5 mL of conc 
HCl, and 5 mL of EtOH.  53.2 mg (93.4%) of a white solid was obtained. mp: 104.1 - 
105.9 oC.  SiO2 TLC Rf 0.35 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): 
δ 9.38 (s, 1 H), 7.66 (m, 1H), 7.46 (m, 1H), 7.35 (m, 1H), 7.35 (d, J = 4.0 Hz, 1 H), 7.34 
(d, J = 2.0 Hz, 1 H), 7.24 (d, J = 2.0 Hz, 1 H), 5.03 (m, 1 H), 4.88 (s, 2 H, NH), 3.76 (m, 
2 H), 3.31 (m, 1 H), 2.52 (s, 3 H), 1.79 (s, 1 H, OH), 1.78 (m, 2 H), 1.72 (d, J = 6.8 Hz, 6 
H), 1.01 (t, J = 7.6 Hz, 3 H).  Anal Calcd for C22H28ClN3O3.1H2O: C, 60.61; H, 6.94; N, 
9.64. Found: C, 60.36; H, 6.67; N, 9.39. 
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3-methyl-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105l).  Compound 105l was synthesized with procedure B 
from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-methylbenzamide (104l; 74.0 mg, 0.15 mmol), 0.5 mL of conc 
HCl, and 5 mL of EtOH. 53.0 mg (93.1%) of a white solid was obtained. mp: 139.2 - 
140.4 oC.  SiO2 TLC Rf 0.36 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): 
δ 9.41 (s, 1 H), 7.91 (s, 1H), 7.87 (m, 1H), 7.48 (m, 1H), 7.46 (d, J = 7.6 Hz, 1 H), 7.43 
(d, J = 2.0 Hz, 1 H), 7.31 (d, J = 2.0 Hz, 1 H), 5.04 (m, 1 H), 4.81 (s, 2 H, NH), 3.79 (m, 
2 H), 3.45 (m, 1 H), 2.47 (s, 3 H), 1.80 (s, 1 H, OH), 1.73 (m, 2 H), 1.77 (d, J = 6.8 Hz, 6 
H), 1.05 (t, J = 7.6 Hz, 3 H).  Anal Calcd for C22H28ClN3O3.1H2O: C, 60.61; H, 6.94; N, 
9.64. Found: C, 60.36; H, 6.67; N, 9.51. 
4-methyl-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105m).  Compound 105m was synthesized with 
procedure B from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-yl)-4-methylbenzamide (104m; 74.6 mg, 0.15 mmol), 0.6 mL of 
conc HCl, and 6 mL of EtOH. 55.0 mg (96.2%) of a white solid was obtained. mp: 115.3 
- 116.0 oC.  SiO2 TLC Rf 0.43 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-
d4): δ 9.37 (s, 1 H), 7.96 (d, J = 8.4 Hz, 2 H), 7.38 (d, J = 8.4 Hz, 2 H), 7.37 (d, J = 2.0 
Hz, 1 H), 7.28 (d, J = 2.0 Hz, 1 H), 5.02 (m, 1 H), 4.51 (s, 2 H, NH), 4.48 (m, 2 H), 3.63 
(m, 1 H), 2.44 (s, 3 H), 1.75 (s, 1 H, OH), 1.74 (m, 2 H), 1.71 (d, J = 6.8 Hz, 6 H), 1.02 
(t, J = 7.6 Hz, 3 H). Anal Calcd for C22H28ClN3O3.1H2O: C, 60.61; H, 6.94; N, 9.64. 
Found: C, 60.45; H, 6.67; N, 9.34. 
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2-methoxy-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105n).  Compound 105n was synthesized with procedure 
B from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-methoxybenzamide (104n; 82.0 mg, 0.16 mmol), 0.6 mL of 
conc HCl, and 6 mL of EtOH.  60.1 mg (95.3%) of a white solid was obtained.  mp: 
101.9 - 102.2 oC.  SiO2 TLC Rf 0.41 (CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR 
(MeOD-d4): δ 9.36 (s, 1 H), 8.05 (m, 1 H), 8.03 (m, 1 H), 7.59 (m, 1 H), 7.39 (d, J = 4.0 
Hz, 1 H), 7.25 (d, J = 2.0 Hz, 1 H), 7.13 (d, J = 2.0 Hz, 1 H), 5.01 (m, 1 H), 4.48 (s, 2 H, 
NH), 4.06 (s, 3 H), 3.76 (m, 2 H), 3.7 (m, 1 H), 1.78 (s, 1 H, OH), 1.74 (m, 2 H), 1.71 (d, 
J = 6.8 Hz, 6 H), 1.03 (t, J = 7.6 Hz, 3 H).  Anal Calcd for C21H28ClN3O4.3/8H2O: C, 
60.06; H, 6.58; N, 9.33. Found: C, 60.32; H, 6.59; N, 9.13. 
3-methoxy-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105o).  Compound 105o was synthesized with  procedure 
B from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-methoxybenzamide (104o; 80.0 mg, 0.16 mmol), 0.6 mL of 
conc HCl, and 6 mL of EtOH.  58.0 mg (93.4%) of a white solid was obtained.  mp: 95.9 
- 96.5 oC.  SiO2 TLC Rf 0.36 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): 
δ 9.41 (s, 1 H), 7.65 (s, 1 H), 7.62 (m, 1 H), 8.47 (m, 1 H), 7.48 (d, J = 7.6 Hz, 1 H), 7.42 
(d, J = 2.0 Hz, 1 H), 7.21 (d, J = 2.0 Hz, 1 H), 5.04 (m, 1 H), 4.81 (s, 2 H, NH), 3.89 (s, 3 
H), 3.78 (m, 2 H), 3.45 (m, 1 H), 1.82 (s, 1 H, OH), 1.78 (m, 2 H), 1.77 (d, J = 6.8 Hz, 6 
H), 1.02 (t, J = 7.6 Hz, 3 H). Anal Calcd for C21H28ClN3O4.2H2O: C, 56.23; H, 6.86; N, 
8.94. Found: C, 56.34; H, 6.52; N, 8.60. 
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4-methoxy-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105p).  Compound 105p was synthesized with procedure 
B from N-(6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-methoxybenzamide (104p; 80.0 mg, 0.16 mmol), 0.6 mL of 
conc HCl, and 6 mL of EtOH.  58.6 mg (93.5%) of a white solid was obtained.  mp: 
114.2 - 115.0 oC.  SiO2 TLC Rf 0.44 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR 
(MeOD-d4): δ 9.38 (s, 1 H), 8.05 (d, J = 8.4 Hz, 2 H), 7.39 (d, J = 8.4 Hz, 2 H), 7.28 (d, J 
= 2.0 Hz, 1 H), 7.10 (d, J = 2.0 Hz, 1 H), 5.03 (m, 1 H), 4.50 (s, 2 H, NH), 3.90 (s, 3 H), 
3.78 (m, 2 H), 3.35 (m, 1 H), 1.74 (s, 1 H, OH), 1.74 (m, 2 H), 1.73 (d, J = 6.8 Hz, 6 H), 
1.01 (t, J = 7.6 Hz, 3 H). Anal Calcd for C21H28ClN3O4.1.5 H2O: C, 57.32; H, 6.78; N, 
9.12. Found: C, 57.59; H, 6.61; N, 9.21. 
General procedure C: Amino-substituted C-4 benzamides (105q-105r):  4-Nitro-N-
(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-yl)benzamide 
hydrochloride,  (105h-105j; 100 mg, 0.24 mmol) was dissolved into the mixture of 50 
mL of EtOH and 10 mL of CHCl3 and added to a Parr hydrogenation vessel previously 
charged with Pd/C (10% w/w, 5 mg).  After 3 vacuum/purge cycles with H2, the vessel 
was charged to 50 psi with H2 and shaken for 12 h on a Parr hydrogenation apparatus.  
The mixture was filtered through a pad of Celite and then washed with an additional 100 
mL of EtOH.  The solvent was removed under reduced pressure.  Products were typically 
obtained with a 97-99% yield. 
2-amino-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105r).  Compound 105r was synthesized with procedure 
C from 2-nitro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
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yl)benzamide hydrochloride (105h; 100.1 mg, 0.24 mmol), 50 mL of EtOH, and 10 mL 
of CHCl3 to give 99.0 mg (97.5%) of brown solid.  mp: 132.3 - 133.4 oC.  SiO2 TLC Rf 
0.46 (CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR (MeOD-d4): δ 9.41 (s, 1 H), 7.94 (m, 
1 H), 7.57 (m, 1 H), 7.49 (m, 1 H), 7.41 (d, J = 4.0 Hz, 1 H), 7.30 (d, J = 2.0 Hz, 1 H), 
7.13 (d, J = 2.0 Hz, 1 H), 5.01 (m, 1 H), 4.48 (s, 2 H, NH), 4.36 (s, 2 H, NH2), 4.06 (s, 3 
H), 3.76 (m, 2 H), 3.7 (m, 1 H), 1.78 (s, 1 H, OH), 1.74 (m, 2 H), 1.71 (d, J = 6.8 Hz, 6 
H), 1.02 (t, J = 7.6 Hz, 3 H). Anal Calcd for C21H28Cl2N4O3.1H2O: C, 53.28; H, 6.39; N, 
11.84. Found: C, 53.46; H, 6.58; N, 11.62. 
3-amino-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105s).  Compound 105s was synthesized with procedure 
C from 3-nitro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105i; 100.0 mg, 0.24 mmol), 50 mL of EtOH, and 10 mL of 
CHCl3 to give 95.6 mg (94.2%) of brown solid.  mp: 127.9 - 128.2 oC.  SiO2 TLC Rf 0.41 
(CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): δ 9.09 (s, 1 H), 7.42 (s, 1H), 
7.3 (m, 1H), 7.31 (m, 1H), 7.28 (d, J = 7.6 Hz, 1 H), 7.27 (d, J = 2.0 Hz, 1 H), 6.99 (d, J 
= 2.0 Hz, 1 H), 4.86 (m, 1 H), 4.81 (s, 2 H, NH), 3.79 (m, 2 H), 3.72 (s, 2 H, NH2), 3.45 
(m, 1 H), 1.82 (s, 1 H, OH), 1.78 (m, 2 H), 1.77 (d, J = 6.8 Hz, 6 H), 1.02 (t, J = 7.6 Hz, 3 
H).  Anal Calcd for C21H28Cl2N4O3.1/6H2O: C, 55.03; H, 6.23; N, 11.92. Found: C, 
55.30; H, 6.43; N, 11.82. 
4-amino-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105t).  Compound 105t was synthesized with procedure C 
from 4-nitro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105j; 100.4 mg, 0.24 mmol), 50 mL of EtOH, and 10 mL of 
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CHCl3 to give 100.2 mg (98.7%) of brown solid.  mp: 137.2 - 138.1 oC.  SiO2 TLC Rf 
0.46 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (MeOD-d4): δ 9.27 (s, 1 H), 7.84 (d, 
J = 8.4 Hz, 2 H), 7.31 (d, J = 8.4 Hz, 2 H), 7.26 (d, J = 2.0 Hz, 1 H), 6.72 (d, J = 2.0 Hz, 
1 H), 4.85 (m, 1 H), 4.45 (s, 2 H, NH), 3.78 (m, 2 H), 3.72 (s, 2 H, NH2), 3.35 (m, 1 H), 
1.97 (s, 1 H, OH), 1.74 (m, 2 H), 1.68 (d, J = 6.8 Hz, 6 H), 1.00 (t, J = 7.6 Hz, 3 H).  Anal 
Calcd for C21H28Cl2N4O3.2H2O: C, 51.33; H, 6.56; N, 11.40. Found: C, 51.68; H, 6.46; 
N, 11.62. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-1-naphthamide (104q).  A dry 25 mL round bottom flask was 
charged with 6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-amine, (103; 150.1 mg, 0.40 mmol), and 1 mL of anhydrous THF 
was added. TEA (0.1 mL, 0.72 mmol) was added to the reaction followed by addition of 
2-naphthoyl chloride (99.12 mg, 0.52 mmol).  The reaction was stirred for 12 h at 23 oC.  
The reaction was quenched with 1mL of NaHCO3 (aq, sat) and then stirred for 5 min.  
The reaction mixture was extracted three times with 15 mL portions of Et2O, washed 
with NaCl (aq, sat), and then dried over Na2SO4.  The organic extract was decanted off 
and the solvent was removed under vacuum. The product was isolated on SiO2 to afford 
105.6 mg (25%).  mp: 42.1 - 42.5 oC.  SiO2 TLC Rf 0.48 (CH2Cl2/5% CH3OH/0.1% 
NH4OH).   1H NMR (CDCl3): δ 8.95 (s, 1 H), 8.47 (d, J = 7.6 Hz, 1 H), 8.31 (s, 1 H), 
7.96 (d, J = 8.0 Hz, 1 H), 7.88 (d, J = 7.6 Hz, 1 H), 7.54 (d, J = 10.4 Hz, 1 H), 7.50 (m, 2 
H), 7.26 (d, J = 2.0 Hz, 1 H), 6.77 (d, J = 2.0 Hz, 1 H), 4.45 (m, 1 H), 4.36 (s, 2 H, NH), 
4.26 (m, 2 H), 3.47 (m, 1 H), 1.66 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 
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3 H), 0.89 (s, 9 H), 0.06 (s, 6 H).  Anal Calcd for C31H41N3O3Si.1/5H2O: C, 69.55; H, 
7.79; N, 7.80. Found: C, 69.75; H, 7.81; N, 7.61. 
N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-yl)-1-
naphthamide hydrochloride (105q).  N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-
yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-yl)-1-naphthamide, 104q was dissolved in 
10 mL of EtOH, and 0.2 mL of conc HCl.  The reaction was stirred for 12 h at 23 oC.  
The reaction mixture was concentrated under vacuum.  The crude product (48.1 mg) was 
triturated three times with 5 mL portions of hexane retaining the solid to afford 45.2 mg 
(96%) of a white solid.  mp: 42.1 - 42.5 oC.  SiO2 TLC Rf 0.48 (CH2Cl2/5% CH3OH/0.1% 
NH4OH).   1H NMR (MeOD-d4): δ 9.41 (s, 1 H), 8.40 (d, J = 7.6 Hz, 1 H), 8.11 (s, 1 H), 
7.99 (d, J = 8.0 Hz, 1 H), 7.94 (d, J = 7.6 Hz, 1 H), 7.62 (d, J = 10.4 Hz, 1 H), 7.59 (m, 2 
H), 7.42 (d, J = 2.0 Hz, 1 H), 6.29 (d, J = 2.0 Hz, 1 H), 5.05 (m, 1 H), 5.04 (s, 2 H, NH), 
4.51 (m, 2 H), 3.47 (m, 1 H), 1.66 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 
3 H).  Anal Calcd for C25H28ClN3O3.2H2O: C, 61.28; H, 6.58; N, 8.58. Found: C, 61.02; 
H, 6.25; N, 8.27. 
General Procedure D: Phenylacetamides (108a-108b):  A dry 25 mL round bottom 
flask was charged with 6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-amine, (103; 150 mg, 0.40 mmol), and 2 mL of anhydrous THF 
was added.  Solid NaHCO3 (67.2 mg, 0.80 mmol) was added to the reaction followed by 
addition of the appropriate acid chloride (0.44 mmol).  The reaction was stirred for 12 h 
at 23 oC.  The reaction was quenched with 1 mL of NaHCO3 (aq, sat) and stirred for 5 
min.  This reaction mixture was then extracted three times with 15 mL portions of Et2O, 
washed with NaCl (aq, sat), and dried over Na2SO4.  The extract was decanted off and the 
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solvent was removed under reduced pressure.  The product was isolated on SiO2 with 
typical yields of 50-60%. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-phenylacetamide (108a).  Compound 108a was synthesized 
with procedure D from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-amine (103; 150.1 mg, 0.40 mmol), 2-phenylacetyl chloride 
(67.9 mg, 0.44 mmol), NaHCO3 (67.2 mg, 0.80 mmol), and 2 mL of anhydrous THF to 
give 141.0 mg (71.6%) of a brown hygroscopic solid.  mp: 32.5 - 33.0 oC. SiO2 TLC Rf 
0.42 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 8.60 (s, 1 H), 8.04 (d, J 
= 7.6 Hz, 2 H), 7.77 (m, 2 H), 7.69 (m, 1 H), 7.29 (d, J = 2.0 Hz, 1 H), 6.81 (d, J = 2.0 
Hz, 1 H), 4.50 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.80 (s, 2 H), 3.47 (m, 1 H), 
1.66 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H), 0.89 (s, 9 H), 0.69 (s, 6 
H).  Anal Calcd for C28H41N3O3Si: C, 67.84; H, 8.34; N, 8.48. Found: C, 67.65; H, 8.17; 
N, 8.27. 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-(2-fluorophenyl)acetamide (108b).  Compound 108b was 
synthesized with procedure D from 6-((1-((tert-butyldimethylsilyl)oxy) butan-2-yl)oxy)-
1-isopropyl-1H-benzo[d]imidazol-4-amine (103; 150.2 mg, 0.40 mmol),  2-(2-
fluorophenyl)acetyl chloride (75.9 mg, 0.44 mmol), NaHCO3 (69.4 mg, 0.80 mmol), and 
2 mL of anhydrous THF to give 150.4 mg (73.7%) of a brown hygroscopic solid.  mp: 
45.7 - 48.3oC. SiO2 TLC Rf 0.45 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR 
(CDCl3): δ 8.60 (s, 1 H), 8.04 (d, J= 4.0 Hz, 2 H), 7.77 (m, 1 H), 7.69 (m, 1 H), 7.29 (d, J 
= 2.0 Hz, 1 H), 6.81 (d, J = 2.0 Hz, 1 H), 4.50 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 
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3.80 (s, 2 H), 3.47 (m, 1 H), 1.66 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 
H), 0.89 (s, 9 H), 0.69 (s, 6 H).  Anal Calcd for C28H41FN3O3Si.2/7H2O: C, 64.81; H, 
7.88; N, 8.10. Found: C, 64.78; H, 7.92; N, 8.01. 
General Procedure E: Phenylacetamides (TBDMS deprotection) (109a-109b):  N-(6-
((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)-2-phenylacetamides, 108a-108b were dissolved in to 12 mL of EtOH. 1.2 mL conc 
HCl was added and the reaction was stirred for 12 h at 23 oC.  The reaction mixture was 
basified with an addition of 10 mL of NaHCO3 (aq, sat) and then extracted three times 
with 15 mL portions of Et2O, washed with NaCl (aq, sat), and then dried over Na2SO4.  
The organic extracts were decanted off and then concentrated under vacuum. The crude 
product was triturated three times with 5 mL portions of hexane retaining the solid to 
afford compounds 109a-109b with typical yields of 35-46%. 
N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-yl)-2-
phenylacetamide (109a).  Compound 109a was synthesized with procedure E from N-
(6-((1-((tert-butyldimethylsilyl) oxy)butan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-
4-yl)-2-phenylacetamide (108a; 130.2 mg, 0.26 mmol), 1.2 mL of conc HCl, and 12 mL 
of EtOH to give 35.0 mg (35.3%) of a white solid. mp: 122.0 - 123.3 oC.  SiO2 TLC Rf 
0.39 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 8.75 (s, 1 H), 8.01 (d, J 
= 7.6 Hz, 2 H), 7.71 (m, 2 H), 7.69 (m, 1 H), 7.29 (d, J = 2.0 Hz, 1 H), 6.81 (d, J = 2.0 
Hz, 1 H), 4.50 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.80 (s, 2 H), 3.47 (m, 1 H), 
1.66 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H).  Anal Calcd for 
C22H27N3O3.H2O: C, 66.14; H, 7.32; N, 10.52. Found: C, 66.37; H, 7.47; N, 10.71. 
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2-(2-fluorophenyl)-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)acetamide (109b).  Compound 109b was synthesized with 
procedure E from N-(6-((1-((tert-butyldimethylsilyl) oxy)butan-2-yl)oxy)-1-isopropyl-
1H-benzo[d]imidazol-4-yl)-2-(2-fluorophenyl)acetamide (108b; 140.0 mg, 0.27 mmol), 
1.2 mL of conc HCl, and 12 mL of EtOH to give 60.0 mg (55.6%) of a white solid.  mp: 
135.5 - 135.9 oC.  SiO2 TLC Rf 0.43 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR 
(CDCl3): δ 8.77 (s, 1 H), 8.00 (m, 1 H), 7.79 (m, 2 H), 7.69 (m, 1 H), 7.29 (d, J = 2.0 Hz, 
1 H), 6.81 (d, J = 2.0 Hz, 1 H), 4.50 (m, 1 H), 4.36 (s, 2 H, NH), 4.26 (m, 2 H), 3.80 (s, 2 
H), 3.47 (m, 1 H), 1.66 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 0.98 (t, J = 7.6 Hz, 3 H).  Anal 
Calcd for C22H27FN3O3: C, 66.15; H, 6.56; N, 10.52. Found: C, 66.49; H, 6.85; N, 10.22. 
2-(2-fluorophenyl)acetyl chloride (107b). A 25 mL round bottom flask was charged 
with 2-(2-fluorophenyl)acetic acid (110; 1 g, 6.49 mmol), and  7 mL of DCM.  The 
reaction mixture was cooled to 0 oC on ice-bath and 100 µL of DMF was added followed 
by slow addition of oxalyl chloride (1.09 mL, 12.97 mmol) over 5 min. The reaction was 
stirred at 23 oC for 3 h and gas (HCl, CO2, CO) was slowly evolved.  The solvent was 
removed under reduced pressure and crude product (yellow oil, 1.1 g, quant.) obtained 
was directly in the next step.  bp: 201.3 - 202.8 oC (lit139 bp: 203 - 204 oC ).  1H NMR 
(CDCl3): δ 8.63 (s, 1 H), 8.21 (m, 1 H), 7.82 (m, 1 H), 7.63 (m, 1 H), 4.26 (s, 2 H). IR 
1759 cm-1.  
6-ethoxy-1-isopropyl-4-nitro-1H-benzo[d]imidazole (117e).  A dry 100 mL one-necked 
flask was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (91; 250.0 mg, 1.1 
mmol), ethyl iodide (0.2 mL, 2.05 mmol) and 2 mL of DMF.  NaH (81.4 mg, 3.4 mmol) 
was added at 0 °C in two portions.  This suspension was stirred at 0 oC for 30 min and at 
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23 °C for an additional 2 h.  The reaction mixture was poured into 10 mL EA and 10 mL 
K2CO3 (aq, sat).  The mixture was extracted three times each with 10 mL portions of EA 
and the combined extracts were washed with NaCl (aq, sat) and dried over Na2SO4.  The 
extract was decanted and the solvent was removed under reduced pressure.  The crude 
material (200.8 mg) was isolated on SiO2 and eluted with hexanes/EA.  Recrystallization 
from EA and hexane gave 169.0 mg (60%) of yellow solid.  mp: 82.7 - 82.9 °C.  SiO2 
TLC Rf 0.52 (CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR (CDCl3): δ 8.11 (s, 1 H), 
7.79 (d, J = 2.0 Hz, 1 H), 7.21 (d, J = 2.0 Hz, 1 H), 4.61 (m, 1 H), 4.16 (q, J = 6.8 Hz, 2 
H), 1.64 (d, J = 6.8 Hz, 6 H), 1.48 (t, J = 7.2 Hz, 3 H).  Anal Calcd for 
C12H15N3O3.1/5H2O: C, 57.00; H, 6.14; N, 16.62. Found: 56.93; H, 6.00; N, 16.49. 
1-isopropyl-4-nitro-6-propoxy-1H-benzo[d]imidazole (117f).  A dry 100 mL one-
necked flask was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (91; 250.0 
mg, 1.1 mmol), 1-iodopropane (0.22 mL, 2.30 mmol), and 2 mL of DMF.  NaH (81.4 mg, 
3.4 mmol) was added at 0 °C in two portions.  This solution was stirred at 0 °C for 30 
min and at 23 °C for an additional 2 h.  The reaction mixture was poured into 10 mL EA 
and 10 mL K2CO3 (aq, sat).  The mixture was extracted three times each with 10 mL 
portions of EA and the combined extracts were washed with NaCl (aq, sat) and dried over 
Na2SO4.  The extract was decanted and the solvent was removed under reduced pressure.  
The crude material (180.9 mg) was isolated on SiO2 and eluted with hexanes/EA.  
Recrystallization from EA gave 163.6 mg (55%) yellow solid.  mp: 121.1 - 121.9 °C.  
SiO2 TLC Rf 0.51 (CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR (CDCl3): δ 8.11 (s, 1 
H), 7.79 (d, J = 2.0 Hz, 1 H), 7.21 (d, J = 2.0 Hz, 1 H), 4.61 (m, 1 H), 4.05 (q, J = 6.8 Hz, 
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2 H), 1.89 (m, 2 H), 1.64 (d, J = 6.8 Hz, 6 H), 1.09 (t, J = 7.2 Hz, 3 H).  Anal Calcd for 
C13H17N3O3: C, 59.30; H, 6.51; N, 15.96. Found: 59.21; H, 6.54; N, 15.58. 
6-butoxy-1-isopropyl-4-nitro-1H-benzo[d]imidazole (117g).  A dry 100 mL one-
necked flask was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (91; 400.0 
mg, 1.8 mmol), 1-iodobutane (0.3 mL, 2.72 mmol), and 2.5 mL of DMF .  NaH (130.2 
mg, 5.4 mmol) was added at 0 °C in two portions.  This solution was stirred at 0 oC for 30 
min and at 23 °C for an additional 2 h.  The reaction mixture was poured into 10 mL EA 
and 10 mL K2CO3 (aq, sat).  The mixture was extracted three times each with 10 mL 
portions of EA and the combined extracts were washed with NaCl (aq, sat) and dried over 
Na2SO4.  The extract was decanted and the solvent was removed under reduced pressure.  
The crude material (235.0 mg) was isolated on SiO2 column and eluted with hexanes/EA.  
Recrystallization from EA and hexane gave 200.6 mg (40%) yellow solid.  mp: 73.9 - 
74.2 °C.  SiO2 TLC Rf 0.55 (CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR (CDCl3): δ 
8.11 (s, 1 H), 7.79 (d, J = 2.0 Hz, 1 H), 7.21 (d, J = 2.0 Hz, 1 H), 4.61 (m, 1 H), 4.08 (t, J 
= 6.4 Hz, 2 H), 1.84 (m, 2 H), 1.64 (d, J = 6.8 Hz, 2 H),  1.53 (m, 6 H), 1.01 (t, J = 7.2 
Hz, 3 H).  Anal Calcd for C14H19N3O3: C, 60.63; H, 6.91; N, 15.15. Found: 60.67; H, 
6.92; N, 15.14. 
6-isopropoxy-1-isopropyl-4-nitro-1H-benzo[d]imidazole (117h).  A dry one-necked 
flask was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (91; 300.0 mg, 
1.36 mmol), 2-iodopropane (0.27 mL, 2.72 mmol), and 2.5 mL of DMF.  NaH (163.2 mg, 
6.8 mmol) was added at 0 °C in two portions.  This solution was stirred at 0 oC for 30 
min and at 23 °C for an additional 2 h.  The reaction mixture was poured into 10 mL EA 
and 10 mL K2CO3 (aq, sat).  The mixture was extracted three times each with 10 mL 
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portions of EA and the combined extracts were washed with NaCl (aq, sat) and dried over 
Na2SO4.  The extract was decanted and the solvent was removed under reduced pressure.  
The crude material (177.1 mg) was isolated on SiO2 and eluted with hexanes/EA.  
Recrystallization from EA and hexane gave 154.0 g (51.3%) yellow solid.  mp: 78.9 - 
80.1 °C.  SiO2 TLC Rf 0.55 (CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR (CDCl3): δ 
8.11 (s, 1 H), 7.79 (d, J = 2.0 Hz, 1 H), 7.21 (d, J = 2.0 Hz, 1 H), 4.61 (m, 1 H), 4.57 (m, 
2 H), 1.64 (d, J = 6.8 Hz, 6 H), 1.40 (d, J = 6.8 Hz, 6 H).  Anal Calcd for C13H17N3O3.1/6 
H2O: C, 58.63; H, 6.56; N, 15.78. Found: 58.85; H, 6.40; N, 15.94. 
6-ethoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (118e).  6-ethoxy-1-isopropyl-4-
nitro-1H-benzo[d]imidazole (117e; 150.0 mg, 0.60 mmol) was dissolved into 75 mL 
EtOH and added to a Parr hydrogenation vessel previously charged with Pd/C (10% w/w, 
8.1 mg).  After 3 vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 
and shaken for 5 h.  The mixture was filtered through a pad of Celite and then washed 
with an additional 25 mL of EtOH.  The solvent was removed under reduced pressure. 
128.0 mg (97%) of a pale brown, hygroscopic solid was obtained.  mp: 37.2 - 38.0 °C.  
SiO2 TLC Rf 0.30 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 7.75 (s, 1 
H), 6.27 (d, J = 2.0 Hz, 1 H), 6.20 (d, J = 2.0 Hz,  1 H), 4.47 (m, 1 H), 4.05 (q, J = 6.8 
Hz, 2 H), 1.57 (d, J = 6.8 Hz, 1 H), 1.42 (t, J = 7.2 Hz, 3 H).  Anal Calcd for 
C12H17N3O.1/3H2O: C, 63.98; H, 7.90; N, 18.05. Found: 63.83; H, 7.77; N, 17.78. 
1-isopropyl-6-propoxy-1H-benzo[d]imidazol-4-amine (118f).  1-isopropyl-4-nitro-6-
propoxy-1H-benzo[d]imidazole (117f; 150.4 mg, 0.57 mmol) was dissolved into 75 mL 
EtOH and added to a Parr hydrogenation vessel previously charged with Pd/C (10% w/w, 
7.7 mg).  After 3 vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 
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and shaken for 5 h.  The mixture was filtered through a pad of Celite and then washed 
with an additional 25 mL of EtOH.  The solvent was removed under reduced pressure. 
119.6 mg (90%) of a pale brown, hygroscopic solid was obtained.  mp: 30.2 - 30.9 °C.  
SiO2 TLC Rf 0.32 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 7.74 (s, 1 
H), 6.27 (d, J = 2.0 Hz, 1 H), 6.20 (d, J = 2.0 Hz, 1 H), 4.47 (m, 1 H), 3.93 (t, J = 6.4 Hz, 
2 H), 1.83 (m, 2 H), 1.59 (d, J = 6.8 Hz, 6 H), 1.05 (t, J = 7.2 Hz, 3 H).  Anal Calcd for 
C13H19N3O.1/5H2O: C, 65.91; H, 8.25; N, 17.74. Found: 66.11; H, 8.21; N, 17.39. 
6-butoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (118g).  6-butoxy-1-isopropyl-4-
nitro-1H-benzo[d]imidazole (117g; 170.3 mg, 0.61 mmol) was dissolved into 75 mL of 
EtOH and added to a Parr hydrogenation vessel previously charged with Pd/C (10% w/w, 
8.5 mg).  After 3 vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 
and shaken for 5 h.  The mixture was filtered through a pad of Celite and then washed 
with an additional 25 mL.  The solvent was removed under reduced pressure. 133.4 mg 
(88%) of a pale brown, hygroscopic solid was obtained.  mp: 33.9 - 35.1 °C.  SiO2 TLC 
Rf 0.34 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 7.74 (s, 1 H), 6.25 (d, 
J = 2.0 Hz, 1 H), 6.19 (d, J = 2.0 Hz, 1 H), 4.47 (m, 1 H), 3.96 (t, J = 6.4 Hz, 2 H), 1.78 
(m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 1.56 (m, 2 H), 0.97 (t, J = 7.2 Hz, 3 H).  Anal Calcd 
for C14H21N3O: C, 67.98; H, 8.56; N, 16.99. Found: 68.23; H, 8.54; N, 16.82. 
6-isopropoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (118h).  6-isopropoxy-1-
isopropyl-4-nitro-1H-benzo[d]imidazole (117h; 110 mg, 0.42 mmol) was dissolved into 
75 mL EtOH and added to a Parr hydrogenation vessel previously charged with Pd/C 
(10% w/w, 6.2 mg).  After 3 vacuum/purge cycles with H2, the vessel was charged to 50 
psi with H2 and shaken for 5 h.  The mixture was filtered through a pad of Celite and then 
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washed with an additional 25 mL of EtOH.  The solvent was removed under reduced 
pressure. 95.2 mg (97.7%) of a pale brown, hygroscopic solid was obtained.  mp: 34.2 - 
35.0 °C.  SiO2 TLC Rf 0.33 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 
7.75 (s, 1 H), 6.27 (d, J = 2.0 Hz, 1 H), 6.20 (d, J = 2.0 Hz, 1 H), 4.47 (m, 1 H), 4.05 (s, 2 
H, NH2, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 1.35 (d, J = 6.8 Hz, 6 H).  Anal Calcd for 
C13H19N3O.1/4H2O: C, 65.66; H, 8.29; N, 17.67. Found: 65.73; H, 7.90; N, 17.62. 
N-benzyl-6-ethoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (119e).  6-ethoxy-1-
isopropyl-1H-benzo[d]imidazol-4-amine (118e; 110.0 mg, 0.50 mmol) and solid 
NaBH(OAc)3 (318.9 mg, 1.5 mmol) were suspended in 2.5 mL of DCE. Benzaldehyde 
(61.0 µL, 0.6 mmol) was added in one portion and the mixture was stirred for 12 h.  The 
reaction mixture was quenched with the addition of 1 mL of NaHCO3 (aq, sat) and stirred 
for an additional 10 min.  The mixture was taken up into 25 mL of 5% K2CO3 (aq, sat) 
and then extracted three times with 15 mL portions of Et2O.  The combined extracts were 
washed three times with 5 mL portions of NaCl (aq, sat) and then dried over Na2SO4.  
The extract was decanted and the solvent was removed under reduced pressure.  The 
crude material was isolated on SiO2 and eluted with hexane/EA.  This material was 
recrystallized from EA and hexanes gave 77.6 mg (50%) of a white crystalline solid.  mp: 
124.1- 124.7 oC.  SiO2 TLC Rf 0.57 (CH2Cl2/5% CH3OH/0.1% NH4OH). 1H NMR 
(CDCl3): δ 7.70 (s, 1 H), 7.40 (d, J = 7.6 Hz, 2 H), 7.32 (t, J = 7.2 Hz, 2 H), 6.19 (d, J = 
2.0 Hz, 1 H), 6.03 (d, J = 2.0 Hz, 1 H), 5.25 (m, 1 H), 4.46 (m, 2 H), 4.02 (q, J = 6.8 Hz, 
2 H), 1.57 (d, J = 6.8 Hz,1 H), 1.39 (t, J = 7.2 Hz, 3 H).  Anal Calcd for C19H23N3O: C, 
73.76; H, 7.49; N, 13.58. Found: C, 73.49; H, 7.12; N, 13.64. 
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N-benzyl-1-isopropyl-6-propoxy-1H-benzo[d]imidazol-4-amine (119f).  1-isopropyl-
6-propoxy-1H-benzo[d]imidazol-4-amine (118f; 100.0 mg, 0.43 mmol) and solid 
NaBH(OAc)3 (272.6 mg, 1.3 mmol) were suspended in 2.5 mL of DCE.  Benzaldehyde 
(53.0 µL, 0.5 mmol) was added in one portion and the mixture was stirred for 12 h.  The 
reaction mixture was quenched with the addition of 1 mL of NaHCO3 (aq, sat) and stirred 
for an additional 10 min.  The mixture was taken up into 25 mL of 5% K2CO3 (aq, sat) 
and then extracted three times with 15 mL portions of Et2O.  The combined extracts were 
washed three times with 5 mL portions of NaCl (aq, sat) and then dried over Na2SO4.  
The extract was decanted and the solvent was removed under reduced pressure.  The 
crude material was isolated on SiO2 and eluted with hexanes/EA.  This material was 
recrystallized from EA and hexanes gave 77.0 mg (55%) of a white crystalline solid.  mp: 
102.4 - 104 °C.  SiO2 TLC Rf 0.58 (CH2Cl2/5% CH3OH/0.1% NH4OH).  1H NMR 
(CDCl3): δ 7.70 (s, 1 H), 7.40 (d, J = 7.6 Hz, 2 H), 7.31 (t, J = 7.2 Hz, 2 H), 6.19 (d, J = 
2.0 Hz, 1 H), 6.05 (d, J = 2.0 Hz, 1 H), 5.23 (m, 1 H), 4.46 (d, J = 6.8 Hz, 2 H), 3.90 (t, J 
= 6.4 Hz, 2 H), 1.80 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H), 1.02 (t, J = 7.6 Hz, 3 H).  Anal 
Calcd for C20H25N3O: C, 74.35; H, 7.90; N, 12.97. Found: C, 74.27; H, 7.79; N, 12.99. 
N-benzyl-6-butoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (119g).  6-butoxy-1-
isopropyl-1H-benzo[d]imidazol-4-amine (118g; 110.0 mg, 0.44 mmol) and solid 
NaBH(OAc)3 (282.8 mg, 1.3 mmol) were suspended in 2.5 mL of DCE. Benzaldehyde 
(54.0 µL, 0.5 mmol) was added in one portion and the mixture was stirred for 12 h.  The 
reaction mixture was quenched with the addition of 1 mL of NaHCO3 (aq, sat) and stirred 
for an additional 10 min.  The mixture was taken up into 25 mL of 5% K2CO3 (aq, sat) 
and then extracted three times with 15 mL portions of Et2O.  The combined extracts were 
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washed three times with 5 mL portions of NaCl (aq, sat) and then dried over Na2SO4.  
The extract was decanted and the solvent was removed under reduced pressure.  The 
crude material was isolated on SiO2 and eluted with hexanes/EA.  This material was 
recrystallized from EA and hexanes gave 75.0 mg (50%) of white crystalline solid.  mp: 
64.5 - 65.9 °C.  SiO2 TLC Rf 0.61 (CH2Cl2/5% CH3OH/0.1% NH4OH). 1H NMR 
(CDCl3): δ 7.70 (s, 1 H), 7.41 (d, J = 7.6 Hz, 2 H), 7.31 (t, J = 7.2 Hz, 2 H), 6.20 (d, J = 
2.0 Hz, 1 H), 6.05 (d, J = 2.0 Hz, 1 H), 5.23 (m, 1 H), 4.48 (d, J = 6.8 Hz, 2 H), 3.95 (t, J 
= 6.8 Hz, 2 H), 1.77 (m, 2 H), 1.58 (d, J = 6.8 Hz, 6 H), 1.51 (m, 2 H), 0.97 (t, J = 7.6 Hz, 
3 H).  Anal Calcd for C21H27N3O.1/7H2O: C, 74.18; H, 8.09; N, 12.36. Found: C, 74.17; 
H, 7.98; N, 12.37. 
N-benzyl-6-isopropoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (119h).  6-
isopropoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (118h; 83.4 mg, 0.36 mmol) and 
solid NaBH(OAc)3 (227.38 mg, 1.07 mmol) were added to 2.5 mL of DCE.  
Benzaldehyde (43.8 µL, 0.43 mmol) was added in one portion and the mixture was 
stirred for 12 h.  The reaction mixture was quenched with the addition of 1 mL of 
NaHCO3 (aq, sat) and stirred for an additional 10 min.  The mixture was taken up into 25 
mL of 5% K2CO3 (aq, sat) and then extracted three times with 15 mL portions of Et2O.  
The combined extracts were washed three times with 5 mL portions of NaCl (aq, sat) and 
then dried over Na2SO4.  The extract was decanted and the solvent was removed under 
reduced pressure.  The crude material was isolated on SiO2 and eluted with hexanes/EA.  
This material was recrystallized from EA and hexanes gave 75.7 mg (65.5%) of white 
crystalline solid.  mp: 101.6 - 101.9 °C.  SiO2 TLC Rf 0.53 (CH2Cl2/5% CH3OH/0.1% 
NH4OH).  1H NMR (CDCl3): δ 7.70 (s, 1 H), 7.41 (d, J = 2.0 Hz, 2 H), 7.31 (t, J = 2.0 
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Hz, 2 H), 6.20 (d, J = 2.0 Hz, 1 H), 6.05 (d, J = 2.0 Hz, 1 H), 5.23 (m, 1 H), 4.48 (s, 2 H), 
3.95 (m, 1 H), 1.58 (d, J = 6.8 Hz, 6 H), 1.31 (d, J = 6.0 Hz, 6 H).  Anal Calcd for 
C20H25N3O: C, 74.27; H, 7.79; N, 12.99. Found: C, 74.13; H, 7.71; N, 12.99. 
1-isopropyl-6-(2-methoxyethoxy)-1H-benzo[d]imidazol-4-amine (118a).  A dry one-
necked flask was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (91; 334.0 
mg, 1.5 mmol), 2-methoxyethanol (0.5 mL, 6.9 mmol), Ph3P (985.0 g, 3.8 mmol), and 4 
mL of anhydrous DMF.  This solution was cooled to 0 oC.  Neat DIAD (0.4 mL, 2.8 
mmol) was added with drop-wise addition over 15 min.  The solution was stirred for 30 
min at 0 oC, and then the ice-bath was removed.  The reaction mixture was stirred for an 
additional 2 h at 23 oC.  The reaction was then cooled to 0 oC and an additional quantity 
of DIAD (0.4 mL, 2.8 mmol) was added at 0 oC in one portion.  The reaction was stirred 
for 30 min at 0 oC and then at 23 oC for 12 h.  The reaction mixture was poured into 10 
mL EA and 10 mL K2CO3 (aq, sat), extracted three times with 10 mL portions of EA and 
then the combined organic extracts were washed with NaCl (aq, sat) and dried over 
Na2SO4.  The extract was decanted and the solvent was removed under reduced pressure.  
The crude material (4.2 g) was dissolved into 75 mL of EtOH and added to a Parr 
hydrogenation vessel previously charged with Pd/C (10% w/w, 119.8 mg).  After 3 
vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 and shaken for 5 
h on a Parr hydrogenation apparatus.  The mixture was filtered through a pad of Celite 
and then washed with an additional 25 mL of EtOH.  The solvent was removed under 
reduced pressure to give 5.1 g of crude product.  The crude oil was poured into 50 mL of 
1 N HCl (aq) (pH = 1) and washed three times with 10 mL portions of EA.  The aqueous 
phase was neutralized and then basified with 6 N NaOH (aq) to a pH of 10 and then 
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extracted three times with 15 mL portions of Et2O. The combined Et2O extracts were 
washed with NaCl (aq, sat) and dried over Na2SO4. The solvent was decanted and then 
removed under reduced pressure. 150.5 mg (40%) of pale brown, hygroscopic solid was 
obtained.  mp: 32.9 - 34.1 °C.  SiO2 TLC Rf 0.31 (CH2Cl2/5% CH3OH/0.1% NH4OH).  
1H NMR (CDCl3): δ 7.75 (s, 1 H), 6.31 (d, J = 2.0 Hz, 1 H), 6.23 (d, J = 2.0 Hz, 1 H), 
4.48 (m, 1 H), 4.14 (t, J = 6.4 Hz, 2 H), 3.76 (t, J = 3.6 Hz, 2 H), 3.46 (s, 3 H), 1.57 (d, J 
= 6.8 Hz, 6 H).  Anal Calcd for C13H19N3O2.1/5H2O: C, 61.74; H, 7.73; N, 16.61. Found: 
61.99; H, 7.81; N, 16.26. 
6-(2-ethoxyethoxy)-1-isopropyl-1H-benzo[d]imidazol-4-amine (118c).  A dry one-
necked flask was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (91; 334.0 
mg, 1.5 mmol), 2-ethoxyethanol (0.52 mL, 5.4 mmol), Ph3P (985.0 g, 3.8 mmol), and 4 
mL of anhydrous DMF. This solution was cooled to 0 oC.  Neat DIAD (0.4 mL, 2.8 
mmol) was added with drop-wise addition over 15 min.  The solution was stirred for 30 
min at 0 oC and then the ice-bath was removed.  The reaction was stirred for an additional 
2 h at 23 oC.  The reaction was then cooled to 0 oC and an additional quantity of DIAD 
(0.4 mL, 2.8 mmol) was added at 0 oC in one portion. The reaction was stirred for 30 min 
at 0 oC, then at 23 oC for 12 h.  The reaction mixture was poured into 10 mL EA and 10 
mL K2CO3 (aq, sat), extracted three times with 10 mL portions of EA and then the 
combined organic extracts were washed with NaCl (aq, sat) and dried over Na2SO4.  The 
extract was decanted and the solvent was removed under reduced pressure to give 4.9 g 
of crude product.  The crude material was dissolved into 75 mL of EtOH and added to a 
Parr hydrogenation vessel previously charged with Pd/C (10% w/w, 120.2 mg). After 3 
vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 and shaken for 5 
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h on a Parr hydrogenation apparatus.  The mixture was filtered through a pad of Celite 
and then washed with an additional 25 mL of EtOH.  The solvent was removed under 
reduced pressure. The crude oil was poured into 50 mL of 1 N HCl (aq) (pH = 1) and 
washed three times with 10 mL portions of EA.  The aqueous phase was neutralized and 
then basified with 6 N NaOH (aq) to a pH of 10 and then extracted three times with 15 
mL portions of Et2O.  The combined Et2O extracts were washed with NaCl (aq, sat) and 
dried over Na2SO4.  The solvent was decanted and then removed under reduced pressure. 
119.0 mg (30%) of a pale brown, hygroscopic solid was obtained.  mp: 37.4 - 38.0 °C.  
SiO2 TLC Rf 0.31 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 7.74 (s, 1 
H), 6.31 (d, J = 2.0 Hz, 1 H), 6.23 (d, J = 2.0 Hz, 1 H), 4.47 (m, 1 H), 4.14 (t, J = 5.2 Hz, 
2 H), 3.80 (t, J = 5.2 Hz, 2 H), 3.62 (q, J = 6.8 Hz, 2 H) 1.57 (d, J = 6.8 Hz, 6 H), 1.25 (t, 
J = 7.2 Hz, 3 H). Anal Calcd for C14H21N3O2: C, 62.29; H, 6.59; N, 9.47. Found: 62.13; 
H, 6.57; N, 9.36. 
1-isopropyl-6-(3-methoxypropoxy)-1H-benzo[d]imidazol-4-amine (118b).  A dry one-
necked flask was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (91; 334.0 
mg, 1.5 mmol), 3-methoxypropan-1-ol (0.52 mL, 5.4 mmol), Ph3P (985.0 g, 3.8 mmol), 
and 4 mL of anhydrous DMF.  This solution was cooled to 0 oC.  Neat DIAD (0.4 mL, 
2.8 mmol) was added with drop-wise addition over 15 min.  The solution was stirred for 
30 min at 0 oC and then the ice-bath was removed.  The reaction was stirred for an 
additional 2 h at 23 oC.  The reaction was then cooled to 0 oC and an additional quantity 
of DIAD (0.4 mL, 2.8 mmol) was added at 0 oC in one portion.  The reaction was stirred 
for 30 min at 0 oC, then at 23 oC for 12 h.  The reaction mixture was poured into 10 mL 
EA and 10 mL K2CO3 (aq, sat), extracted three times with 10 mL portions of EA and then 
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the combined organic extracts were washed with NaCl (aq, sat) and dried over Na2SO4.  
The extract was decanted and the solvent was removed under reduced pressure to give 
4.5 g of crude product.  The crude material was dissolved into 75 mL of EtOH and added 
to a Parr hydrogenation vessel previously charged with Pd/C (10% w/w, 120.1 mg). After 
3 vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 and shaken for 
5 h on a Parr hydrogenation apparatus.  The mixture was filtered through a pad of Celite 
and then washed with an additional 25 mL of EtOH.  The solvent was removed under 
reduced pressure. The crude oil was poured into 50 mL of 1 N HCl (aq) (pH = 1) and 
washed three times with 10 mL portions of EA.  The aqueous phase was neutralized and 
then basified with 6 N NaOH (aq) to pH = 10 and then extracted three times with 15 mL 
portions of Et2O.  The combined Et2O extracts were washed with NaCl (aq, sat.) and 
dried over Na2SO4.  The solvent was decanted and then removed under reduced pressure.  
159.0 mg (40%) of pale brown, hygroscopic solid was obtained.  mp: 43.1 - 44.7 °C.  
SiO2 TLC Rf 0.32 (CH2Cl2/5% CH3OH/0.1% NH4OH).   1H NMR (CDCl3): δ 7.74 (s, 1 
H), 6.28 (d, J = 2.0 Hz, 1 H), 6.19 (d, J = 2.0 Hz, 1 H), 4.47 (m, 1 H), 4.06 (t, J = 6.4 Hz, 
2 H), 3.57 (t, J = 6.4 Hz, 2 H), 3.36 (s, 3 H), 2.06 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H).  
Anal Calcd for C14H21N3O2.1/3H2O: C, 62.43; H, 8.11; N, 15.60. Found: 62.64; H, 8.15; 
N, 15.38. 
N-benzyl-1-isopropyl-6-(2-methoxyethoxy)-1H-benzo[d]imidazol-4-amine oxalate 
(119a).  1-isopropyl-6-(2-methoxyethoxy)-1H-benzo[d]imidazol-4-amine (118a; 120.0 
mg, 0.48 mmol) and solid NaBH(OAc)3 (279.7 mg, 1.4 mmol) were added to 2.5 mL of 
DCE.  Benzaldehyde (53.6 µL, 0.5 mmol) was added in one portion and the mixture was 
stirred for 12 h.  The reaction mixture was quenched with the addition of 1 mL of 
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NaHCO3 (aq, sat) and then stirred for an additional 10 min.  The mixture was taken up 
into 50 mL of 5% of K2CO3 (aq, sat) and then extracted three times with 15 mL portions 
of Et2O.  The combined extracts were washed with NaCl (aq, sat) and then dried over 
Na2SO4.  The extract was decanted and the solvent was removed under reduced pressure.  
The crude material was isolated on SiO2 and eluted with hexanes/EA.  The isolated 
product (69.3 mg, 0.19 mmol) was dissolved into 2.5 mL of EA, followed by addition of 
the solution of anhydrous oxalic acid (20.1 mg, 0.22 mmol) in 2.5 mL of EA.  The 
solvent was removed under reduced pressure to afford 82.6 mg (40%) of a white 
crystalline solid.  mp: 164.6 - 165.1 oC.  SiO2 TLC Rf 0.55 (CH2Cl2/5% CH3OH/0.1% 
NH4OH). 1H NMR (MeOD-d4): δ 8.90 (s, 1 H), 7.41 (d, J = 7.6 Hz, 2 H), 7.33 (t, J = 7.2 
Hz, 2 H), 7.25 (t, J = 7.6 Hz, 1 H), 6.56 (d, J = 2.0 Hz, 1 H), 6.19 (d, J = 2.0 Hz, 1 H), 
4.88 (m, 1 H), 4.47 (s, 2 H), 4.11 (t, J = 2.0 Hz, 2 H), 3.72 (t, J = 2.8 Hz, 2 H), 3.40 (s, 3 
H), 1.64 (d, J = 6.8 Hz, 6 H).  Anal Calcd for C22H27N3O6.1/6H2O: C, 61.10; H, 6.37; N, 
9.72. Found: C, 61.08; H, 6.31; N, 9.78. 
N-benzyl-6-(2-ethoxyethoxy)-1-isopropyl-1H-benzo[d]imidazol-4-amine oxalate 
(119c).  6-(2-ethoxyethoxy)-1-isopropyl-1H-benzo[d]imidazol-4-amine (118; 90.0 mg, 
0.34 mmol) and solid NaBH(OAc)3 (217.3 mg, 1.0 mmol) were added to 2.5 mL of DCE.  
Benzaldehyde (53.6 µL, 0.5 mmol) was added in one portion and the mixture was stirred 
for 12 h.  The reaction mixture was quenched with the addition of 1 mL of NaHCO3 (aq, 
sat) and then stirred for an additional 10 min.  The mixture was taken up into 50 mL of 
5% K2CO3 (aq, sat) and then extracted three times with 15 mL portions of Et2O.  The 
combined extracts were washed with NaCl (aq, sat) and then dried over Na2SO4.  The 
extract was decanted and the solvent was removed under reduced pressure.  The crude 
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material was isolated on SiO2 and eluted with hexanes/EA.  The isolated product (50.2 
mg, 0.14 mmol) was dissolved in 2.5 mL of EA, followed by addition of the solution of 
anhydrous oxalic acid (15.5 mg, 0.16 mmol) into 2.5 mL of EA.  The solvent was 
removed under reduced pressure to afford 60.6 mg (40%) of a white crystalline solid.  
mp: 158.7 - 158.8 oC.  SiO2 TLC Rf 0.57 (CH2Cl2/5% CH3OH/0.1% NH4OH). 1H NMR 
(MeOD-d4): δ 8.87 (s, 1 H), 7.41 (d, J = 7.6 Hz, 2 H), 7.33 (t, J = 7.2 Hz, 2 H), 7.26 (t, J 
= 7.2 Hz, 1 H), 6.56 (d, J = 2.0 Hz, 1 H), 6.24 (d, J = 2.0 Hz, 1 H), 4.80 (m, 1 H), 4.46 (s, 
2 H), 4.11 (t, J = 4.4 Hz, 2 H), 3.76 (t, J = 1.6 Hz, 2 H), 3.56 (q, 2 H), 1.63 (d, J = 6.8 Hz, 
6H), 1.19 (t, J = 7.2 Hz, 3 H).  Anal Calcd for C29H23N3O6: C, 62.29; H, 6.59; N, 9.47. 
Found: 62.13; H, 6.57; N, 9.36. 
N-benzyl-1-isopropyl-6-(3-methoxypropoxy)-1H-benzo[d]imidazol-4-amine (119b).  
1-isopropyl-6-(3-methoxypropoxy)-1H-benzo[d]imidazol-4-amine (118b; 120.0 mg, 0.46 
mmol) and solid NaBH(OAc)3 (289.8 mg, 1.4 mmol) were added to 2.5 mL of DCE.  
Benzaldehyde (53.6 µL, 0.5 mmol) was added in one portion and the mixture was stirred 
for 12 h.  The reaction mixture was quenched with the addition of 1 mL of NaHCO3 (aq, 
sat) and then stirred for an additional 10 min.  The mixture was taken up into 5% K2CO3 
(aq, sat) and then extracted three times with 15 mL portions of Et2O.  The combined 
extracts were washed with NaCl (aq, sat) and then dried over Na2SO4.  The extract was 
decanted and the solvent was removed under reduced pressure.  The crude material was 
isolated on SiO2 and eluted with hexanes/EA.  Recrystallization from EA and hexane 
gave 101.4 mg (63%) of a white crystalline solid.  mp: 75.7 - 75.9 oC.  SiO2 TLC Rf 0.58 
(CH2Cl2/5% CH3OH/0.1% NH4OH). 1H NMR (CDCl3): δ 7.70 (s, 1 H), 7.40 (d, J = 7.6 
Hz, 2 H), 7.32 (t, J = 7.2 Hz, 2 H), 7.29 (d, J = 7.2 Hz, 1 H), 6.20 (d, J = 2.0 Hz, 1 H), 
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6.04 (d, J = 2.0 Hz, 1 H), 5.23 (m, 1 H), 4.46 (m, 2 H), 4.04 (t, J = 6.4 Hz, 2 H), 3.55 (t, J 
= 6.0 Hz, 2 H), 3.34 (s, 3 H), 2.03 (m, 2 H), 1.57 (d, J = 6.8 Hz, 6 H).  Anal Calcd for 
C21H27N3O2: C, 71.36; H, 7.70; N, 11.89. Found: 71.22; H, 7.71; N, 11.89. 
N-benzyl-1-isopropyl-6-(3-morpholinopropoxy)-1H-benzo[d]imidazol-4-amine 
hydrochloride (119d).  A dry one-necked flask was charged with 1-isopropyl-4-nitro-
1H-benzo[d]imidazol-6-ol (91; 249.8 mg, 1.1 mmol), 3-morpholinopropan-1-ol (0.45 
mL, 3.3 mmol), Ph3P (737.2 g, 2.75 mmol), and 2 mL of anhydrous DMF.  This solution 
was cooled to 0 oC.  Neat DIAD (0.32 mL, 1.65 mmol) was added with drop-wise 
addition over 15 min.  The solution was stirred for 30 min at 0 oC and then the ice-bath 
was removed.  The reaction was stirred for an additional 2 h at 23 oC.   The reaction was 
then cooled to 0 oC and an additional quantity of DIAD (0.22 mL, 1.1 mmol) was added 
at 0 oC in one portion.  The reaction was stirred for 30 min at 0 oC, then at 23 oC for 12 h. 
The reaction mixture was poured into 10 mL EA and 10 mL K2CO3 (aq, sat), extracted 
three times with 10 mL portions of EA and the combined organic extracts were washed 
with NaCl (aq, sat) and dried over Na2SO4.  The extract was decanted and the solvent was 
removed under reduced pressure.  The crude material was dissolved into 75 mL of EtOH 
and added to a Parr hydrogenation vessel previously charged with Pd/C (10% w/w).  
After 3 vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 and 
shaken for 5 h on a Parr hydrogenation apparatus.  The mixture was filtered through a 
pad of Celite and washed with an additional 25 mL of EtOH.  The solvent was removed 
under reduced pressure.  The crude oil was poured into 50 mL of 1 N HCl (aq) (pH = 1) 
and washed three times with 10 mL portions of EA.  The aqueous phase was neutralized 
and then basified with 6 N NaOH (aq) to a pH of 10 and then extracted three times with 
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15 mL portions of Et2O.  The combined Et2O extracts were washed with NaCl (aq, sat) 
and dried over Na2SO4.  The solvent was decanted and then removed under reduced 
pressure to give 100 mg of crude product.  1H NMR (CDCl3): δ 7.29 (d, J = 7.2 Hz, 1 H), 
6.20 (d, J = 2.0 Hz, 1 H), 6.04 (d, J = 2.0 Hz, 1 H), 5.23 (m, 1 H), 4.06 (m, 2 H), 4.04 (t, 
J = 6.4 Hz, 2 H), 3.67 (m, 4 H), 3.34 (m, 2 H), 2.46 (m, 2 H), 2.03 (m, 4 H), 1.57 (d, J = 
6.8 Hz, 6 H). 
Crude product (118d; 100.0 mg, 0.31 mmol) was dissolved in 2.5 mL of DCE.  
NaBH(OAc)3 ( 199.5 mg, 0.93 mmol) and benzaldehyde (31.0 µL, 0.31 mmol) were 
added in one portion and the mixture was stirred for 12 h.  The reaction mixture was 
quenched with the addition of 1 mL of NaHCO3 (aq, sat) and then stirred for an 
additional 10 min.  The mixture was taken up into 50 mL of 5% K2CO3 (aq, sat) and then 
extracted three times with 15 mL portions of Et2O.  The combined extracts were washed 
with NaCl (aq, sat) and then dried over Na2SO4.  The extract was decanted and the 
solvent was removed under reduced pressure.  The crude material was isolated on SiO2 
and eluted with hexanes/EA.  Recrystallization from EA and hexane gave 60.0 mg 
(46.8%) of a white solid.  mp: 186.0 - 186.7 °C.  SiO2 TLC Rf 0.41 (CH2Cl2/5% 
CH3OH/0.1% NH4OH).  1H NMR (CDCl3): δ 7.70 (s, 1 H), 7.40 (d, J = 7.6 Hz, 2 H), 
7.32 (t, J = 7.2 Hz, 2 H), 7.29 (d, J = 7.2 Hz, 1 H), 6.20 (d, J = 2.0 Hz, 1 H), 6.04 (d, J = 
2.0 Hz, 1 H), 5.23 (m, 1 H), 4.06 (m, 2 H), 4.04 (t, J = 6.4 Hz, 2 H), 3.67 (m, 4 H), 3.34 
(m, 2 H), 2.46 (m, 2 H), 2.03 (m, 4 H), 1.57 (d, J = 6.8 Hz, 6 H).  Anal Calcd for 
C14H21N3O2.2H2O: C, 55.40; H, 7.40; N, 10.83. Found: 55.10; H, 7.13; N, 11.20. 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid (75).  A 250 mL round 
bottom flask was charged with 2-fluoro-4-iodoaniline, (73; 5.2 g, 22 mmol), 2,3,4-
178 
trifluorobenzoic acid, (74; 3.7 g, 21 mmol), and 100 mL of anhydrous THF.  The reaction 
mixture was cooled with an ice-bath to 0 oC and LiNH2 (1.2 g, 52.5 mmol) was added in 
portions 2 portions over 5 min.  The reaction was then warmed to 68 oC and stirred for 4 
h.  A mixture of 25 mL of H2O and 10 mL of conc HCl was added to the reaction at 0 oC.   
The reaction mixture was extracted three times with 30 mL portions of Et2O, washed 
with NaCl (aq, sat) and dried over Na2SO4.  The extract was decanted and the solvent was 
removed under reduced pressure. Recrystallization from EtOH/H2O (10:1) provided 7.1 g 
(85%) of a brown solid.  mp: 199.0 - 200.1 oC (lit130 200 - 201 oC).  SiO2 TLC Rf  0.51 
(2:1 hexane/EA).  1H NMR (MeOD-d4): δ 7.86 (m, 1 H),  7.46 (d, J = 1.6 Hz, 1 H), 7.38 
(d, J = 1.6 Hz, 1 H), 7.18 (m, 1 H, OH), 6.86 (m, 1 H), 6.72  (m, 1 H), 2.31 (m, 1 H, NH).  
Anal Calcd for C13H7F3INO2: C, 39.72; H, 1.79; N, 3.56. Found: C, 39.41; H, 1.91; N, 
3.52. 
General procedure: amide coupling (122a-122d): Procedure F:  A dry 25 mL round 
bottom flask was charged with 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic 
acid, (75; 0.51 mmol) and 0.5 mL of DCM.  The reaction mixture was cooled on ice-bath 
to 0 oC. 100 μL of anhydrous DMF was added followed by dropwise addition of oxalyl 
chloride (1.02 mmol) over 5 min.  The reaction was stirred at 23 oC for 4 h. The solvent 
was then removed under reduced pressure.  The crude product was dissolved in 0.5 mL of 
DCM and the appropriate amine (2.55 mmol) was added neat at 0 oC.  The reaction was 
stirred at 23 oC for 6 h; completion of reaction was determined by TLC.  A mixture of 10 
mL of H2O and 10 mL of Et2O was added and the resultant mixture was extracted with 
Et2O, washed with NaCl (aq, sat), and dried over Na2SO4. The extract was decanted and 
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then the solvent was removed under reduced pressure. The crude product was isolated on 
SiO2 using hexane/EA followed by recrystallization from EA.  
(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(4-methylpiperazin-1-
yl)methanone (122b).  Compound 122b was synthesized using procedure F from 3,4-
difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, (75; 200.8 mg, 0.51 mmol) and 
1-methylpiperazine (0.3 mL, 2.55 mmol). Recrystallization from EA gave 145.0 mg 
(60%) of a white solid.  mp: 136.4 - 137.0 oC.  SiO2 TLC Rf 0.32 (2:1 hexane/EA).  1H 
NMR (CDCl3): δ 7.41 (d, J = 1.6 Hz, 1 H),  7.29 (d, J = 1.6 Hz, 1 H), 7.05 (d, J = 1.6 Hz, 
1 H), 6.98 (m, 1 H), 6.56  (m, 1 H), 3.64 (m, 2H), 3.39 (m, 2 H),  2.25 (m, 4 H), 1.57 (s, 3 
H), 1.41 (s, 1 H, NH).  Anal Calcd for C18H17F3IN3O: C, 45.49; H, 3.61; N, 8.84. Found: 
C, 45.40; H, 3.47; N, 8.81. 
(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(morpholino)methanone 
(122c).  Compound 122c was synthesized using procedure F from 3,4-difluoro-2-((2-
fluoro-4-iodophenyl)amino)benzoic acid, (75; 200.7 mg, 0.51 mmol) and morpholine 
(0.25 mL, 2.55 mmol).  Recrystallization from EA gave 164.6 mg (70%) of a white solid.  
mp: 180.4 - 181.2 oC. SiO2 TLC Rf 0.47 (2:1 hexane/EA).  1H NMR (CDCl3): δ 7.41 (d, J 
= 1.6 Hz, 1 H),  7.29 (d, J = 1.6 Hz, 1 H), 7.05 (d, J = 1.6 Hz, 1 H), 6.98 (m, 1 H), 6.56  
(m, 1 H), 3.59 (d, 8H), 2.31 (m, 1 H, NH).  Anal Calcd for C17H14F3IN2O2: C, 44.18; H, 
3.05; N, 6.06. Found: C, 44.15; H, 3.00; N, 5.95. 
(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(piperidin-1-yl)methanone 
(122d).  Compound 122d was synthesized using procedure F from 3,4-difluoro-2-((2-
fluoro-4-iodophenyl)amino)benzoic acid, (75; 200.3 mg, 0.51 mmol) and piperidine (0.3 
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mL, 2.55 mmol). Recrystallization from EA gave 147.5 mg (63%) of a white solid.  mp: 
121.4 - 121.6 oC.  SiO2 TLC Rf 0.48 (2:1 hexane/EA).  1H NMR (CDCl3): δ 7.41 (d, J = 
1.6 Hz, 1 H),  7.29 (d, J = 1.6 Hz, 1 H), 7.05 (d, J = 1.6 Hz, 1 H), 6.98 (m, 1 H), 6.56  (m, 
1 H), 3.57 (m, 2 H), 3.31 (m, 2 H), 1.61 (m, 2 H), 1.56 (m, 4 H), 1.54 (m, 1 H, NH).  
Anal Calcd for C18H16F3IN2O: C, 46.97; H, 3.50; N, 6.09. Found: C, 47.00; H, 3.51; N, 
6.00. 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (122a).  Compound 122a 
was synhthesized using procedure F from 3,4-difluoro-2-((2-fluoro-4-
iodophenyl)amino)benzoic acid, (75; 200.2 mg, 0.51 mmol) and 1.2 mL of 2 M solution 
of NH4OH/EtOH.  Recrystallization from EA gave 135.6 mg (68%) of a white crystalline 
solid.  mp: 161.2 - 162.0 oC.  SiO2 TLC Rf 0.29 (2:1 hexane/EA).  1H NMR (CDCl3): δ 
8.69 (s, 1 H, NH), 7.41 (d, J = 1.6 Hz, 1 H),  7.29 (d, J = 1.6 Hz, 1 H), 7.05 (d, J = 1.6 
Hz, 1 H), 6.98 (m, 1 H), 6.56  (m, 1 H), 1.72 (s, 2 H, NH2).  Anal Calcd for C13H8F3IN2O: 
C, 39.82; H, 2.06; N, 7.14. Found: C, 39.86; H, 1.97; N, 7.02. 
General procedure for the transient TMS protection of oxygen-bearing groups 
(124a-124c):  A dry 50 mL round bottom flask was charged with the appropriate amine, 
(123a-123c) (1.28 mmol) and 1.5 mL of anhydrous DCM.  The mixture was cooled to 0 
oC and then TEA (0.45 mL, 3.2 mmol) was added followed by dropwise addition of neat 
chlorotrimethylsilane (0.25 mL, 1.9 mmol).  The reaction stirred for 4 h at 23 oC.  The 
solvent was removed under reduced pressure and the crude product was obtained as white 
solid along with TEA.HCl.  This crude material was used directly without further 
purification. 
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General procedure: amide coupling (122e-122g): Procedure G:  A dry 25 mL round 
bottom flask was charged with 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic 
acid, (75; 0.64 mmol) and 0.6 mL of DCM.  The reaction mixture was cooled with an ice-
bath to 0 oC. 100 µL of anhydrous DMF was added followed by dropwise addition of 
oxalyl chloride (1.28 mmol) over 5 min.  The reaction was stirred at 23 oC for 4 h. The 
solvent was removed under reduced pressure; the residue was dissolved into 5 mL of 
anhydrous THF and the appropriate protected crude amine (6.40 mmol) was added at 0 
oC.  The reaction was stirred at 23 oC for 6 h.  Progress of the reaction was followed by 
TLC. After consumption of acid chloride, 5 mL of 1M citric acid/MeOH was added to 
the reaction in one portion and the reaction was stirred for 1 h at 23 oC.  A mixture of 10 
mL of H2O and 10 mL of Et2O was added and then the reaction mixture was extracted 
three times with 10 mL portions of Et2O, washed with NaCl (aq, sat), and dried over 
Na2SO4.  The solvent was removed under reduced pressure.  The product was isolated on 
SiO2 using hexane/EA followed by recrystallization from EA. 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethyl)benzamide (122e).  
Compound 122e was synthesized using procedure G from 3,4-difluoro-2-((2-fluoro-4-
iodophenyl)amino)benzoic acid, (75; 250.3 mg, 0.64 mmol) and crude 2-
((trimethylsilyl)oxy)ethanamine, (124a; 173.2 mg, 6.40 mmol).  Recrystallization from 
EA gave 163.6 mg (59%) of a white solid. mp: 156.0 - 156.7 oC.  SiO2 TLC Rf 0.49 (2:1 
hexane/EA). 1H NMR (CDCl3): δ 8.69 (s, 1 H, NH), 7.41 (d, J = 1.6 Hz, 1 H),  7.29 (d, J 
= 1.6 Hz, 1 H), 7.05 (d, J = 1.6 Hz, 1 H), 6.98 (m, 1 H), 6.56  (m, 1 H), 3.77 (t, 2 H), 3.55 
(t, 2 H), 1.57 (s, 1 H, NH), 1.25 (s, 1 H, OH).  Anal Calcd for C15H12F3IN2O2: C, 41.31; 
H, 2.77; N, 6.42. Found: C, 41.20; H, 2.68; N, 6.32. 
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(S)-2-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamido)-3-
hydroxypropanoic acid (122f).  Compound 122f was synthesized using procedure G 
from 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, (75; 250.2 mg, 0.64 
mmol) and crude (S)-trimethylsilyl 2-amino-3-((trimethylsilyl)oxy)propanoate, (124b; 
720.0 mg, 3.2 mmol).  Recrystallization from EA gave 139.0 mg (57%) of a white solid.  
mp: 91.8 - 92.3 oC.  SiO2 TLC Rf 0.52 (2:1 hexane/EA). 1H NMR (MeOD-d4): δ 7.82 (s, 
1 H, NH), 7.63 (m, 1 H),  7.44 (d, 1 H), 7.41 (d, 1 H), 7.32 (m, 1 H), 6.58  (m, 1 H), 4.60 
(t, 1 H), 3.93 (d, 1 H), 3.88 (d, 1 H).  Anal Calcd for C16H12F3IN2O4: C, 40.02; H, 2.52; 
N, 5.83. Found: C, 40.22; H, 2.14; N, 5.91. 
(R)-2-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamido)-3-
hydroxypropanoic acid (122g).  Compound 122g was synthesized using procedure G 
from 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, (75; 300.7 mg, 0.76 
mmol) and crude (R)-trimethylsilyl 2-amino-3-((trimethylsilyl)oxy)propanoate, (124c; 
947.9 mg, 5.8 mmol).  Recrystallization from EA gave 201.5 mg (55%) of a white solid.  
mp: 89.3 - 90.1 oC.  SiO2 TLC Rf 0.50 (2:1 hexane/EA). 1H NMR (MeOD-d4): δ 7.82 (s, 
1 H, NH), 7.63 (m, 1 H),  7.44 (d, J = 1.6 Hz, 1 H), 7.41 (d, J = 1.6 Hz, 1 H), 7.32 (m, 1 
H), 6.58  (m, 1 H), 4.58 (t, 1 H), 3.91 (q, 1 H), 3.84 (q, 1 H).  Anal Calcd for 
C16H12F3IN2O4: C, 40.02; H, 2.52; N, 5.83. Found: C, 40.36; H, 2.60; N, 5.83. 
Flavones (140, 133a, 133b): General Procedure H134:  A 250 mL 3-necked flask was 
charged with a two-phase mixture of a hydroxyacetophenone (6.58 mmol) and the 
appropriate aroyl chloride (2 eq) in toluene and K2CO3 (aq, sat).  This mixture was then 
stirred vigorously at 60 °C for 30 min.  TBAHS (4.9 mmol) was added and stirring at 60 
°C was continued for an additional 3 h.  Progress was monitored by TLC.  During this 
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period, the organic layer acquired an orange color and an orange-brown interface 
resulted. The toluene layer was separated and the orange-brown liquid was extracted 
three times with 20 mL portions of DCE.  The two organic extracts were washed in a 
parallel manner with 30 mL of H2O, and then combined.  After drying over Na2SO4 and 
decanting, the solvent was removed under reduced pressure and the resultant crude 
material was dried under high vacuum (150 mm Hg) for 12 h.  The crude was dissolved 
into a mixture of 10 mL of glacial acetic acid and 1 mL of conc H2SO4.  The reaction 
mixture was then maintained at 95 oC for 3 h.  The solvent was removed under reduced 
pressure and the residue was dissolved into 100 mL of DCE and 50 mL of H2O.  The 
DCE layer was washed three times with 20 mL portions of H2O, three times with 10 mL 
portions of NaCl (aq, sat) and then dried over Na2SO4.  The solvent was removed, and the 
crude product was purified using SiO2 followed by recrystallization from EtOH.  
2-(2-chlorophenyl)-4H-chromen-4-one (140).  Compound 140 was synthesized using 
procedure H from 2-chlorobenzoyl chloride (138; 0.46 mL, 3.66 mmol), 
hydroxyacetophenone (137; 250.2 mg, 1.83 mmol), 12 mL of toluene, and 12 mL of 
K2CO3 (aq, sat).  Recrystallization from EtOH gave 234.3 mg (50%) of white crystalline 
solid.  mp: 193.7 - 194.2 °C.  SiO2 TLC Rf 0.51 (1:1 EA/hexane).  1H NMR (CDCl3): δ 
8.28-8.26 (dd, 1 H), 7.74-7.71 (m, 1 H), 7.64-7.54 (dd, 1 H), 7.52-7.45 (m, 2 H), 7.44-
7.42 (m, 3 H), 6.67 (s, 1 H). Anal Calcd for C15H9ClO2: C, 70.19; H, 3.53; Cl, 13.81. 
Found: C, 69.93; H, 3.43; Cl, 13.90. 
5-hydroxy-2-(3-methoxy-2-nitrophenyl)-4H-chromen-4-one (133a).  Compound 133a 
was synthesized using procedure H from 3-methoxy-2-nitrobenzoyl chloride (136; 1.40 g, 
6.58 mmol), hydroxyacetophenone (131a; 500.1 mg, 3.3 mmol), 22 mL of toluene, and 
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22 mL of K2CO3 (aq, sat).  Recrystallization from EtOH gave 400.3 mg (38.9%) of 
yellow solid.  mp: 230.1 - 230.5 °C.  SiO2 TLC Rf 0.35 (1:1 EA/hexane).  1H NMR 
(CDCl3): δ 12.26 (s, 1 H, OH), 7.60-7.52 (m, 2 H), 7.29-7.25 (m, 2 H), 6.88-6.81 (m, 2 
H), 6.57 (s, 1 H), 3.97 (s, 3 H).  Anal Calcd for C16H11NO6.1/6H2O: C, 60.76; H, 3.61; N, 
4.43. Found: C, 60.93; H, 3.52; N, 4.52. 
7-hydroxy-2-(3-methoxy-2-nitrophenyl)-4H-chromen-4-one (133b).  Compound 133b 
was synthesized using procedure H from 3-methoxy-2-nitrobenzoyl chloride (136; 1.40 g, 
6.58 mmol), hydroxyacetophenone (131b; 500.5 mg, 3.3 mmol), 22 mL of toluene, and 
22 mL of K2CO3 (aq, sat).  Recrystallization from EtOH gave 100.0 mg (10%) of buff-
colored solid.  mp: 246.7 - 247.3 °C.  SiO2 TLC Rf 0.24 (1:1 EA/hexane).  1H NMR 
(DMSO-d6): δ 8.31 (s, 1 H, OH), 7.88 (d, J = 8.8 Hz, 1 H), 7.73 (m, 1 H), 7.58 (m, 2 H), 
6.95 (d, J = 7.6 Hz, 1 H), 6.72 (s, 1 H), 6.67 (s, 1 H), 3.96 (s, 3 H).  Anal Calcd for 
C16H11NO6.1/6H2O: C, 60.76; H, 3.61; N, 4.43. Found: C, 60.73; H, 3.56; N, 4.40. 
Flavones (134a, 134b): General procedure I:  The appropriate (0.64 mmol) nitro 
flavone was dissolved into a mixture of 90 mL EtOH and 10 mL CHCl3.  This solution 
was added to a Parr hydrogenation vessel previously charged with Pd/C (10% w/w, 10.3 
mg).  After 3 vacuum/purge cycles with H2, the vessel was charged to 50 psi with H2 and 
shaken for 6 h.  The mixture was filtered through a pad of Celite and then washed with an 
additional 50 mL of EtOH.  The solvent was removed under reduced pressure and the 
product was recrystallized from EtOH.  
2-(2-amino-3-methoxyphenyl)-5-hydroxy-4H-chromen-4-one hydrochloride (134a).  
Compound 134a was synthesized using procedure I from 5-hydroxy-2-(3-methoxy-2-
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nitrophenyl)-4H-chromen-4-one (133a; 198.9 mg, 0.64 mmol).  Recrystallization from 
EtOH gave 100 mg (55.5%) of brown solid.  mp: 197.9 - 198.3 °C.  SiO2 TLC Rf 0.33 
(1:1 EA/hexane).  1H NMR (CDCl3): δ 12.26 (s, 1 H, OH) 7.58-7.52 (m, 2 H), 7.29-7.25 
(m, 2 H), 6.88-6.81 (m, 2 H), 6.57 (s, 1 H), 3.97 (s, 3 H).  Anal Calcd for C16H11ClNO4: 
C, 60.10; H, 4.41; N, 4.38. Found: C, 60.47; H, 4.21; N, 4.38. 
2-(2-amino-3-methoxyphenyl)-7-hydroxy-4H-chromen-4-one hydrochloride (134b).  
Compound 134b was synthesized using procedure I in which 7-hydroxy-2-(3-methoxy-2-
nitrophenyl)-4H-chromen-4-one (133b; 79.9 mg, 0.26 mmol) was used.  Recrystallization 
from EtOH gave 50 mg (69%) of brown solid.  mp: 212.3 - 212.7 °C.  SiO2 TLC Rf 0.56 
(EA).  1H NMR (DMSO-d6): δ 10.93 (s, 1 H, OH), 7.90 (d, J = 8.8 Hz, 1 H), 7.73 (m, 1 
H), 7.60 (m, 2 H), 6.96 (d, J = 7.6 Hz, 1 H), 6.74 (s, 1 H), 6.69 (s, 1 H), 3.97 (s, 3 H).  
Anal Calcd for C16H11ClNO4: C, 60.10; H, 4.41; N, 4.38. Found: C, 60.22; H, 4.32; N, 
4.52. 
3-methoxy-2-nitrobenzoyl chloride (136).  A 50 mL round-bottom flask was charged 
with 3-methoxy-2-nitrobenzoic acid (2.0 g, 10.14 mmol), 10 ml of DCE, and 100 μL of 
DMF.  Neat oxalyl chloride (1.75 mL, 20.28 mmol) was added with dropwise addition at 
0 oC over 15 min.  The reaction was then stirred for an additional 4 h at 25 oC.  The 
reaction mixture was concentrated under reduced pressure to give the crude acid chloride 
(2.32 g).  This solid was broken into a finely divided powder and then dried under high 
vacuum (150 mm Hg) for 12 h to give 2.18 g (99%) of a white solid.  mp: 81.6 - 82.9 °C 
(lit135 mp: 83-85 °C); 1H NMR (CDCl3): δ 7.96 (d, J = 8.8 Hz, 1 H), 7.71 (t, 1 H), 7.35 (d, 
J = 7.6 Hz, 1 H), 3.89 (s, 3 H).  
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General procedure (ortho-carboxamides, 142a-142d): Procedure J:  A dry 50 mL 
round bottom flask was charged with phthalic anhydride, (141; 1.69 mmol) and 2 mL of 
anhydrous THF, DMAP (0.07 mmol) and the appropriate amine (8.37 mmol).  The 
reaction was stirred for 4 h at 23 oC. The solvent was removed under reduced pressure.  
The product was isolated on SiO2 using EA.  
2-(4-methylpiperazine-1-carbonyl)benzoic acid (142a).  Compound 142a was 
synthesized by procedure J from phthalic anhydride (141; 251.0 mg, 1.69 mmol) and 1-
methylpiperazine (0.9 mL, 8.4 mmol). 305.8 mg (73%) of white solid was obtained.  mp: 
130.5 - 131.0 oC.  SiO2 TLC Rf 0.39 (EA).  1H NMR (MeOD-d4): δ 8.02 (d, J = 6.4 Hz, 1 
H), 7.54 (m, 2 H), 7.29 (d, J = 6.4 Hz, 1 H), 3.32 (m, 4 H), 3.31 (m, 2 H), 2.92 (m, 2 H), 
2.77 (s, 3 H).  Anal Calcd for C13H16N2O3: C, 62.89; H, 6.50; N, 11.28. Found: C, 62.66; 
H, 6.49; N, 11.22. 
2-(morpholine-4-carbonyl)benzoic acid (142b).  Compound 142b was synthesized by 
procedure J from phthalic anhydride (141; 251.0 mg, 1.69 mmol) and morpholine (0.7 
mL, 8.4 mmol). 298.5 mg (75.2%) of white solid was obtained.  mp: 77.2 - 78.0 oC.  SiO2 
TLC Rf 0.42 (EA).  1H NMR (CDCl3): δ 8.08 (d, J = 6.4 Hz, 1 H), 7.54 (m, 1 H), 7.43 (m, 
1 H), 7.27 (d, J = 6.4 Hz, 1 H), 3.59 (br, 8 H).  Anal Calcd for C12H13NO4.1/2H2O: C, 
59.01; H, 5.78; N, 5.73. Found: C, 58.73; H, 5.82; N, 5.75. 
2-(piperidine-1-carbonyl)benzoic acid (142c).  Compound 142c was synthesized by 
procedure J from phthalic anhydride (141; 251.0 mg, 1.69 mmol) and piperidine (0.8 mL, 
8.4 mmol).  294.1 mg (74.1%) of white solid was obtained.  mp: 102.1-102.5 oC.  SiO2 
TLC Rf 0.44 (EA).  1H  NMR (CDCl3): δ 8.08 (d, J = 6.4 Hz, 1 H), 7.54 (m, 1 H), 7.43 
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(m, 1 H), 7.27 (d, J = 6.4 Hz, 1 H), 3.82 (br, 2 H), 3.64 (s, 2 H), 1.63 (m, 4 H), 1.61 (m, 2 
H).  Anal Calcd for C13H15NO3.1H2O: C, 62.14; H, 6.82; N, 5.57. Found: C, 61.98; H, 
6.43; N, 5.78. 
2-((2-hydroxyethyl)carbamoyl)benzoic acid (142d).  Compound 142d was synthesized 
by procedure J from phthalic anhydride (141; 250.3 mg, 1.69 mmol) and ethane-1,2-diol 
(0.5 mL, 8.4 mmol).  282.4 mg (80%) of white solid was obtained. mp: 111.2 - 111.9 oC.  
SiO2 TLC Rf 0.31 (EA).  1H  NMR (MeOD-d4): δ 8.02 (d, J = 6.4 Hz, 1 H), 7.60 (m, 1 
H), 7.54 (m, 1 H), 7.46 (d, J = 6.4 Hz, 1 H), 3.72 (m, 2 H), 3.46 (m, 2 H).  Anal Calcd for 
C10H11NO4: C, 57.41; H, 5.30; N, 6.70. Found: C, 57.20; H, 5.15; N, 6.51. 
1-methylpiperidine-2-carboxylic acid hydrochloride (146).  A microwave reactor tube 
was charged with D,L-pipecolinic acid (5.1 g, 39.5 mmol). 15.6 mL of formic acid was 
added followed by addition of 38% aqueous formaldehyde (3.1 mL, 39 mmol). The 
reaction was subjected to 300 Watt microwave irradiation with the temperature 
maintained at 120 oC for 5 min.  The solvent was removed under reduced pressure.  The 
crude yellow oil (7.8 g) obtained was dissolved in 15 mL of EtOH and 5 mL of conc HCl 
was added.  The solvent was removed under reduced pressure. 6.5 g (92%) of white solid 
was obtained.  mp: 262.1 - 263.4 oC (lit137 mp: 263 - 266 oC). 1H NMR (DMSO): δ 3.70 
(s, 3 H), 3.22 (d, J = 4.8 Hz, 1 H), 2.17 (m, 1 H, OH), 1.81 (m, 1 H), 1.46 (m, 1 H), 1.23 
(m, 1 H), 0.93 (m, 6 H).  
L-tert-butyl 2-amino-3-methylpentanoate (148).  A 250 mL Parr hydrogenation vessel 
was charged with L-isoleucine (5 g, 26.7 mmol) and 100 mL of anhydrous 1,4-dioxane. 
Conc H2SO4 (5 mL, 50.5 mmol) was added with stirring followed by addition of 50 mL 
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of isobutene.  The vessel was closed with ¼” quick fit valve.  The reaction was stirred for 
12 h at 23 oC.  The reaction was cooled to 0 oC and poured into ice-cold 1N NaOH.  The 
reaction mixture was extracted three times with 50 mL portions of Et2O, washed with 1N 
NaOH, NaCl (aq, sat), and dried over Na2SO4.  The solvent was decanted off and then 
removed under reduced pressure. 5.3 g (74.6%) of colourless oily liquid was obtained 
with.  bp: 53.5 oC (lit138 bp: 52 oC).  1H NMR (CDCl3): δ 3.39 (br, 2 H, NH2), 3.35 (br, 3 
H), 2.78 (s, 3 H), 2.49 (s, 9 H), 2.13 (m, 1 H), 1.74 (m, 2 H), 1.71 (m, 1 H). 
(2S)-tert-butyl 3-methyl-2-(1-methylpiperidine-2-carboxamido)pentanoate (149).  A 
50 mL round bottom flask was charged with N-methyl pipecolinic acid hydrochloric acid 
(146; 880.8 mg, 4.9 mmol), 6 mL of DCM, DIEA (2.8 mL, 17.64 mmol), DMAP (50 mg, 
0.27 mmol), and HOBt (50 mg, 0.27 mmol).  A solution of L-isoleucine tert-butylester 
(148; 1.2 g, 6.4 mmol) in 6 mL of DCM was added to the amine mixture followed by the 
addition of solid DCC (2.5 g, 12.1 mmol) was added.   The reaction was stirred for12 h at 
23 oC.   The reaction was cooled to 0 oC and the white precipitate (DCC-urea) was 
filtered away.  The solvent was removed from the filtrate under reduced pressure.  The 
resultant white solid was dissolved in a mixture of 50 mL of Et2O and 10 mL H2O.  
Extraction was carried out with 0.5 N HCl.  Aqueous extracts were combined and 
basified with 1N NaOH (pH>9).  Extraction was carried out three times with 50 mL 
portions of Et2O, washed with NaCl (aq, sat) and dried over Na2SO4.  The solvent was 
removed under reduced pressure.  The product was isolated on SiO2. 920 mg (60%) of 
colourless oil was obtained.  bp: 210.5 – 212.0 oC . 1H NMR (CDCl3): δ 4.43-4.48 (m, 1 
H), 2.90 (m, 1 H), 2.46 (m, 1 H), 2.23 (d, J = 10.0 Hz, 3 H), 2.16 (s, 3 H), 1.89 (m, 2 H), 
1.71 (m, 1 H), 1.62 (m, 2 H), 1.45 (s, 9 H), 1.22 (m, 2 H), 0.92 (m, 3 H) 0.91 (t, 3 H) . 
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(S)-ethyl 4-((tert-butoxycarbonyl)amino)-2-methyl-5-phenylpent-2-enoate136 (81).  A 
1 L 3-necked flask was equipped with an overhead stirrer and an addition funnel was 
charged with commercially available (R)-tert-butyl (1-hydroxy-3-phenylpropan-2-
yl)carbamate (80; 18 g, 71.6 mmol), Tempo (342 mg, 2.15 mmol), NaBr (7.42 g, 71.6 
mmol), 36 mL of H2O, and 360 ml of DCM.  The reaction was cooled to 0 oC.  A solution 
of 6% NaOCl (Chlorox bleach) (198 g, 143.2 mmol) with NaHCO3 (17.6 g, 207.6 mmol) 
was added dropwise from the addition funnel maintaining the reaction at 0 oC over a 4 h 
period with continuous stirring.  The reaction was stirred for additional 2 h.  The reaction 
was extracted four times with 100 mL portions of DCM.  The combined extracts were 
washed sequentially with a solution of KI (573 mg) in 10% KHSO4 (aq) (144 mL), 180 
mL of 10% NaS2O3 (aq), NaCl (aq, sat), and dried over MgSO4.  The mixture was filtered 
and the filtrate was removed under reduced pressure.  16.1 g (90%) of white solid was 
obtained which was used within one day of preparation.  SiO2 TLC Rf 0.63 (Hexane/EA 
2:1). (Carbethoxyethylidene)triphenylphosphorane (27.2 g, 75 mmol) was added to a 
solution of the freshly prepared aldehyde (151; 17 g, 68.1 mmol) in 205 mL of DCM at 0 
oC.  The reaction was allowed to warm slowly to 23 oC and stirred for 12 h.  The solvent 
was removed under reduced pressure.  The product was isolated using SiO2 and eluted 
with 10:1 hexanes/EA. 12.3 g (55%) of white solid was obtained.  SiO2 TLC Rf 0.70 
(Hexanes/EA 2:1).  mp: 62.1 - 63.0 oC (lit136 63.0 – 64.0 oC).  1H NMR (CDCl3): δ 7.17 – 
7.28 (m, 5 H), 6.51 (d, J = 9.4, 1 H), 4.57 (br, 1 H), 4.17 (q, J = 7.3, 2 H), 2.89 (m, 1 H), 
2.75 (q, 1 H), 1.68 (s, 3 H), 1.39 (s, 9 H), 1.26 (t, 3 H). 
(S)-4-((tert-butoxycarbonyl)amino)-2-methyl-5-phenylpent-2-enoic acid136 (153).  1 N 
aqueous NaOH (90 mL, 90 mmol) was added to the solution of (S)-ethyl 4-((tert-
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butoxycarbonyl)amino)-2-methyl-5-phenylpent-2-enoate (81; 12 g, 36 mmol) in 485 mL 
of EtOH at 0 oC.  The mixture was allowed to warm to 23 oC and reaction was then 
stirred for an additional 12 h.  The solvent was removed under reduced pressure and the 
crude oil was dissolved in 30 mL of 1 N aqueous NaOH.  The solution was washed three 
times with 15 mL portions of Et2O, and then acidified to pH <3 with 2 N aqueous HCl.  
The mixture was extracted three times with 20 mL portions of Et2O, washed with NaCl 
(aq, sat) and dried over Na2SO4.  The extract was decanted off and then the solvent was 
removed under reduced pressure and 11.1 g (99%) of white solid was obtained with.  mp: 
140.6 - 140.9 oC.  SiO2 TLC Rf 0.47 (Hexane/EA 2:1). 1H NMR (CDCl3): δ 7.17 – 7.30 
(m, 5 H), 6.34 (d, J = 9.4, 1 H), 4.54 (br, 1 H), 2.91 (m, 1 H), 2.77 (q, 1 H), 1.66 (s, 3 H), 
1.38 (s, 9 H). 
(2S,4R)-4-((tert-butoxycarbonyl)amino)-2-methyl-5-phenylpentanoic acid (154a).  A 
hydrogenation flask containing 10% Pd/C (100 mg) was charged with solution of (S)-4-
((tert-butoxycarbonyl)amino)-2-methyl-5-phenylpent-2-enoic acid (153; 5.0 g, 18 mmol) 
in 100 mL of EtOH.  The hydrogenation flask was charged with hydrogen at 50 psi after 
3 vacuum purge cycles and the vessel was shaken was for 24 h at 23 oC.  The mixture 
was filtered through a pad of Celite and then washed with an additional 50 mL of EtOH.  
The solvent was removed under reduced pressure and 10.1 g of a white solid was 
obtained, which was recrystallized from Et2O and hexane (1:1) to afford 5.21 g (52.5%) 
of colorless crystals.  mp: 63.1- 64.5 oC (lit136 mp: 62-64 oC).  1H NMR (CDCl3): δ 7.17 – 
7.30 (m, 5 H), 6.32 (d, J = 9.4, 1 H), 3.97 (br, 1 H), 2.79 (m, 2 H), 2.55 (br, 1 H), 1.87 
(m, 1 H), 1.40 (s, 9 H), 1.17 (s, 3 H). 
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Chapter 6 
 
Summary 
 
5.1 CDK-5 and MEK-5 
49 novel target compounds 
2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol hydrochloride 
(94a) 
2-(4-(benzylamino)-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (94e) 
2-(4-(3-chlorobenzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol 
hydrochloride (94f) 
N-benzyl-1-isopropyl-6-((1-methylpiperidin-4-yl)methoxy)-1H-benzo[d]imidazol-4-
amine hydrochloride (94g) 
N-benzyl-1-isopropyl-6-(1-methylpiperidin-4-yloxy)-1H-benzo[d]imidazol-4-amine 
hydrochloride (94b) 
N-benzyl-1-isopropyl-6-(piperidin-4-ylmethoxy)-1H-benzo[d]imidazol-4-amine 
hydrochloride (94d)  
N-benzyl-6-(1-(dimethylamino)butan-2-yloxy)-1-isopropyl-1H-benzo[d]imidazol-4-
amine hydrochloride (94c) 
N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-yl)benzamide 
hydrochloride (105a) 
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2-chloro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105b) 
3-chloro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105c) 
4-chloro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105d) 
2-fluoro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105e) 
3-fluoro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105f) 
4-fluoro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105g) 
2-nitro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105h) 
3-nitro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105i) 
4-nitro-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105j) 
2-methyl-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105k) 
3-methyl-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105l) 
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4-methyl-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105m) 
2-methoxy-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105n) 
3-methoxy-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105o) 
4-methoxy-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105p) 
2-amino-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105r) 
3-amino-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (105s) 
4-amino-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
yl)benzamide hydrochloride (10t) 
N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-yl)-1-naphthamide 
hydrochloride (105q) 
N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-yl)-2-
phenylacetamide (109a) 
2-(2-fluorophenyl)-N-(6-((1-hydroxybutan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-
4-yl)acetamide (109b) 
N-benzyl-6-ethoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (119e) 
N-benzyl-1-isopropyl-6-propoxy-1H-benzo[d]imidazol-4-amine (119f) 
N-benzyl-6-butoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (119g) 
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N-benzyl-6-isopropoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (119h) 
N-benzyl-1-isopropyl-6-(2-methoxyethoxy)-1H-benzo[d]imidazol-4-amine oxalate 
(119a) 
N-benzyl-6-(2-ethoxyethoxy)-1-isopropyl-1H-benzo[d]imidazol-4-amine oxalate (119c) 
N-benzyl-1-isopropyl-6-(3-methoxypropoxy)-1H-benzo[d]imidazol-4-amine (119b) 
N-benzyl-1-isopropyl-6-(3-morpholinopropoxy)-1H-benzo[d]imidazol-4-amine 
hydrochloride (119d) 
(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(4-methylpiperazin-1-
yl)methanone (122b) 
(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(morpholino)methanone (122c) 
(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(piperidin-1-yl)methanone (122d) 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (122a) 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethyl)benzamide (122e) 
(S)-2-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamido)-3-hydroxypropanoic 
acid (122f) 
(R)-2-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamido)-3-hydroxypropanoic 
acid (122g) 
2-(2-chlorophenyl)-4H-chromen-4-one (140) 
5-hydroxy-2-(3-methoxy-2-nitrophenyl)-4H-chromen-4-one (133a) 
7-hydroxy-2-(3-methoxy-2-nitrophenyl)-4H-chromen-4-one (133b) 
2-(2-amino-3-methoxyphenyl)-5-hydroxy-4H-chromen-4-one hydrochloride (134a) 
2-(2-amino-3-methoxyphenyl)-7-hydroxy-4H-chromen-4-one hydrochloride (134b) 
36 novel intermediates 
2-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol (93a) 
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2-(4-amino-1-cyclopentyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol (93e) 
1-isopropyl-6-((1-methylpiperidin-4-yl)methoxy)-4-nitro-1H-benzo[d]imidazole (92g) 
1-isopropyl-6-((1-methylpiperidin-4-yl)methoxy)-1H-benzo[d]imidazol-4-amine (93g) 
tert-butyl 4-((4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-
yloxy)methyl)piperidine-1-carboxylate (93d) 
6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-benzo[d]imidazol-4-
amine (103) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)benzamide (104a) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-chlorobenzamide (104b) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-chlorobenzamide (104c) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-chlorobenzamide (104d) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-fluororobenzamide (104e) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-fluororobenzamide (104f) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-fluororobenzamide (104g) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-nitrobenzamide (104h) 
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N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-nitrobenzamide (104i) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-nitrobenzamide (104j) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-methylbenzamide (104k) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-methylbenzamide (104l) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-methylbenzamide (104m) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-methoxybenzamide (104n) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-3-methoxybenzamide (104o) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-4-methoxybenzamide (104p) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-1-naphthamide (104q) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-phenylacetamide (108a) 
N-(6-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-1-isopropyl-1H-
benzo[d]imidazol-4-yl)-2-(2-fluorophenyl)acetamide (108b) 
6-ethoxy-1-isopropyl-4-nitro-1H-benzo[d]imidazole (117e) 
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1-isopropyl-4-nitro-6-propoxy-1H-benzo[d]imidazole (117f) 
6-butoxy-1-isopropyl-4-nitro-1H-benzo[d]imidazole (117g) 
6-isopropoxy-1-isopropyl-4-nitro-1H-benzo[d]imidazole (117h) 
6-ethoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (118e) 
1-isopropyl-6-propoxy-1H-benzo[d]imidazol-4-amine (118f) 
6-butoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (118g) 
6-isopropoxy-1-isopropyl-1H-benzo[d]imidazol-4-amine (118h) 
1-isopropyl-6-(2-methoxyethoxy)-1H-benzo[d]imidazol-4-amine (118a) 
6-(2-ethoxyethoxy)-1-isopropyl-1H-benzo[d]imidazol-4-amine (118b) 
1-isopropyl-6-(3-methoxypropoxy)-1H-benzo[d]imidazol-4-amine (118c) 
5 compounds partialy characterized in literature 
2-(4-methylpiperazine-1-carbonyl)benzoic acid (142a) 
2-(morpholine-4-carbonyl)benzoic acid (142b) 
2-(piperidine-1-carbonyl)benzoic acid (142c) 
2-((2-hydroxyethyl)carbamoyl)benzoic acid (142d) 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid (75) 
 
5.2 Tubulysin 
Large scale synthesis 
(+/-)Mep fragment: 1-methylpiperidine-2-carboxylic acid hydrochloride (146) (6.5 g) 
Ile fragment: L-tert-butyl 2-amino-3-methylpentanoate (148) (5.3 g) 
Dipeptide fragment: (2S)-tert-butyl 3-methyl-2-(1-methylpiperidine-2-
carboxamido)pentanoate (149) (920 mg) 
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Tup fragment: (2S,4R)-4-((tert-butoxycarbonyl)amino)-2-methyl-5-phenylpentanoic acid 
(154a) (5.21 g) 
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Appendix 
 
Biological evaluation 
CDK-5 
Biological assay  
The biological testing of these compounds was conducted in the laboratory of Dr. Laurent 
Meijer (CNRS Station Biologique, Roscoff, France).  
Activities of CDK-1, CDK-2, CDK-5, GSK3β, CK1, DyrK1A and ERK-2 were assayed 
in 25 mM Mops Buffer (pH 7.2) with 60 mM β-glycerophosphate, 5 mM EDTA, 15 mM 
MgCl2, and 1 mM DTT.  
The protein histone H1 (Sigma; 1 mg/ml) was used as the substrate, in the presence of 15 
μm [γ-
33
P] ATP (3,000 Ci/mmol; 1 mCi/ml) to a final volume of 30 μl. After a 10 minute 
incubation period at 30 °C, 25 μl aliquots of supernatant were removed and spotted onto 
2.5 x 3 cm pieces of Whatman P81 phosphocellulose paper. After 20 seconds the filter 
paper was washed five times (for at least 5 min. each time) with a solution of 10 ml 
phosphoric acid/liter of water. The wet filter paper was then counted in the presence of 1 
ml ACS (Amersham) scintillation fluid to determine the degree of substrate 
phosphorylation. 
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Biological data 
C6-O linked series 
 
Data provided by Dr. Laurent Meijer. 
Table 4. Biological activity of C6-O linked benzimidazoles. 
C-4 Benzamides and C-4 Phenylacetamides 
C-4 Benzamide series (105 a-q) and C-4 Phenylacetamide series (109 a,b) are inactive 
against CDK-5. 
 
1.2 MEK-5 
Biological assay 
The biological testing of these compounds was conducted in the laboratory of Dr. Jane 
Cavanaugh (Duquesne University, Pittsburgh). 
Cell Culture and treatment 
 
Compound 
no. 
IC50 (µM) 
CDK1 CDK5 GSK3β CK1 DyrK1A CDK2A Erk2 
94a 13 13 >10 >10 30 10 >10 
94b - >100 - - >10 - - 
94c >10 >10 >10 - >10 - - 
94d - >100 - - >10 - - 
94g - >100 - - >10 - - 
94e 9.0 9.2 >10 >10 11 8.3 >10 
94f - 22 - - >10 - - 
Standard 0.45 0.16 130 2.3 - 0.7 14 
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HEK293 cells were grown on 10cm cell culture plates [Sarstedt] in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Gibco) with 10% heat-inactivated FBS [Atlanta Biological], 
and 0.5% penicillin/ streptomycin [Gibco].  Cells were maintained at 37°C with 5% CO2. 
Cells were plated 36 hours before treatment in 60mm culture plates [Sarstedt] and 
allowed to reach confluence.  To test MEK-5 inhibitors, the cells were treated with 
epidermal growth factor (EGF; Sigma) 30 minutes before treatment with the compounds. 
After the addition of compounds, the cells were lysed 30 minutes later.  The cells were 
washed with 1XPBS [Sigma] and then lysed in 1% Triton X-100 buffer containing 20 
mM Tris (pH 6.8), 137 mM NaCl, 25 mM beta glycerophosphate, 2 mM NaPPi, 2 mM 
EDTA, 1 mM Na3VO4, 10% glycerol, 5 µg/mL leupeptin, 5 µg/mL aprotinin, 2 mM 
benzamidine, 0.5 mM DTT, and 1 mM PMSF.  The lysates were then centrifuged at 
10,000 rpm for 10 min at 4°C.  Determination of protein in the supernatant was done by a 
Bradford assay [Biorad]. 
Western Blot Analysis 
Equal amounts of protein (60 µg) from each treatment were separated on SDS gels and 
transferred to nitrocellulose membrane [BioRad Laboratories] for Western blot analysis. 
Blots were blocked in 5% nonfat milk in 1XTBS/0.1%Tween/0.02%NaN3 for 1 hr and 
then incubated overnight at 4°C in primary antibody (pERK-1/2, pERK-5, Cell 
Signaling). Blots were washed with 1XTBS/0.1%Tween for 30 min and then incubated 
with secondary antibody (horseradish peroxidase-conjugated antirabbit, Upstate).  
Proteins were visualized with enhanced chemiluminescence (Upstate). The signal was 
quantified using the ImageJ program (NIH). 
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Biological results 
Blot A 
Compound 
p-ERK1/2  
Phosphorylation 
Relative  
(%) 
p-ERK5  
Phosphorylation 
Relative  
(%) 
142c 153.9 38.8 85.1 175.5 
122f 218.2 85.0 99.8 205.8 
142a 250 107.9 103.6 213.6 
142b 234.6 96.8 92.4 190.5 
142d 251.4 108.9 85.5 176.3 
U0126  0.34 -71.7 60.4 124.5 
+ (Positive Control) 239.5 100.4 48.5 100.0 
No Treatment 100 0.0 0 0.0 
 
Blot B 
Compound 
p-ERK1/2  
Phosphorylation
Relative 
(%)   
  
p-ERK5 
Phosphorylation  
Relative 
(%) 
  
122g 174.3 80.8 121.2 126.9 
PD 98059 (31) 152.8 57.4 122.4 128.2 
Staurosporine 156.6 61.5 77.4 81.0 
flavopyridol 127.1 29.5 94.9 99.4 
119d 92.7 -7.9 84.8 88.8 
U0126  15.3 -92.1 64.1 67.1 
+ (Positive Control) 192.9 101.0 95.5 100.0 
No Treatment 100 0.0 0 0.0 
 
Blot C 
Compound 
p-ERK1/2 
Phosphorylation
 Relative 
(%) 
  
p-ERK5  
Phosphorylation  
 Relative 
(%) 
134a 294.7 155.8 223.1 145.7 
133b 312.1 169.7 341.6 223.1 
134b 297.7 158.2 315.6 206.1 
133a 223.6 98.9 185.2 121.0 
140 302.7 162.2 201.8 131.8 
U0126  5 -76.0 8.9 5.8 
+ (Positive Control) 225 100.0 153.1 100.0 
No Treatment 100 0.0 0 0.0 
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Blot D 
Compound 
p-ERK1/2 
Relative 
Phosphorylation 
(%) 
Relative 
(%) 
  
p-ERK5 Relative 
Phosphorylation 
(%) 
Relative 
(%) 
  
122c 251.2 47.8 72.2 76.3 
122b 254 48.7 63.1 66.7 
122d 233.9 42.4 82.4 87.1 
122a 3.2 -30.6 41.1 43.4 
122e 1.7 -31.1 45.3 47.9 
U0126  45.2 -17.3 47.2 49.9 
+ (Positive Control) 416.4 100.1 94.6 100.0 
No Treatment 100 0.0 0 0.0 
 
 
Blot E 
Compound 
p-ERK1/2  
Phosphorylation
Relative  
(%) 
  
p-ERK5  
Phosphorylation  
Relative  
(%) 
  
119b 4652.7 1081.4 1468.8 125.3 
119f 3343.6 770.5 2218.1 189.3 
119e 2661.9 608.5 1121.8 95.7 
118b 115 3.6 182 15.5 
119c 126.6 6.3 160.7 13.7 
119h 562.8 109.9 933.8 79.7 
119a 724.2 148.3 1333.3 113.8 
119g 743.9 152.9 1115.5 95.2 
   UO126 95.4 -1.1 308.1 26.3 
+(positive  control) 521.5 100.1 1172.4 100.0 
No treatment 100 0.0 0 0.0 
 
Table 5: Biological activity of benzimidazole, diphenylamine, orthocarboxyamide, flavone classes 
of compounds (Blots A – E). Duplicate assays within ±5%.  
+ = positive control (HEK293 cells + epidermal growth factor (EGF)) 
NT = no treatment 
 
Kinome scan 
To identify the specific mechanism for inhibition of ERK-5 phosphorylation a high-
throughput analysis of the kinases involved in the signaling cascade was surveyed.  
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Ambit Biosciences screened compound 119b against a panel of 124 tyrosine receptor 
kinases (TK) and src-like (STE) kinases1 at the same concentration as the HEK assay: 10 
µM.  The MEK, MEKK, and MEKKK enzymes are in the STE branch. Surprisingly, this 
compound did not display activity against MEK-5 or any other kinase in the known ERK-
5 signaling pathway but did inhibit MEK-4.  Given that this HTS specifically seeks ATP-
competitive inhibitors, a non-ATP competitive mechanism may be involved. 
Tyrosine Receptor Kinases
SRC-like kinases
 
Figure 54.  Organization of different kinases. 
 
KINOMEscan™ is based on a competition binding assay that quantitatively measures the 
ability of a compound to compete with an immobilized, active-site directed ligand. The 
assay is performed by combining three components: DNA-tagged kinase; immobilized 
ligand; and a test compound. The ability of the test compound to compete with the 
immobilized ligand is measured via quantitative PCR of the DNA tag. 
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Figure 55. Working of KINOMEscan™. 
Kinase assays  
For most assays, kinase-tagged T7 phage strains were grown in parallel in 24-well blocks 
in an E. coli host derived from the BL21 strain. E.coli were grown to log-phase and 
infected with T7 phage from a frozen stock (multiplicity of infection = 0.4) and incubated 
with shaking at 32 °C until lysis (90-150 minutes). The lysates were centrifuged (6,000 x 
g) and filtered (0.2 μm) to remove cell debris. The remaining kinases were produced in 
HEK-293 cells and subsequently tagged with DNA for qPCR detection. Streptavidin-
coated magnetic beads were treated with biotinylated small molecule ligands for 30 
minutes at room temperature to generate affinity resins for kinase assays. The liganded 
beads were blocked with excess biotin and washed with blocking buffer (SeaBlock 
(Pierce), 1% BSA, 0.05 % Tween 20, 1 mM DTT) to remove unbound ligand and to 
reduce non-specific phage binding. Binding reactions were assembled by combining 
kinases, liganded affinity beads, and test compounds in 1x binding buffer (20 % 
SeaBlock, 0.17x PBS, 0.05 % Tween 20, 6 mM DTT). Test compounds were prepared as 
40x stocks in 100% DMSO and directly diluted into the assay. All reactions were 
performed in polypropylene 384-well plates in a final volume of 0.04 ml. The assay 
plates were incubated at room temperature with shaking for 1 hour and the affinity beads 
were washed with wash buffer (1x PBS, 0.05 % Tween 20). The beads were then re-
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suspended in elution buffer (1x PBS, 0.05 % Tween 20, 0.5 μm non-biotinylated affinity 
ligand) and incubated at room temperature with shaking for 30 minutes. The kinase 
concentration in the eluates was measured by qPCR. 
 
Percent Control (%Ctrl) 
The compound(s) were screened at the concentration(s) requested, and results for primary 
screen binding interactions are reported as '% Ctrl', where lower numbers indicate 
stronger hits in the matrix. 
%Ctrl Calculation 
 
negative control = DMSO (100%Ctrl) 
positive control = control compound (0%Ctrl) 
S-scores 
KINOMEscan's selectivity score (S) is a quantitative measure of compound selectivity. It 
is calculated by dividing the number of kinases that bind to the compound by the total 
number of distinct kinases tested, excluding mutant variants. 
 
S-score Calculation 
S(35) = (number of non-mutant kinases with %Ctrl <35)/(number of non-mutant kinases 
tested) 
S(10) = (number of non-mutant kinases with %Ctrl <10)/(number of non-mutant kinases 
tested) 
S(1) = (number of non-mutant kinases with %Ctrl <1)/(number of non-mutant kinases 
tested) 
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Table 6. Results of the kinome scan assay. 
 
Molecular modeling 
CDK-5 
Variations from the 6-position of the benzimidazole sought to survey the solvent exposed 
area of the ribose binding area and the phosphate triester binding region.  Specific 
residues that were targeted included Asp86, Leu133, Gln130, and Asp144.  Additional 
hydrophobic interactions were sought in the pocket of the non-solvent exposed region of 
the ribose binding pocket. 
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Figure 56. Survey volume for the C6-O linked benzimidazole derivatives. 
 
C-4 benzamides 
An analysis of the rotational energy around the benzamide dihedral angle as shown below 
for compound 105a identified a large energetic barrier as the phenyl ring or the acyl 
group  rotated past the lone pair electrons on the 3-nitrogen (+/- 90 o).  Two local energy 
minima were identified with dihedral angles of 0 o or 179 o.  Although the two rotamers 
were separated by approximately 1 kcal, there was a significant barrier to rotation of 
about 75 kcal.  The end result is that rotational isomer of the benzamide moiety selected 
by MOE is likely to represent a low-energy conformation, rotamer A, is likely to be 
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populated to a reasonable extent.   The analysis was conducted in both MOE and 
Chem3D using either the MM2 or MMF94 force fields.   
 
 
 
     
  Rotamer A  
  (Dihedral angle: 5 o, 51.7 kcal/mole)   
 
 
 
Rotamer B  
(Dihedral angle: 179 o, 51.0  kcal/mole)   
 
 
 
Figure 57. Dihedrial energy plot of dihedral angle versus energy (kcal) Rotomer with a dihedral 
angle of 140 o was the rotamer that had the best fit in CDK-5.  
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Figure 58. Interaction of benzamide with CDK‐5. 
 
MEK-5: homology model 
Two strategies were utilized for the homology model of MEK-5.  The primary sequence 
of MEK-5 beta DD was aligned to either the structure of MEK-1 (1SJ9) or MEK-6 
(3FME).  In either case, the standard MOE protocol was utilized with an initial 
determination of secondary structure, then alignment of the secondary structure of the 
target enzyme followed by molecular mechanics to minimize the strain on the molecules. 
An overlay of the original structure MEK-1 (1SJ9, in yellow) and the generated MEK-5 
homology model (in green is shown). 
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Figure 59. MEK-5 homology model. 
 
A Ramanchandran plot of the generated phi and psi angles is presented below: 
A duplicate run generated identical results.  The outliers are mostly in the lower platform 
binding domain with the exception of Gln15 which is contained on the Gly loop.  Efforts 
to resolve this strained angle are currently underway. 
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Figure 60. Ramachandaran plots representing the generated phi and psi angles.  
 
 
